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Breast cancer is the second most common cause of cancer death in females in 
the UK. It is a heterogenous disease with subtypes which behave differently. 
There are targeted treatments available for luminal and HER2+ cancers but 
treatment resistance and cancer recurrences occur. There are currently no 
targeted treatments for triple negative breast cancer (TNBC). New prognostic 
tools to stratify risk to guide use of the most aggressive treatments, and new 
therapeutic targets are desirable. The role of the tumour microenvironment in 
tumour progression is increasingly recognised. Features of the tumour such as 
necrosis and budding have been reported to have a prognostic role in cancer and 
may be influenced by the tumour microenvironment. Cell signalling pathways 
such as the IL6/JAK/STAT3 pathway provide a link between the tumour 
microenvironment and tumour cells. Better understanding of these features and 
pathways may lead to identification of new prognostic and predictive tools and 
of new therapeutic targets.  
The work of this thesis is carried out in two cohorts of patients with primary 
operable breast cancer with mature follow up. Data was available from clinical 
records for both regarding patient age, tumour pathology, treatment details and 
survival. Full section slides from surplus tissue were available from both cohorts 
and a tissue microarray (TMA) had been previously constructed for the largest 
cohort. The majority of the work in this thesis is carried out using haematoxylin 
and eosin (H&E)-stained full section slides and TMA slides stained using 
immunohistochemistry (IHC) techniques for various proteins. Staining for IL6 
expression was carried out using RNA scope. Transcriptomics was carried out 
using TempOSeq to identify genes associated with tumour budding. 
The work of this thesis describes a new combined score of tumour necrosis, 
budding and tumour-stroma percentage (TSP) which has prognostic value in 
primary operable breast cancer. It identifies a poor prognostic group in 
oestrogen receptor positive (ER+) disease which could be targeted for more 
aggressive treatment, and stratifies risk in ER- disease. 9 genes of potential 
interest for further investigation are identified as being associated with the high 
budding phenotype in ER- cancers. For the first time in the literature, this work 
will describe, in luminal A cancers, an association between tumour IL6 and 
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membranous IL6R expression and worse cancer specific survival (CSS), and an 
association between pSTAT3(Ser727) and improved CSS, indicating potential 
roles as prognostic markers in this subtype. It will describe the expression and 
associations with survival of other members of the pathway, informing further 
research regarding in which subtypes inhibiting targets in the pathway may be of 
clinical value.  
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This introductory chapter will first describe the epidemiology, diagnosis, 
pathology and treatment of breast cancer to provide background and context. It 
will then outline the current tools used to aid individualised treatment decision 
making and their limitations, and thus the desirability of novel prognostic tools. 
Finally it will outline current understanding of the tumour microenvironment and 
of the IL6/JAK/STAT3 pathway to explain why this thesis will focus on these 
areas in the search for novel prognostic markers which may be of use in clinical 
practice. 
1.1 Breast Cancer Epidemiology 
1.1.1 Incidence and trends 
Breast cancer is the most common cancer in females in the UK, with 
approximately 55,200 new cases every year. It accounts for 15% of the total 
cancer cases diagnosed. In females, breast cancer represents 30% of new cancer 
cases but in males it is less than 1%. Incidence rates increase with age, with an 
average of 24% of new cases occurring in those aged over 75 years. Incidence 
rates have increased by 18% in the UK since the early 1990s (23% in females) and 
are projected to rise by 2% between 2014 and 2035(1).  
1.1.2 Mortality and trends 
Overall, breast cancer is the fourth most common cause of cancer-related death 
in the UK. In females it is the 2nd most common cause of cancer-related death. It 
accounts for approximately 11,500 deaths every year. Mortality rates from 
breast cancer have reduced by 39% since the early 1970s in the UK, and by 19% 




Figure 1-1. Breast cancer European age-standardised mortality rates per 100,000 females in 
the UK, 1971-2018.   Credit: Cancer Research UK. 
1.1.3 Risk factors 
A woman born after 1960 in the UK has a 15% estimated lifetime risk of 
developing breast cancer(1). Increasing age is the primary risk factor for breast 
cancer. Genetics also have an important role to play. Risk of breast cancer 
increases with each first-degree relative affected, and with relatives affected 
under 50 years of age. A number of genetic mutations are associated with an 
increased risk of breast cancer (over 80% lifetime risk in some(2)), of which the 
most common are BRCA 1, BRCA2 and TP53. However, 23% of breast cancer cases 
in the UK are preventable(3). Environmental and lifestyle factors which have 
been shown to contribute to breast cancer risk include being overweight and 
obesity (8% of cases), alcohol (8%), not breastfeeding (5%), post-menopausal 
hormone replacement therapy (2%), ionising radiation (1%) and oral 
contraceptives (<1%)(1).  
1.2 Breast cancer diagnosis 
1.2.1 Symptomatic clinics and the breast screening programme 
The two main routes of presentation with breast cancer in the UK are via 
symptomatic clinics or the national breast screening programme. Symptomatic 
patients are referred by their GP to a breast clinic where they undergo triple 
assessment. This term encompasses clinical assessment, imaging if required, and 
 
biopsy where indicated. The most common presenting symptoms of breast 
cancer(4) are illustrated below.  
 
Figure 1-2. Breast cancer presenting symptoms.  Chart illustrating the rates of symptoms in 
patients with a symptomatic presentation of breast cancer (Breast lump 83%, nipple abnormalities 
7%, breast pain 6% and breast skin abnormalities 2%)  
The UK National Health Service Breast Screening Programme (NHSBSP) was 
established in 1988. Currently, women aged 50-70 years are invited every three 
years for screening mammography, though women over the age of 70 years can 
self-refer for screening and selected patients who have been identified as being 
at high or moderate risk of developing breast cancer may be offered screening 
from a younger age and at more frequent time intervals(2). Screening is in the 
form of two-view digital mammography comprising MLO and CC projections of 
each breast(2). In the case of an abnormal mammogram, women are recalled to 
second stage screening when they will undergo clinical examination and further 
assessment may include further mammographic views, ultrasound and tissue 
sampling if indicated(2). If biopsy confirms in situ or invasive cancer, the patient 
is referred on to a breast surgeon for further assessment. In 2015/2016 in 
Scotland, 1392 breast cancer cases were diagnosed through the screening 
programme(5). 
Where indicated, women presenting to a symptomatic breast clinic will undergo 
imaging. In women 40 years and over this is in the form of mammography with or 
without ultrasound. Ultrasound is the imaging modality of choice in women 
under 40 years due to breast density but mammography may be carried out in 
younger patients where there is a high degree of suspicion of cancer(6). In 
selected cases MRI imaging of the breast is also carried out though this does not 
 
form part of the one stop clinic. This is indicated if there is a discrepancy 
regarding the extent of the disease from other assessment modalities, if 
accuracy of mammographic assessment is jeopardised by breast density, or if 
breast conserving surgery (BCS) is being considered for lobular cancer(7).  
 
Figure 1-3. Abnormal mammogram.  Example of an abnormal bilateral mammogram (MLO view). 
Case courtesy of Dr Alexandra Stanislavsky, Radiopaedia.org, rID: 62207 
Lesions are biopsied using either a 14-gauge spring-loaded core biopsy needle or 
by a large volume vacuum-assisted biopsy(2). Regardless of whether the lesion is 
palpable or impalpable, the gold standard is for biopsy to be performed under 
image guidance(6) though a freehand core biopsy may be required when there is 
a palpable abnormality but imaging is normal. The core biopsy method allows 
the pathologist to report on the presence of in situ and/or invasive cancer, the 
grade of the tumour (using the Nottingham Bloom Richardson grading system 
based on nuclear pleomorphism, tubule formation and mitotic rate(8)), the 
oestrogen and HER2 receptor status of the tumour, and often the histological 
type(9).  
1.2.2 Breast cancer staging 
The stage of breast cancer describes the extent of disease. Currently the TNM 
system is used, with ‘T’ representing the local extent of the tumour, ‘N’ the 
degree of nodal involvement and ‘M’ the presence or absence of distant 
metastatic disease. The tumour extent is assessed using a combination of clinical 
examination and the imaging techniques described previously. T stage is denoted 
as shown in Table 1-1. In the UK, all patients diagnosed with invasive breast 
cancer undergo axillary ultrasound, with needle biopsy of any abnormal lymph 
nodes, as preoperative staging of the axillary nodes(7). Routine imaging for 
 
metastatic disease is not indicated in asymptomatic patients with early (T1/2 
and clinically node negative) disease, due to the low rate of metastases at 
presentation in these patients(10, 11). In symptomatic patients, appropriate 
investigations are carried out as indicated by the symptom and may include CT 
scan of chest, abdomen and pelvis. For asymptomatic patients with advanced 
disease, a CT scan is carried out in the first instance followed by a bone scan 
and/or liver ultrasound if required(12) though there is slight variation in staging 
practice regionally(10). The most common sites of breast cancer metastases are 
bone, lung, brain and liver(13).  
  
 
Tumour stage Description 
TX Primary tumour cannot be assessed 





Carcinoma in situ 
Ductal carcinoma in situ 
Lobular carcinoma in situ 
Paget’s disease of the nipple without invasive carcinoma, 






Tumour <20mm greatest diameter 
Tumour <1mm 
Tumour >1mm but <5mm 
Tumour >5mm but <10mm 
Tumour >10mm but <20mm 
T2 Tumour >20mm but <50mm 








Tumour any size with direct extension to the chest wall 
and/or skin 
Extension to the chest wall 
Ulceration and/or ipsilateral satellite nodules and/or skin 
oedema 
T4a and T4b 
Inflammatory carcinoma 
Nodal stage  
cN0 No nodal metastases 




Either of the below. 
Ipsilateral level I&II axillary LNs matted or fixed. 





Any of the below.  
Metastases in ipsilateral infraclavicular LN. 
Metastases in ipsilateral internal mammary AND axillary LNs. 
Metastases in ipsilateral supraclavicular supraclavicular LN. 
Metastases  
M0 No distant metastases 
M1 Distant metastases 
Table 1-1. Breast cancer staging.   Table created using information from Breast Cancer Staging 
System: AJCC Cancer Staging Manual, Eighth edition, Part XI: Breast. cN = clinical nodal stage. 
This is specified as post operative pathological lymph node staging uses different definitions. LN = 
lymph node. Levels I & II = axillary lymph nodes lateral to and behind pectoralis minor respectively. 
1.2.3 The role of the multidisciplinary team (MDT)  
Multi-disciplinary team-based decision making in breast cancer care has evolved 
as diagnostic and treatment options have become more complex, as will be 
outlined later in this chapter. Their role is variable worldwide(14) but in the UK 
it is mandatory for each patient diagnosed with breast cancer to be discussed 
within the MDT. These teams comprise breast surgeons, a clinical and a medical 
oncologist, radiologists, pathologists, breast cancer nurse specialists and a MDT 
 
coordinator/secretary with other optional members(15). This allows for 
discussion between different health professionals with different areas of 
expertise, to determine the optimal care pathway for each individual patient. 
While high quality evidence is lacking, some studies have reported improved 
patient outcomes with the use of multidisciplinary care(16).  
1.3 Breast Cancer Pathology 
1.3.1 Histological subtypes 
Breast cancer is a heterogenous disease which can be classified by histological or 
molecular subtype. There are various histological types of breast cancer which 
differ in pattern of spread and prognosis. The most common is ductal cancer 
accounting for 70-75% of all breast cancer cases, followed by lobular cancer (5-
15%)(17). Less common subtypes include mucinous, medullary and tubular 
cancers. Pre-invasive cancer which has not breached the basement membrane is 
termed in situ carcinoma(9). It may be ductal (ductal carcinoma in situ, DCIS) or 





Figure 1-4. Histological subtypes of breast cancer. Images showing examples of the two most 
common types of breast cancer. H&E-stained slides of a) ductal cancer and b) lobular cancer. 
Images courtesy of John Hopkins University Department of Pathology 
https://pathology.jhu.edu/breast/types-of-breast-cancer/ 
1.3.2 Receptors 
Breast cancers may express various receptors. Three of these are routinely 
reported on pathology reports because of their significance in terms of prognosis 
and tumour response to systemic treatments. 
The oestrogen receptor (ER) is an intracellular, nuclear, oestrogen-binding 
receptor protein. Upon ligand activation, it regulates target gene expression. ER 
 
is expressed in normal breast tissues and is important for breast 
development(18). It is upregulated in 70% of breast cancers(19) and is related to 
tumour cell proliferation. It can be targeted in the treatment of breast cancer 
by anti-oestrogens such as tamoxifen, which will be covered in greater detail 
later in this chapter. ER expression is therefore an important predictive factor 
for response to these therapies. It can be identified by immunohistochemistry 
techniques using specific antibodies. The results are reported as an Allred score, 
calculated using the percentage of cells which stain positive and a numerical 
rating of the staining intensity from 0-3(19). The score ranges from 0-8 and 





Figure 1-5. ER staining. Images of breast cancer tissue stained using immunohistochemistry for 
the oestrogen receptor at a) x10 magnification and b) x40 magnification. 
Like the ER, the progesterone receptor (PR) is a steroid hormone nuclear 
receptor which acts as a ligand-activated transcription factor and is involved in 
pro-proliferative signalling in the breast(20). There is considerable cross talk 
between the two pathways. The independent predictive power and clinical 
utility of PR above that of ER alone is controversial and NICE no longer 
recommend routine measurement. However, a number of studies have reported 
its prognostic power(21-24). Unlike ER, targeted therapies against the PR have 
not come into widespread use as early clinical trials reported intolerable side 
effects due to significant cross-reactivity with the glucocorticoid receptor(20). 
PR is identified by IHC and reported using the Allred score as described above. 
Human epidermal growth factor receptor 2 (HER2 or HER2/neu) is alternatively 
named receptor tyrosine-protein kinase erbB-2 or protooncogene Neu. It has no 
identifiable ligand and can undergo ligand-independent dimerization with other 
 
epidermal growth factor receptors leading to tumour promotion(25). HER2 
overexpression is present in approximately 15% of breast tumours. It is 
associated with poorer prognosis but its expression does allow targeted 
treatment for the tumour by therapies such as the monoclonal antibody 
trastuzumab. Similarly to the other receptors, HER2 expression is identified 
using IHC. However, the scoring system is different. It is reported based on the 
intensity of reaction product and the percentage of membrane positive cells to 
give a score 0-3+. Scores of 0 or 1+ are reported as negative, 3+ as positive and 
2+ as borderline. These latter samples therefore undergo fluorescence in situ 





Figure 1-6. HER2 staining. Examples of staining for HER2: a) immunohistochemistry staining of 
breast cancer tissue at x 40 magnification, b) HER2 amplification by FISH in breast cancer cells. 
Image b) attributable to IrinaPav, CC BY-SA 4.0 <https://creativecommons.org/licenses/by-sa/4.0>, 
via Wikimedia Commons  
1.3.3 Molecular subtypes 
The presence or absence of these receptors, along with other features, allow 
breast cancers to be categorised into specific molecular subtypes to guide 
targeted systemic treatments. The different subtypes behave differently and 
have varying prognosis. The different molecular subtypes, as described in the 
report of the 12th St Gallen International Breast Cancer Conference (2011) are 





ER/PR HER2 Ki67 Systemic Therapy 
Luminal A Positive Negative Low (<14%) Endocrine therapy. 



















Endocrine therapy +/- 
chemotherapy 
Endocrine therapy + 









Negative Negative Any Chemotherapy 
Table 1-2. Molecular subtypes of breast cancer.  Table summarising the four main molecular 
subtypes of breast cancer as determined by the ER/PR, HER2 and Ki67 status of the tumour. The 
final column summarises the types of systemic treatment which might be offered in each case. 
1.4 Breast Cancer Management 
1.4.1 Breast surgery 
1.4.1.1 Standard breast conserving surgery 
Surgical resection of the tumour remains the mainstay of treatment for early 
breast cancer. Standard breast conserving surgery (SBCS) in the form of a wide 
local excision aims to resect the tumour with a clear margin of healthy tissue 
around it. If malignant cells are seen by the pathologist <1mm from the margin 
of the specimen, then further resection is required due to the risk of residual 
disease in the breast and therefore an increased risk of recurrence(27). The 
definition of a clear margin is controversial and varies worldwide, for instance 
“no tumour on ink” is used to define a clear margin in the USA and in DCIS, a 
2mm margin is required(28). With the addition of adjuvant radiotherapy, SBCS 
has comparable survival outcomes to mastectomy(29). Traditionally SBCS can be 
carried out for tumours which occupy less than one third of the total volume of 
the breast. Resecting tumours larger than this is likely to result in considerable 
deformity.  
1.4.1.2 Oncoplastic breast conserving surgery 
With improved survival from breast cancer, aesthetic outcome following breast 
cancer surgery has become almost as important as safe oncological resection of 
 
the tumour. Developments in plastic surgery techniques have led to an 
increasing role for oncoplastic breast conserving surgery (OBCS). This 
encompasses a range of therapeutic mammoplasty techniques which allow 
preservation of the breast shape following resection of larger tumours which 
would be considered too large for SBCS. OBCS accounted for nearly 3% of the 
definitive operations for primary breast cancer in Scotland in 2014 and 2015(30). 
The improved cosmetic outcomes which these techniques provide are important 
to the psychosocial well-being and quality of life of patients(31, 32) but there 
are some concerns related to post-operative complications. OBCS is more 
extensive surgery than SBCS, and complication rates have been reported to be as 
high as 28.4%(33). Post-operative complications may lead to a delay in adjuvant 
treatments, though the evidence to date is mixed as to whether OBCS is 
associated with delay to adjuvant therapies compared to SBCS or 
mastectomy(34). 
1.4.1.3 Mastectomy 
For those patients with tumours which are not suitable for breast conserving 
surgery, mastectomy is required. The modified radical mastectomy involves 
excision of all of the breast tissue, down to the pectoral fascia, and includes an 
ellipse of overlying skin with the nipple-areolar complex. To improve cosmetic 
outcome following breast reconstruction, several skin and/or nipple-preserving 
mastectomy techniques have been developed which can be used if the patient is 
to undergo immediate breast reconstruction and when oncologically safe to do 
so. 
1.4.1.4 Breast reconstruction 
All patients who undergo mastectomy should be offered breast reconstruction if 
fit enough(7). This can be performed immediately or in the delayed setting, 
once adjuvant treatments are complete. There are advantages and 
disadvantages to each approach. Delayed reconstructions allow more time for 
decision making and do not risk delay to adjuvant therapies in the event of post-
operative complications but may have an inferior aesthetic outcome and incur 
higher costs(35). Immediate reconstruction, at the time of mastectomy, may be 
carried out in the context of a skin-sparing or nipple-sparing mastectomy 
 
resulting in superior aesthetic outcome including preserved breast shape, though 
there is a risk of delay to adjuvant therapy in the event of a complication and 
the final appearance, particularly in the case of implant reconstruction, may be 
affected by radiotherapy.  
Reconstructions can be implant-based, autologous or a combination of both. 
Autologous reconstructions utilise musculocutaneous flaps of the patient’s own 
tissue. They may be pedicled flaps, such as the latissimus dorsi (LD) flap and the 
transverse rectus abdominus myocutaneous (TRAM) flap, or free flaps such as the 
deep inferior epigastric perforator (DIEP) flap which requires anastomosis of 
donor site microvessels to the intercostal perforator vessels at the recipient site. 
For this reason, it may not be suitable for patients at high risk of microvascular 
disease, such as smokers and diabetics, as they have a much higher risk of 
postoperative wound necrosis and flap failure. 
1.4.2 Radiotherapy 
Radiotherapy is given in cancer to administer high doses of radiation to cancer 
cells, causing radiation-induced cell death(36). Breast radiotherapy is offered to 
patients who have had breast-conserving surgery as it has been shown to reduce 
the risk of recurrence(7). For patients who have had mastectomy, radiotherapy 
is offered to node-positive patients and those with involved resection margins. It 
may also be given to node-negative patients with T3-4 disease but is not 
recommended for those at low risk of recurrence(7). Radiotherapy can also be 
offered to the regional lymph nodes in selected patients, such as supraclavicular 
fossa irradiation for those with 4 or more involved axillary lymph nodes(7). 
1.4.3 Systemic therapy 
In early stage (operable) breast cancer, systemic therapy is given in the adjuvant 
(after surgery) setting with the aim of destroying any circulating tumour cells or 
micrometastatic deposits. The choice of systemic therapy, in terms of endocrine 
therapy, chemotherapy, both or neither, is determined by the receptor status of 
the tumour, the stage of the cancer and the fitness of the patient. Systemic 
therapy can also be given in the neoadjuvant (before surgery) setting with the 
aim of reducing the size of the tumour preoperatively to allow less extensive 
 
surgery to be performed. Neoadjuvant chemotherapy also has the advantage 
that the oncologist is able to observe the response of the tumour to the specific 
chemotherapy agent, and to alter treatment if necessary.  
1.4.3.1 Endocrine therapy 
Endocrine therapy is suitable for use against tumours which express the 
oestrogen receptor, as the growth of these tumours is driven by oestrogen. 
Currently it is given for 5 or more years following surgical resection of the 
tumour(7). 
Tamoxifen was first tested in the 1970s. It is a non-steroidal anti-oestrogen, 
otherwise termed a selective oestrogen receptor modulator. It binds the 
oestrogen receptor, thus disrupting oestrogen-binding which consequently blocks 
hormone-dependent tumour cell proliferation(18) by blocking the transcription 
of key growth factors(37). It has been shown in various trials to reduce 
recurrence of ER positive breast cancer in both pre and post-menopausal 
women(37). Whilst it blocks the action of oestrogen on breast cancer cells, it 
seems to have a partial agonist effect in endometrial tissue(37), resulting in 
increased endometrial cell proliferation and the increased risk of endometrial 
cancer(18). 
Subsequently, aromatase inhibitors such as anastrozole and letrozole were 
developed and introduced in 1995(37). They act by blocking the conversion of 
testosterone to oestrogen by inhibiting the enzyme aromatase, and consequently 
are suitable for use in post-menopausal ER positive breast cancer but have little 
effect in pre-menopausal breast cancer. The ATAC trial demonstrated superior 
disease-free survival in post-menopausal breast cancer treated with anastrozole 
compared to tamoxifen(38). The main side effects of aromatase inhibitors are 
musculoskeletal problems including osteopenia and osteoporosis with the 
associated fracture risk.  
Aromatase inhibitors are currently the first-line choice of endocrine agent in 
post-menopausal women at medium or high risk of recurrence, whereas 
tamoxifen is recommended for those with low recurrence risk, and in pre-
menopausal women and all men(7). Premenopausal women may also be offered 
 
ovarian function suppression, particularly if deemed at high risk of disease 
recurrence(7). 
Despite the effectiveness of these therapies, resistance does occur resulting in 
breast cancer recurrence in some patients whilst on these treatments, or once 
they have been stopped. There is currently debate, and trials are ongoing, to 
determine the optimum duration and combination of endocrine treatment for 
various tumour types and stages. The potential benefits of reduced recurrence 
rates when extending endocrine therapy beyond 5 years must be weighed against 
the side effects of the treatment. Currently in the UK, it is recommended to 
offer extension of endocrine therapy beyond 5 years (by continuation of 
tamoxifen or switch to/continuation with an aromatase inhibitor) in patients 
who have been treated with tamoxifen for 2-5 years of those 5 years(7).  
1.4.3.2 Chemotherapy 
Chemotherapy is offered to patients with ER negative cancer and those with high 
risk ER positive cancers. In the UK, regimen include an anthracycline with or 
without a taxane, usually given over 6 cycles(7). Chemotherapy has significant 
risks and side effects, including nausea, alopecia, cardiotoxicity, neutropenia, 
neuropathy and hypersensitivity reactions. Therefore these risks must be 
weighed against the potential benefits, and in patients with multiple or 
significant comorbidity, the risk may be deemed too high. 
In patients with ER positive cancer who are considered to be at an intermediate 
risk of disease recurrence, the decision regarding whether to give chemotherapy 
can be challenging. Currently, online tools such as PREDICT(39) can be used to 
help stratify risk. For patients with ER positive, HER2 negative, node negative 
cancer stratified as at intermediate risk, tumour gene-profiling tests such as 
EndoPredict® or Oncotype DX® Breast Recurrence Score can be used to help 
guide chemotherapy decisions(19). These tools will be considered in more detail 
later in this chapter.   
1.4.3.3 Herceptin 
Herceptin, or trastuzumab, is a monoclonal antibody used in the treatment of 
patients with HER2+ breast cancer. Its mechanism of action is complex and not 
 
fully understood but includes antibody-dependent cellular toxicity, intracellular 
mechanisms involving apoptosis and cell cycle arrest, inhibition of angiogenesis 
and prevention of DNA repair following chemotherapy-induced damage(25). The 
addition of Herceptin to chemotherapy has been shown to improve outcomes in 
early (in the neoadjuvant and adjuvant settings) and advanced HER2+ breast 
cancer(25). It is administered at 3-week intervals for 1 year(7). Adverse effects 
include reversible cardiotoxicity (25) and therefore the presence of significant 
pre-existing cardiac disease may preclude its use in some patients. Pertuzumab 
is also a monoclonal antibody which inhibits HER2 dimerisation. It is 
recommended by NICE, in combination with trastuzumab and chemotherapy, for 
neoadjuvant treatment of HER2 positive breast cancer which is locally advanced, 
inflammatory, or early-stage but at high risk of recurrence(40). In the adjuvant 
setting it is recommended for use in lymph node positive disease(41). More 
recently, the KATHERINE trial reported that use of T-DM1, a conjugate of 
trastuzumab and the cytotoxic drug emtansine, in patients with HER2 positive 
breast cancer with residual invasive disease following neoadjuvant therapy 
resulted in a 50% reduction in risk of invasive recurrence or death(42). 
1.4.3.4 Bisphosphonates 
Bisphosphonates have traditionally been used to slow bone thinning and reduce 
the risk of fractures in people with osteoporosis. In cancer, they are used to 
reduce the risk of fractures, slow disease progression and reduce pain in the 
context of malignant bone disease. In breast cancer they have been used to 
reduce bone thinning in patients receiving aromatase inhibitors. However, they 
do have effects on T-cell function and so it has been suggested that they could 
prevent or delay disease recurrence in early breast cancer. A recent review of 
current evidence has led NICE to recommend that bisphosphonates are offered 
to postmenopausal women with node-positive breast cancer as there is good 
evidence for improved disease-free and overall survival in these patients, when 
treated with zoledronate or sodium clodronate. It can also be considered in 
those with high-risk node negative cancer(7). 
 
 
1.4.4 Novel treatments 
1.4.4.1 Immune checkpoint inhibitors 
In view of the important role of the immune system in the progression of cancer, 
which will be discussed later in this chapter, there has been considerable focus 
on the development of therapeutics which enhance the anti-tumour immune 
response. The most investigated immunotherapy agents in breast cancer to date 
are PD-1/PD-L1 immune checkpoint inhibitors. Programmed death receptor-1 
(PD-1) is a transmembrane receptor found on thymus-derived (T), bone marrow-
derived (B) and natural killer (NK) cells which acts to inhibit unrestrained 
cytotoxic T cell activity in inflammation. Its ligands are programmed death 
ligand 1(PD-L1), found on many cell types including tumour cells, and 
programmed death ligand 2 (PD-L2), found predominantly on haematopoietic 
cells. Blockade of this checkpoint in cancer is aimed at reactivating cytotoxic T 
lymphocytes, thus improving the anti-tumour activity of the host immune 
system(43).  This may be in the form of PD-1 blockade, for instance with 
pembrolizumab (a selective monoclonal antibody to PD-1), or PD-L1 blockade, 
for instance with atezolizumab (a high-affinity monoclonal antibody that inhibits 
PD-L1 – PD-1 interaction)(43).  
Trials have shown a good response to immune checkpoint inhibitors in some 
cancers including melanoma and non-small cell lung cancer and it is licensed for 
use in selected patients with these tumour types(44). However, research in 
breast cancer is at a much earlier stage. Some trials, both those investigating 
immune checkpoint inhibitors as monotherapy and those which use them in 
combination with other therapies, have shown promising results in metastatic 
TNBC with response rates of 5.4-33.3% observed(44). The response tends to be 
prolonged in those who do respond and the therapy is generally well tolerated. 
In some studies patients are pre-selected for PD-L1 positivity while in others 
they are not. However, there is little evidence at this time for their use in ER+ 
and HER2+ disease(44). Studies of immune checkpoint inhibitors as neoadjuvant 
therapy in early stage breast cancer have reported particularly promising results 
with tripling of the pathological complete response (pCR) rates(44). However, 
these response rates are modest compared to some other tumour types and 
trials are very much in the early stages. Identifying predictive biomarkers which 
 
aid in the identification of those patients who do respond to immune checkpoint 
inhibition is therefore important going forwards. Some factors which have been 
reported as displaying some predictive utility to date include having a normal 
LDH, high tumour infiltrating lymphocytes (TILs), fewer lines of previous therapy 
and PD-L1 expression(44). 
1.4.5 Current challenges in treatment selection 
With these various treatment options come a number of challenges in 
management decision-making. Both surgical and medical treatments have 
associated complications, side effects and toxicities. It is therefore important 
that patients are not exposed to these risks if they will not derive significant 
benefit from the treatment. Currently, tumour factors such as tumour size, 
tumour grade, lymph node status and ER status are used to assess the risk of 
tumour recurrence with small, low grade, lymph node negative, ER positive 
tumours carrying the best prognosis. However, a proportion of patients with ER 
positive, lymph node negative cancers will recur and ultimately prove lethal. 
Therefore, additional prognostic tools are desirable to help identify these 
patients to be targeted with more aggressive therapy, such as extended 
endocrine therapy and/or chemotherapy. The current movement within the 
breast surgical community to carry out less extensive axillary surgery when safe 
to do so, because of the morbidity associated with this surgery, may mean that 
less detailed information regarding the burden of axillary disease will be 
available to oncologists to aid decisions such as post-mastectomy 
radiotherapy(45). This is another reason why novel prognostic markers are 
desirable. 
1.4.5.1 Current prognostic tools 
As already touched on in this chapter, several tools currently exist to aid 
adjuvant therapy decisions. One of the older and simplest is the Nottingham 
Prognostic Index (NPI) which calculates a score based on the size of the tumour, 
tumour grade and lymph node status. This score then stratifies patients into up 
to 6 prognostic groups. It has been widely validated and its strength lies in its 
simplicity with no requirement for a computer. However, variability in prognosis 
 
for the different groups has been reported(46). More recently, NPI+ has been 
developed to incorporate receptor subtypes of the tumour(47).  
Various online tools exist, of which the use of Predict is recommended by 
NICE(7). Predict incorporates tumour pathological characteristics, receptor 
status, Ki-67, route of presentation and patient age and menopausal status(48). 
Adjuvant! Online was another alternative but this is no longer available. The 
benefits of these tools are that they allow an individualised recurrence risk 
prediction to be calculated in the clinic and the expected benefit of adjuvant 
treatments can also be calculated. Predict has been widely validated(49, 50). 
However, there is concern that it is less accurate in patients at the extremes of 
age (<30 years with ER positive breast cancer or >70 years), women with tumours 
>50mm or <10mm ER positive tumours, and it has not been validated in men(51). 
It is also not of use in patients who have been treated with neoadjuvant therapy. 
In addition to these online tools, several gene signatures used to predict the risk 
of distant disease recurrence have been developed, of which EndoPredict, 
Oncotype DX and Prosigna are currently recommended by NICE(52). They are 
recommended for use in patients with ER positive, HER2 negative, lymph node 
negative breast cancer with an intermediate risk prediction using one of the 
online tools, and in whom the result of the test would affect the decision 
whether to give chemotherapy. EndoPredict measures expression of 12 genes, 
Oncotype DX measures 21 genes and Prosigna measure 50 genes. They all require 
RNA extracted from formalin-fixed, paraffin-embedded (FFPE) breast cancer 
tissue. As an example, Oncotype DX generates a recurrence score between 0-
100(53) with low, intermediate and high risk scores within this range. Evidence 
in the literature does support the prognostic power of these high and low risk 
groups(52), though the implications of the intermediate risk group are less clear 
and are the subject of the TAILORx trial, the initial results of which suggest that 
chemotherapy can safely be omitted in these intermediate score patients(54). 
Interestingly, while the different tests do seem to allocate a similar proportion 
of patients to the different risk groups, on an individual patient basis, variability 
in the risk group to which a patient is assigned has been reported(52). These 
tests are also applied to a specific subset of patients, namely those with ER 
positive, HER2 negative disease and so have no clinical utility for risk 
stratification in other subtypes. They are made up primarily of proliferative 
 
genes and therefore have very limited utility in highly proliferative breast cancer 
subtypes such as ER negative, HER2 positive tumours. They are designed for use 
in lymph node negative and lymph node positive (up to 3 positive nodes) disease 
but the evidence in lymph node positive or micrometastatic disease is less strong 
at present. The other limitation of these tests is cost and time. They are 
expensive, limiting their availability in low resource settings, and Oncotype DX 
tests, for example, is processed in a central US laboratory so the sample must be 
sent there and then it will be a further 7-10 days before the result is 
available(52).  
In view of the limitations of the above tests, additional prognostic tools are 
desirable to help stratify risk and guide treatment. These may be as standalone 
tests, or factors to add to online tools such as Predict to further refine their 
prognostic accuracy.  
1.4.5.2 Predictive tools and targeted treatments 
Another, related factor is the question of which cancers will respond to certain 
therapies, such as particular chemotherapy drugs or newer therapeutics such as 
the immune checkpoint inhibitors, and which cancers will not so that patients 
are not subjected to the side effects unnecessarily. Therefore, predictive 
biomarkers for use in these situations are also desirable. 
There are currently no targeted treatments for triple negative breast cancers 
and therefore all patients who are fit enough are offered chemotherapy as their 
only systemic treatment option, with all of its associated toxicities. Therefore 
targeted treatments for these patients are required, as well as novel treatments 
for other breast cancer patients who develop resistance to their primary 
therapy. 
In the search for new prognostic and predictive markers and for new treatment 
targets, interest has developed in the role of the tumour microenvironment in 
cancer growth.   
 
1.5 The Tumour Microenvironment 
The hallmarks of cancer, which a tumour requires in order to grow and spread, 
include the ability to sustain proliferative signalling, evade growth suppressors, 
resist cell death, induce angiogenesis, activate invasion and metastasis, and 
enable replicative immortality(55). Genomic instability and mutations within the 
cancer cells themselves are important for acquisition of these characteristics, 
but over the last 2-3 decades it has become increasingly recognised that the 
tumour microenvironment and the host immune system also play an important 
role in enabling a tumour to acquire these characteristics and therefore to 
spread. Various components of the tumour microenvironment will be outlined 
below.  
1.5.1 Tumour-associated stroma 
A tumour is made up not just of a collection of malignant cells, but also of 
tumour-associated stroma contained within which are a number of different cell 
types(56). These include, endothelial cells, pericytes, cancer-associated 
fibroblasts and immune inflammatory cells. These components interact with the 
cancer cells in complex ways which may promote growth of the tumour by 
secretion of signalling molecules including growth factors, cytokines, 
chemokines and pro-angiogenic factors. There is evidence that the tumour 
actively recruits these cells to the tumour microenvironment to help facilitate 
its progression(56). The role of specific types of immune cell in cancer 
progression is outlined in more detail below. 
1.5.2 Immune cells 
1.5.2.1 Innate immune cells 
Innate immune cells include mast cells, macrophages, neutrophils, dendritic 
cells (DC), basophils, eosinophils and NK cells. Their role in immunity includes 
the identification and removal of foreign substances, recruitment of other 
immune cells through secretion of cytokines and antigen presentation to 
adaptive immune cells. 
 
Neutrophils are the first inflammatory effectors recruited, followed by 
monocytes which differentiate into macrophages in tissues. These are then the 
main source of growth factors and cytokines which then act on endothelial, 
epithelial and mesenchymal cells in the local microenvironment(57). Monocytes 
can also differentiate into DCs which migrate into tissue where they capture 
antigens then migrate to lymph nodes to stimulate T lymphocyte activation(57). 
Tumour associated macrophages may kill neoplastic cells but they also produce 
angiogenic and lymphangiogenic growth factors, cytokines and proteases which 
can promote tumour progression, as well as producing IL-10 which blunts the 
anti-tumour response by cytotoxic T lymphocytes(57). There is also evidence 
that neutrophils, mast cells and eosinophils may contribute to neoplastic growth 
through secretion of proteases, pro-angiogenic factors and chemokines(57).  
NK cells have been shown to kill tumour cells without MHC restriction(58). 
Reduced NK cell activity and dysfunction is associated with breast cancer 
progression and higher disease stage(58). There is also evidence that they 
potentiate the effects of certain chemo- and immunotherapies(58).  
1.5.2.2 Adaptive immune cells 
Lymphocytes form the cellular basis of the adaptive immune system. They can 
broadly be divided into B and T lymphocytes. B lymphocytes originate in the 
bone marrow and go on to mature in secondary lymphoid tissue such as the 
lymph nodes and spleen. They express clonally diverse cell surface 
immunoglobulin receptors recognising specific antigenic epitopes(59). In addition 
to antibody production, B lymphocytes have a role in T lymphocyte activation, 
antigen presentation, DC regulation and cytokine production(59). T lymphocytes 
develop in the thymus from bone-marrow derived progenitors(60). They 
differentiate initially by progressing from expressing neither to expressing both 
of the glycoproteins CD8 and CD4 and then become positive for one or the 
other(60). CD4+ lymphocytes differentiate into different subtypes in response to 
stimulation by various cytokines. These subtypes include the T helper 
lymphocytes (Th1, Th2, Th9, Th17 and Th22), T regulatory lymphocytes (Treg) 
and T follicular helper lymphocytes (Tfh). These different subtypes release 
different cytokine profiles and play a critical role in immune response(61). On 
 
exposure to an antigen, T lymphocytes proliferate and differentiate into effector 
cells which migrate to the site of infection and memory cells which ensure a 
faster immune response on subsequent exposure to that antigen(61). CD8+ 
effector cells have a cytotoxic function. A much less common type of T 
lymphocyte, γδT lymphocytes, are proposed to represent a link between the 
adaptive and innate immune response(62). 
In cancer, evidence suggests that lymphocytes may in some contexts have an 
anti-tumour role, for instance through direct cytotoxicity, but in others may 
have a pro-tumour role through the secretion of certain cytokines and pro-
angiogenic factors(63). As might be expected by their cytotoxic role, there is 
some evidence that high levels of CD8+ lymphocytes in breast tumours are 
associated with better outcomes(64-66). On the other hand, there is evidence 
that CD4+ lymphocytes are associated with worse cancer outcomes(64). Further 
work is required to better understand their role in primary operable breast 
cancer. 
1.6 Tumour features that may interact with the 
microenvironment 
1.6.1 Tumour necrosis 
Tumour necrosis is a feature of solid tumours. It is presumed to be the 
consequence of rapid tumour growth which exceeds the rate of growth of its 
blood supply leading to ischaemia(67). However, necrosis can still occur in small 
tumours and therefore impaired oxygen delivery to tissues may be a factor(68). 
Tumour necrosis has been reported to be independently associated with poor 
prognosis in a number of cancers including bladder(69), renal(70), lung(71) and 
colorectal cancers(67). There are few studies in breast cancer but one small 
study has reported an association between necrosis and reduced CSS(72). A 
couple of studies, one in breast(73) and one in colorectal cancer(68), report that 
this association is not independent of systemic and local inflammation. This has 
led to the suggestion that inflammation related to tumour necrosis and stimulus 
of inflammatory pathways by release of mediators by necrotic tissue may be 
important in the link between necrosis and poor prognosis(68). Further work to 
 
investigate the prognostic role of necrosis in breast cancer and its relationship to 
inflammation and the tumour microenvironment is warranted.   
1.6.2 Tumour budding 
Tumour budding is a feature which has been observed in some tumour types, 
particularly in colorectal cancer, though it was first described in stomach 
cancer(74). The term refers to single tumour cells or small clusters which are 
detached from the main tumour(75). They are most commonly observed in the 
stroma, at the invasive front of the tumour. These buds may show disruption of 
E-cadherin expression and overexpress markers of invasion, locomotion, 
migration and EMT, leading to the hypothesis that tumour budding is involved in 
the process of tumour dissemination(76) and therefore poorer prognosis. Indeed, 
associations between high numbers of tumour buds and vessel invasion, lymph 
node and distant metastases have been reported. A role for the tumour stroma 
in promoting tumour budding has been hypothesised in view of correlations 
observed between the two(75). 
The association between high tumour budding and poorer prognosis has been 
widely reported in colorectal cancer(74), driving interest in its use clinically as a 
prognostic marker. However, its adoption in clinical practice has been slowed by 
the lack of consensus in terms of definition and assessment. For example, 
tumour buds have been variably defined in the literature as clusters of >5 
malignant cells, clusters of <4 malignant cells and the definition more recently 
favoured of isolated cells or clusters <5 malignant cells(74). Additionally, 
budding can be assessed either by H&E staining or by pancytokeratin staining. 
With a view to addressing these issues, the International Tumor Budding 
Consensus Conference 2016 agreed a standardised method for assessment and 
reporting of tumour budding and recommended that budding should be included 
in guidelines and protocols for colorectal cancer reporting(77). Subsequently, it 
has been included in the College of American Pathologists guidelines for 
reporting and is included in the Union for International Cancer Control’s TNM 
classification for colorectal cancer(75). 
Despite the bulk of literature regarding tumour budding in colorectal cancer, 
little is known about its role in breast cancer. A few small studies have reported 
 
an association between tumour budding and breast cancer outcomes(78-80). 
They observe associations between high tumour budding and lymph node 
metastases, lymphovascular invasion and poorer survival outcomes. However, 
they are small studies, two of them analysing fewer than 200 patients(79, 80), 
which limits subtype analysis, and all use a different threshold to define high 
budding. Therefore, further work in larger cohorts is warranted to validate these 
observed associations, to define a consistent threshold for high budding and to 
establish whether there is a potential clinical role for its routine assessment in 
breast cancer.  
1.7  The JAK/STAT3 Cell Signalling Pathway 
To affect tumour growth, signals from the tumour microenvironment must be 
conveyed to the tumour cell nucleus via cell signalling pathways. One of these 
pathways is the JAK/STAT3 cell signalling pathway. 
1.7.1 The pathway 
Signalling pathways transmit signals from external stimuli to the cell nucleus to 
control gene expression. The Janus kinase (JAK)/signal transducers and 
activators of transcription (STAT) pathway is an evolutionary conserved 
signalling pathway which facilitates direct communication between 
transmembrane receptors and the nucleus(81). It is stimulated by a vast array of 
cytokines and growth factors(82). The pathway mediates numerous cellular 
processes including proliferation, differentiation, migration and apoptosis which 
are critical processes in haematopoiesis, immune development, stem cell 
maintenance and mammary gland development(82, 83). There are 4 JAKs (JAK1, 
JAK2, JAK3 and TYK2) and 7 STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, 
STAT5b and STAT6) in mammals(81). STAT3 is recognised as an important factor 
in mammary epithelial cell growth, differentiation, apoptosis and involution(84, 
85). 
The JAK/STAT3 pathway is stimulated by IL-6. Il-6 binds to either the 
membrane-bound or soluble IL-6 receptor, which induces homodimerization of 
glycoprotein 130 (gp130) and a high affinity functional receptor complex of 
IL6/IL6R/gp30 is formed(86). This leads to activation of receptor-associated JAKs 
 
which can then phosphorylate each other as well as the intracellular portion of 
their receptors and cytoplasmic STAT3(83). This phosphorylation occurs at a 
conserved tyrosine residue (Tyr705) near the C-terminus(82), permitting the 
dimerisation of STAT3 which then translocates to the nucleus where the dimer 
binds to regulatory DNA sequences to activate or repress target gene 
transcription(82).  
This pathway in isolation is relatively straightforward. However, it is 
complicated by interactions with other cell signalling pathways. For example, 
STAT3 can also undergo phosphorylation of a serine residue (Ser727) within the C 
terminus via the mitogen-activated protein kinase (MAPK) pathways, particularly 
the classical extracellular signal-regulated kinase (ERK) pathway(87). The 
JAK/STAT3 pathway also interacts with the NFκB pathway at multiple levels(88). 
A further complicating factor is that STAT3 can also localise to mitochondria 
where it promotes oxidative phosphorylation and membrane permeability(81).   
 
 
Figure 1-7. The Il-6/JAK/STAT3 pathway.  Diagram illustrating the IL6/JAK/STAT3 pathway. IL6 
binds with the IL6 receptor leading to activation of JAKs and phosphorylation of STAT3 which 
dimerises, translocates to the nucleus and regulates gene transcription. 
1.7.2 The JAK/STAT3 pathway in solid tumours 
The hallmarks of cancer include activating invasion and metastasis, enabling 
replicative immortality, inducing angiogenesis, resisting cell death, sustaining 
proliferative signalling and evading growth suppressors(55). Given the influence 
the JAK/STAT3 pathway has on cell proliferation, migration and apoptosis, it is 
not surprising that aberrant activation of the pathway has been identified in a 
number of tumours, both haematological and solid(81). In addition to 
haematological malignancies, high levels of STAT3 activation have been 
observed in head and neck, breast, brain, prostate, renal, pancreatic and 
ovarian tumours and melanoma(85). Several mechanisms support a pro-
tumorigenic role for STAT3. Firstly, activation of STAT3 can bring about 



















example, constitutive STAT3 activation is required for oncogenic transformation 
by v-Src(85).  Secondly, activation of STAT3 mediates tumour-promoting 
inflammation by promoting pro-oncogenic inflammatory pathways and opposing 
anti-tumour immune responses(88). 
1.7.3 The JAK/STAT3 pathway in breast cancer 
As in other tumours, constitutively activated STAT3 has been observed in breast 
cancer cell lines but not in non-malignant mammary epithelial cell lines(89, 90). 
In preclinical studies, high activation of STAT3 has been reported to be 
associated with increased breast cancer cell proliferation, survival and 
metastases(91-94). Studies have shown STAT3 to be required for migration and 
metastases in mice(95, 96). In addition to this, other cell line studies have 
reported apoptosis, growth inhibition and reduced invasion in breast cancer cells 
when STAT3 expression is suppressed(97-100).  
This preclinical evidence suggests a pro-tumourigenic role for STAT3 in breast 
cancer. However, studies involving human tissue and cancer outcomes have 
provided mixed results to date. In human breast cancer tissue, one small study 
reported no difference in total STAT3 expression levels compared to paired 
normal tissue from the same patient, but did observe increased pSTAT3(Ser727) 
expression in the tumour compared to adjacent non-cancer tissue in 62% of 
patients(101). A positive correlation with cancer stage was observed. 
Conversely, another study reported that expression levels of pSTAT3(Tyr705) 
decreased as tumours progressed (normal tissue compared to DCIS, to invasive 
tumours, to lymph node metastases) in unpaired tissues(102).  
Concerning the prognostic role of STAT3, one small study reported high levels of 
total STAT3 expression (nuclear and/or cytoplasmic) to be associated with worse 
overall survival (OS)(103) whereas a slightly larger study found no statistically 
significant association between either nuclear or cytoplasmic expression and OS, 
though there was an association with better 5yr OS on univariate analysis(104). 
Other studies have investigated pSTAT3 as an indicator of STAT3 activation 
rather than total STAT3. Some studies have reported improved patient outcomes 
in those with high levels of nuclear pSTAT3(Tyr705) expression(104-107) though 
in one study this association was seen in lymph node positive cancers only(76) 
 
while in another only lymph node negative patients were included(104). On the 
other hand, one study reported no significant association between nuclear 
pSTAT3(Tyr705) association and OS, though improved survival was seen in low 
grade tumours on univariate analysis only(102). In view of this variation in 
results in the published literature, further studies in large breast cancer cohorts 
are warranted. 
1.8 Summary and thesis aims 
Despite significant improvements in breast cancer mortality over the last three 
to four decades, breast cancer remains the second most common cause of 
cancer-related death in females in the UK. It is a heterogenous disease with 
several different subtypes which behave and respond to treatments differently. 
There are a number of breast cancer treatments available with their own side 
effects and toxicities. It is important, therefore, to have risk stratification tools 
to aid treatment decisions. Several tools are already in widespread use, however 
each has limitations which may include impaired performance in certain groups 
of patients, cost and logistical issues. It is therefore desirable to identify new 
prognostic biomarkers which could be used alongside existing prognostic tools to 
further refine prognostic accuracy and tailor management for the individual 
patient. As prognostic markers are validated, it can also be anticipated that 
potential novel targets for treatment may be identified and this is particularly 
desirable in triple negative breast cancers who currently have no targeted 
treatments available, and in those other subtypes who develop resistance to 
initial therapies. To address these challenges, attention has turned towards the 
tumour microenvironment and the interactions of its components with the 
tumour. There is evidence that tumour stroma and various immune cells 
influence tumour progression via various cytokines and growth factors, and that 
the tumour in turn can recruit tumour-promoting cells to the tumour 
microenvironment. New prognostic biomarkers may therefore be identified 
within the tumour microenvironment. One cell signalling pathway which can 
transmit signals from the microenvironment to the tumour cell nucleus resulting 
in regulation of transcription of various genes related to tumour growth is the 
JAK/STAT3 pathway. Activation of this pathway has been observed in breast 
cancer, and various molecules which target different steps in the pathway are 
already in existence. Therefore, a better understanding of the role of this 
 
pathway in breast cancer is important, to ascertain whether targeting this 
pathway would be beneficial in any groups of breast cancer patients. With all of 
this in mind, the aims of this thesis were as follows: 
• to examine the prognostic significance of systemic markers of 
inflammation and the local inflammatory response in primary operable 
breast cancer and its molecular subtypes. 
• to investigate the prognostic role of tumour necrosis in primary operable 
breast cancer and its molecular subtypes. 
• to investigate the prognostic role of tumour budding in primary operable 
breast cancer and its molecular subtypes. 
• to investigate the prognostic role of tumour stroma, as measured by 
tumour stroma percentage, in primary operable breast cancer and its 
molecular subtypes. 
• to describe the IL-6/JAK/STAT3 pathway in primary operable breast 
cancer and its molecular subtypes. 
• to investigate the associations between systemic markers of 
inflammation, tumour necrosis, tumour budding, TSP, T lymphocyte 
subsets and components of the IL-6/JAK/STAT3 pathway along with known 
prognostic clinicopathological characteristics in primary operable breast 







2 Materials and Methods 
2.1 Patient cohorts 
The work in this thesis was carried out using two distinct patient cohorts. Ethical 
approval for the work was obtained from the West of Scotland Research Ethics 
Committee 3 (study number 12/WS/0131). Some studies were carried out using 
the ‘1800 cohort’ of 850 patients, some studies were carried out using the ‘FJ 
cohort’ of 450 patients, and some studies were carried out on the two cohorts 
combined. 
2.1.1 1800 cohort 
A cohort of 850 breast cancer patients had previously been formed. It is made up 
of patients who underwent curative resection for primary breast cancer at one 
of three breast units in Glasgow (Glasgow Royal Infirmary, Western Infirmary 
Glasgow or the Victoria Hospital Glasgow) between 1995 and 2001. All patients 
were managed according to the standard local protocols at the time of 
treatment. A database was available in the Glasgow Safehaven which included 
clinicopathological details, adjuvant treatment and survival and recurrence data 
for this cohort (database number GSH/18/ON/008, available at 
http://researchdata.gla.ac.uk/784/).  Details of proteins previously examined in 
Professor Edwards’ laboratory in this cohort were also available in the database. 
ER, PR and HER2 profiling had all been carried out retrospectively in the lab to 
ensure standardisation of technique, as techniques had changed in diagnostic 
labs over the time period of this cohort and routine HER2 testing had not been 
established. Characteristics of the cohort are summarised in Table 2-1.  
  
 




Number of patients 850 451 
Years tumours resected 1995-1998 2001-2007 
Median follow up (survivors) 162 months 145 months 
Events 
Breast cancer death 











































































































































Adjuvant endocrine therapy 
Yes (tamoxifen) 





































Table 2-1. Clinicopathological characteristics of the cohorts. Table detailing the composition 
and clinicopathological characteristics of the two patient cohorts used for studies in this thesis. 
 
2.1.2 1800 cohort tissue microarray construction 
The tissue microarray (TMA) for this cohort had been constructed previously by 
Clare Orange (currently Greater Glasgow & Clyde Biorepository Manager). 
Briefly, formalin-fixed paraffin-embedded (FFPE) tissue blocks were obtained 
from pathology archives and full sections cut. Following haematoxylin and eosin 
(H&E) staining, they were marked up by Dr Elizabeth Mallon (Consultant 
pathologist, Queen Elizabeth University Hospital, Glasgow) to identify tumour-
rich areas. Three 0.6mm cores were lifted from each block and placed into three 
separate recipient paraffin blocks. Several cores from other tissue types were 
also placed into the recipient blocks to act as positive controls during staining. 
TMA maps were drawn up so that each core could be identified by a unique 
TMAID which would link it anonymously to the data in the cohort database.  
2.1.3 FJ cohort 
The FJ cohort was made up of 450 patients who had undergone curative 
resection for breast cancer in the aforementioned Glasgow hospitals between 
2001-2007. Clinicopathological and follow up data for the patients was obtained 
retrospectively from patient notes (both electronic and physical), and from local 
laboratory systems. The key characteristics of this cohort are summarised in 
Table 2-1. Unfortunately, despite repeated attempts, over the course of this 
research it proved impossible to retrieve the tissue blocks for these patients so 
only previously-stained full section H&E slides were available for analysis in this 
cohort. Therefore ER, PR and HER2 data for these patients is extracted from the 
pathology reports.  
2.2 Systemic inflammatory markers 
For the FJ cohort, the Glasgow laboratory system was used to collect the 
preoperative haemoglobin, total white cell count, neutrophil, lymphocyte, 
monocyte and platelet counts for each patient. The closest date to the 
operation date was used. If this was more than 60 days preoperatively, the 
patient was excluded from analysis. This data is not available for the 1800-
cohort and unable to be obtained due to the cohort age. 
 
2.3 Haematoxylin and eosin staining of full sections 
Full section slides were cut from surplus tissue of both the 1800 and FJ cohorts, 
obtained from the NHS Research Scotland Greater Glasgow and Clyde 
Biorepository. These slides had been previously stained in the lab using 
haematoxylin and eosin (H&E) standard protocol. The slides were scanned using 
a Hamamatsu NanoZoomer (Welwyn Garden City, Hertfordshire, UK) into the 
Slidepath Digital Image Hub, version 4.0.9 (Slidepath, Leica Biosystems, Milton 
Keynes, UK) at x20 resolution. 
2.3.1 Necrosis scoring  
Scoring for the extent of tumour necrosis was carried out in the 1800 cohort by 
Fadia Gujam and for the FJ cohort by the author. Both scorers were blinded to 
clinicopathological data and outcomes. Using Slidepath software and a high-
definition computer screen, each slide was initially assessed at 10x 
magnification to look for areas of necrosis. Subsequently, at 20x magnification, 
the extent of necrosis was visually assessed as the proportion of the visual field 
occupied by necrotic tissue, using a method adapted from Ikpatt et al(108). This 
was recorded as none (no necrosis or only single necrotic cells), mild or focal 
(<25% field occupied by necrotic tissue), moderate (25-50% field occupied by 
necrotic tissue) or extensive (>50% field occupied by necrotic tissue). For 
analysis, patients were grouped as low (no or <25% necrosis) and high (>25% 
necrosis). Only necrosis within the invasive tumour was included, comedo 
necrosis was visually excluded. 
2.3.2 Tumour budding scoring 
Scoring for tumour budding was carried out in the 1800 cohort by Fadia Gujam 
and for the FJ cohort by the author. Using Slidepath software and a high-
definition computer screen, the invasive edge was identified at 4x 
magnification. At 20x magnification, a 10mm2 grid was placed at the invasive 
tumour edge. The number of tumour buds within the grid was counted. A tumour 
bud was defined as an isolated group of 1-5 tumour cells. This process was 
repeated for 4 further grids placed at different locations along the invasive 
tumour edge. The highest of the 5 bud counts was used for analysis. Patients 
were subsequently divided into low budding (<20 buds) or high budding (>20 
 
buds) for analysis, as this threshold has previously been reported to have the 
highest prognostic power(78).  
2.3.3 Tumour-stroma percentage scoring 
Scoring for the tumour-stroma percentage (TSP) was carried out in the 1800 
cohort by Fadia Gujam and for the FJ cohort by the author. Using Slidepath 
software and a high-definition computer screen, at 10% magnification, a 
representative area of tumour was selected to include tumour cells at all 4 
corners of the visual field. The proportion of stroma within the visual field was 
visually assessed and recorded. For analysis, patients were grouped as TSP <50% 
or >50%, as previously described(72). 
2.3.4 Klintrup-Makinen scoring 
Klintrup Makinen (KM) scoring was carried out in the 1800 cohort by Fadia Gujam 
and for the FJ cohort by the author. Using Slidepath software and a high-
definition computer screen, at 10% magnification the invasive tumour edge was 
visually assessed for the degree of peri-tumoral inflammatory infiltrate. This was 
scored as 0 (no inflammatory infiltrate at invasive tumour edge), 1 (patchy 
inflammatory infiltrate at invasive tumour edge), 2 (continuous layer of 
inflammatory cells at invasive tumour edge) or 3 (‘cup’ of inflammatory 
infiltrate at invasive tumour edge). 
2.4 Immunohistochemistry 
IHC was used to identify specific types of immune cell, for example different 
subsets of T lymphocytes, and to visualise levels of expression of various 
components of the IL-6/JAK/STAT3 pathway. The technique uses a specific 
antibody to the target antigen of interest. A labelled secondary antibody is then 
used which reacts with the primary antibody. A chromagen is applied as a signal 
enhancer so that expression of the antigen can be visualised under a light 
microscope as a brown stain. The slides are then counterstained with 
haematoxylin so that the primary stain is more distinct. The various steps in the 
process are described in more detail below. There was some variation between 
antibodies in terms of specific timings of stages of the protocol and types of 
reagents used, because of variability in the optimal conditions for certain 
 
antibodies or changed suppliers to the laboratory. These variations are 
summarised in Table 2-2. A negative control slide was included in each batch of 
slides. Each TMA slide included a row of cores of liver, kidney, prostate, lung, 
colon, tonsil and pancreas tissue to act as positive controls for the various 
antibodies. 






































































































































Table 2-2. Antibodies and conditions. Table detailing the antibodies used in the 
immunohistochemistry studies in this thesis with the retrieval, blocking and incubation conditions 
and the secondary antibody used for each. 
2.4.1 TMA construction and slide preparation 
Sections from previously-constructed patient TMAs from the 1800 cohort were 
requested from the NHS Research Scotland Greater Glasgow and Clyde 
 
Biorepository. TMAs were cut into 2.5µm thick paraffin wax sections and 
mounted onto slides. They were baked overnight at 56ºC prior to being stored at 
4ºC. Before staining they were baked again for 20 minutes at 56ºC to minimise 
the risk of core loss. 
2.4.2 Dewaxing and rehydration 
Slides were immersed in histoclear twice for 3 minutes to dewax them. They 
were then dehydrated by immersion in a series of graded alcohols (100% twice 
for 3 minutes, 90% once for 2 minutes then 70% once for 2 minutes) before being 
rinsed in water for 10 minutes. 
2.4.3 Antigen retrieval 
Antigen retrieval is carried out to break down any protein crosslinks which have 
formed during the tissue fixation process, unmasking the antigen so that the 
antibody can bind. Heat-mediated antigen retrieval was carried out using one of 
two buffer solutions. The TRIS-EDTA buffer is made up of 0.55g Tris Base (Fisher 
Bioreagents) and 0.37g sodium EDTA (Diaminoethanetetra-acetic acid disodium 
salt dihydrate, Fisher Scientific) in 1L distilled water. The citrate buffer is made 
up of 2.41g tri-sodium citrate dihydrate (Fisher Scientific) and 0.346g citric acid 
(Sigma-Aldrich) in 1L distilled water. The buffer was adjusted to the required pH 
using 0.1M hydrochloric acid or 0.1M sodium hydroxide. The buffer and pH used 
for each antibody is detailed in Table 2-2.The buffer was heated for 13.5 
minutes before the slides were immersed in it within a pressure cooker. They 
were brought up to pressure before being heated at pressure in a microwave for 
5 minutes. The slides were then left to cool in the buffer for 30 minutes prior to 
rinsing in water. 
2.4.4 Blocking endogenous peroxidase and non-specific binding 
To block binding of the antibody to endogenous peroxidase, slides were 
immersed in 3% hydrogen peroxide for 20 minutes. They were then washed in 
Tris buffer solution (TBS) twice for 5 minutes. TBS was made up of 300g Tris-
Base and 438g sodium chloride (VWR Chemicals) in 8L distilled water brought to 
pH 7.5, and then was further diluted in distilled water 10x prior to use.  
 
Next, a ring was drawn around the tissue on each slide using a Dako Pen (S2002, 
Dako, Glostrup, Denmark) to create a hydrophobic barrier. To block the binding 
of antibody to non-specific proteins in the tissue, which would result in 
background staining, each slide was covered with 500µl of 1.5%, 5% or 10% 
normal horse serum (Vector) (horse serum diluted in TBS) for either 30 or 60 
minutes in a dark box.  
2.4.5 Incubation with primary antibody 
The blocking solution was tipped off the slides and then each slide covered with 
200µl of the appropriate dilution of the primary antibody. Antibody was diluted 
in antibody diluent (S0809, Dako, Glostrup, Denmark). The negative control slide 
was covered with antibody diluent only. The slides were then incubated within 
the dark box either overnight at 4ºC or for 30 minutes at room temperature. 
2.4.6 Incubation with secondary antibody 
Slides which had been incubated at 4ºC were first brought to room temperature. 
Slides were washed twice in TBS for 5 minutes. Each slide was then covered with 
Dako REAL™ EnVision™ (K5007, Dako, Glostrup, Denmark) or ImmPRESS™ HRP 
Reagent Kit (MP-7500, Vector, Burlingame, CA, USA) and incubated at room 
temperature in the dark box for 30 minutes before washing twice in TBS for 5 
minutes.  
2.4.7 Detection and visualisation 
The chromogen used for visualisation was 3,3’-Diaminobenzidine (DAB). One of 
two DAB peroxidase substrate kits was used. When using the DAB Peroxidase 
Substrate Kit (SK-4100, Vector, Burlingame, CA, USA) 2 drops of buffer, 4 drops 
of DAB and two drops of hydrogen peroxidase were added to 5mls of distilled 
water. If the ImmPACT™ DAB Peroxidase Substrate kit (SK-4105, Vector, 
Burlingame, CA, USA) was used, 1 drop/30µl ImmPACT™ DAB chromogen 
concentrate was added per 1ml of ImmPACT™ DAB diluent. Each slide was 
covered in the DAB solution and left for 10 minutes prior to washing in water for 
10 minutes.  
 
2.4.8 Counterstaining 
Counterstaining was carried out by immersing the slides in Harris haematoxylin 
for 1 minute then washing in running water. The slides were then immersed in 
Scott’s tap water for 45 seconds before returning to the water. Scott’s tap water 
was made using 40g magnesium sulphate and 7g sodium bicarbonate in 2L 
distilled water. 
2.4.9 Dehydration and mounting 
The slides were immersed in a series of graded alcohols (70% for 1 minute, 90% 
for 1 minute, 100% twice for 1 minute) followed by histoclear twice for 1 
minute. Finally, they were mounted on individual cover slips using Omnimount 
Histological Mounting Medium (National Diagnostics) and allowed to dry. The 
slides were scanned in the same way as the full sections described above. 
2.4.10 Scoring of immune cells 
Antibodies to specific cell surface markers for each individual immune cell of 
interest were used. For example, CD4 was used for helper T lymphocytes and 
CD8 for cytotoxic T lymphocytes. A quantitative method was used to score the 
number of specific types of immune cell in each core. At 20x magnification, the 
number of stained cells in the tumour and in the stroma of each core were 
counted and recorded separately. For each patient, 3 cores were scored and the 
mean calculated. For analysis, patients were divided into high and low groups 
using either a ROC curve-derived threshold or the median.   
2.4.11 Weighted histoscore 
The weighted histoscore (WHS) was used for scoring of the level of expression of 
various components of the IL6/JAK/STAT3 pathway, including IL6 receptor, 
JAK1, JAK2, pSTAT3 (Tyr705), pSTAT3 (Ser727) and total STAT3. Protein 
expression levels were assessed visually on a single high definition computer 
monitor at 20x magnification by a scorer blinded to clinicopathological data and 
outcomes. The proportion of cells with no staining (score 0), weak staining 
(score 1), moderate staining (score 2) and strong staining (score 3) was 
recorded. The WHS was calculated as (0x proportion score 0) + (1x proportion 
 
score 1) +(2x proportion score 2) + (3x proportion score 3). A separate score was 
recorded for tumour nuclear staining, tumour cytoplasmic staining, tumour 
membranous staining (where applicable) and stromal cell staining. 10% of cores 
were co-scored independently by a second scorer and the correlation coefficient 
calculated to ensure good agreement. Three cores were scored for each patient 
and the mean of the three scores calculated. For analysis, either a ROC-derived 
threshold, the median or tertiles were used to divide patients into high and low 
expression groups.   
2.5 RNA scope 
RNA scope was used to stain for IL-6 RNA expression within cells, as it was not 
possible to optimise IHC for the IL-6 protein itself. This is an in situ hybridisation 
assay for detection of target RNA. Slides are first pre-treated to make the cells 
permeable and unmask the target RNA. A target Z probe to the RNA is applied. 
The lower region of the base probe has an 18-25 base region complementary to 
the target RNA. To ensure specificity, two Z probes are required to bind to the 
target RNA before signal amplification will occur. Preamplifiers hybridise to the 
binding site formed by the double Z probe, then amplifiers bind to the multiple 
binding sites on the preamplifier. Labelled probes containing a chromogenic 
enzyme bind to the amplifiers to allow visualisation.  
2.5.1 RNA scope for IL-6 
Staining of freshly cut (<2weeks) TMA slides was carried out using a Leica Bond 
RX autostainer, strictly adhering to the manufacturer’s instructions, by Colin 
Nixon (head of histology department, Cancer Research UK Beatson Institute, 
Glasgow; staining was carried out as a service). Briefly, in situ-hybridisation 
detection for IL-6 and PPIB (Advanced Cell Diagnostics, Hayward, CA, USA) mRNA 
was performed using RNA scope 2.5 LS (Brown) detection kit(Advanced Cell 
Diagnostics, Hayward, CA, USA). This was done for all patients in triplicate. PPIB 
was selected as a housekeeping (HK) gene.  
2.5.2 Scoring of slides stained for IL-6 RNA 
Stained slides were scanned using a Leica SCN400f slide scanner. HALO™ Image 
Analysis Software (PerkinElmer, Waltham, MA, USA) was used to analyse the 
 
slides. Algorithms were set up within the software to distinguish between 
tumour and stroma. The software quantified the number of probe copies per µm2 
for each tissue core in tumour and stroma separately. This analysis was carried 
out both for the slides stained with the IL-6 probe and those stained with the HK 
probe. For each patient, means of the three cores were calculated for IL-6 probe 
copies in tumour, IL-6 copies in stroma, HK copies in tumour and HK copies in 
stroma. The quantity of IL-6 was normalised by dividing by the number of HK 
copies in each location to give a ratio. For example, mean IL-6 copies per µm2 in 
tumour / mean HK copies per µm2 in tumour = tumour IL-6/HK ratio. This ratio 
value was used in the further analysis. Patients were divided into tertiles of 
high, medium and low IL-6 expression for analysis. 
2.6 Statistical analysis 
For each of the variables described above, associations with clinicopathological 
characteristics were calculated using the appropriate Chi square test. The 
relationship with oncological outcomes was assed using Kaplan Meier survival 
analysis and log rank test. 5 and 10 year survival rates were obtained from life 
tables and recorded as percentage of population surviving. Cox regression 
survival analysis was carried out for each variable of interest, as well as other 
known prognostic factors, and recorded as a hazard ratio with 95% confidence 
interval (CI). Variables which were statistically significant (p<0.05) on univariate 
analysis were entered into the multivariate analysis using a backwards 
conditional model. For all analysis, statistical significance was defined as 
p<0.05. All analysis was carried out using SPSS software (version 22, IBM Corp, 
Armonk, NY, USA). 
2.7 Transcriptomics 
Transcriptomics involves the study of the transcriptome, the RNA transcript of 
the genome. Comparison of the transcriptome of different populations can lead 
to the identification of specific genomic sequences associated with a specific 
phenotype or function. We carried out RNA sequencing for a small sub-cohort of 
the 1800 cohort with the aim of identifying specific sequences associated with 
tumour budding. 
 
2.7.1 Patient selection 
Due to financial constraints, a cohort of 50 patients was selected to undergo 
whole transcriptome sequencing. Patients were selected from within the 1800 
cohort as these patients had tissue blocks which were easily accessible. Only ER 
negative patients were selected for reasons related to our tumour budding 
results which will be fully explained later in this thesis. Within these 
specifications, the 25 patients with the highest and the 25 patients with the 
lowest tumour budding counts, for whom tissue blocks were available, were 
selected. 
2.7.2 Preparation of slides 
One 5µm full tissue section per patient was cut from the tissue blocks by Colin 
Nixon using a Finesse microtome. They were fixed to glass slides and passed on 
immediately to Ditte Anderson (Scientist, BioClavis Ltd) untreated and unbaked 
for sequencing. This was to ensure the tissue was as fresh as possible to reduce 
oxidation.  
2.7.3 RNA sequencing using TempOSeq® 
This technique involves targeting RNAs with detector oligos and removing excess 
probes and enzymatic inhibitors. Then, correctly hybridised detector oligos are 
ligated and amplified through primer landing sites that are shared among all 
probes. The RNA sequencing was carried out by Ditte Anderson and Harper van 
Steenhouse of Bioclavis Ltd, using TempOSeq® (BioSpyder, Carlsbad, CA, USA), 
using the protocol outlined below.  
Areas of interest were excised from FFPE slides and added to 80µL BioSpyder 1 x 
FFPE lysis buffer. Each sample was overlaid with mineral oil and incubated at 
95°C for 5 minutes to dissolve paraffin. FFPE lysate was incubated in FFPE 
protease reagent for 30 minutes at 37°C and homogenized by vortexing. The 
lysate was combined with annealing buffer and detector oligonucleotides (DOs) 
and incubated overnight at 45°C following a ramp in temperature from 70°C to 
45°C. Unbound DOs were degraded by a nuclease mix followed by ligation of 
bound DOs into a complete probe sequence. The enzymes were deactivated by 
 
incubation at 80°C for 15 minutes and PCR was performed to amplify ligated 
probes and samples were purified. 
2.7.4 Data analysis 
Initial analysis was carried out by Bioclavis using the TempOSeqR data analysis 
program (BioSpyder technologies, USA). Assay performance metrics were 
calculated using positive and negative controls. Heatmaps were constructed and 
principle component analysis was carried out to identify any clustering of 
samples. Differential expression analysis was carried out using MA plots. Results 
of this analysis as well as the raw data were transferred back to EM in a 
Microsoft® Office Excel 16 (Microsoft, Redmond, WA, USA) spreadsheet with the 
TMAID for each patient. The raw data included the log2 fold change and 
adjusted p value for 22357 genes and this was used to identify genes with a 
statistically significant (adjusted p<0.10) fold change between cohorts. The data 
was ordered by log2 fold change to identify the top over-expressed and the top 
under-expressed genes in the high budding cohort.
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3 The prognostic role of preoperative circulating 
markers of the systemic inflammatory response 
in primary operable breast cancer 
3.1 Introduction 
Breast cancer is the most common cancer in females and the second most 
common cause of cancer death in females in the UK(109). It is a heterogenous 
disease with considerable variation in tumour behaviour and prognosis. Tumour 
factors such as tumour size, grade, nodal involvement, ER and PR status and 
HER2 status are well recognised to be associated with prognosis (110-114). More 
recently, genomic assays have been used as additional prognostic tools to 
stratify risk and to aid in treatment decisions, particularly regarding 
chemotherapy in hormone receptor positive patients(115-117). However, these 
tests are comparatively expensive and not routinely available in all units 
worldwide. Therefore, clinical prognostic markers are still required. 
Increasingly it is being recognised that the host systemic inflammatory response 
has a role to play in tumour progression(56, 118, 119). Therefore, a number of 
serum inflammatory markers, and scores made up of their components, have 
been investigated as routinely available prognostic markers in several cancers. 
These include components of the differential white cell count (WCC) such as 
neutrophils, monocytes and lymphocytes, platelets, and also acute phase 
proteins such as CRP and albumin. Scores made up of combinations of these 
markers include the neutrophil-lymphocyte ratio (NLR), the platelet lymphocyte 
ratio (PLR), the lymphocyte-monocyte ratio (LMR) and the modified Glasgow 
Prognostic Score (mGPS) which gives a score 0-2 based on elevation of CRP and 
low albumin. These scores have been shown to have prognostic value, mainly in 
lung and gastrointestinal cancers, particularly in advanced disease(120, 121). 
To date there is little consensus as to the prognostic role and clinical utility of 
these markers in primary operable breast cancer. In this context, a systematic 
review and meta-analysis of the literature relating to circulating markers of the 
systemic inflammatory response as prognostic markers in primary operable 
breast cancer was carried out. Secondly, a cohort study was carried out to 
 
investigate the prognostic role of these markers in primary operable breast 
cancer in our population. 
3.2 Materials and methods 
3.2.1 Systematic review 
A search up to July 2017 was made of the databases MEDLINE and Embase 
(Excerpta Medica Database) using combinations of MeSH terms and keywords. 
Search terms used were ‘breast neoplasms’, ‘white cell count’, ‘neutrophils’, 
‘lymphocytes’, ‘monocytes’, ‘platelets’, ‘neutrophil-lymphocyte ratio’, 
‘platelet-lymphocyte ratio’, ‘lymphocyte-monocyte ratio’, ‘albumin’, ‘CRP’, and 
‘Glasgow Prognostic Score’. Titles and abstracts were initially reviewed for 
suitability. Duplicates were removed. Full text articles of the remaining titles 
were then obtained and reviewed. Inclusion criteria were, available full English 
language papers investigating a measurable prognostic outcome (overall survival, 
disease-free survival, cancer specific survival, or recurrence), relating to one or 
more preoperative serum inflammatory marker or a related score. To be 
included in the review they required to have investigated breast cancer patients 
only or, if several cancers were being studied, have identifiable outcomes for 
the breast cohort within it. Studies were excluded if they included metastatic 
patients only, did not have a recordable outcome measure, had fewer than 100 
patients (to reduce the risk of bias associated with smaller studies), fewer than 
10 outcome events, were published before 2000 (to reflect modern treatment 
practices), or studied levels of inflammatory markers taken after surgery. Where 
two papers by the same author appeared to use the same cohort, the more 
recent paper with the larger cohort and more mature follow up was retained. In 
addition, references in the included papers were checked for any other relevant 
studies. Results are presented in a descriptive fashion for each inflammatory 
marker in turn. 
3.2.2 Meta-analysis 
Meta-analysis for each inflammatory marker was carried out where there were 
three or more studies which reported a hazard ratio with a 95% confidence 
interval, and which used the same outcome measure. The hazard ratio from 
 
multivariate analysis was used unless unavailable, in which case the hazard ratio 
from univariate analysis was used. Review Manager 5.3 was used for all analysis. 
3.2.3 Pilot study 
3.2.3.1 Data collection 
The FJ cohort was used for this study as patient identifiers were available to 
allow searching of lab systems, and because this is the more recent of the two 
cohorts so blood results were more easily retrievable. Preoperative lab results, 
postoperative pathology and clinical outcome data were collected as described 
in chapter 2. For OS and CSS, patients were censored at the time of data 
collection (August 16).  
3.2.3.2 Analysis 
Components of the full blood count, CRP and albumin were first analysed as 
continuous variables. Then, for each component of the full blood count 
analysed, ROC curves were used to determine the threshold value for division 
into high and low groups. Where this did not produce a clear threshold, tertiles 
or the median were used. Statistical analysis was carried out, as described in 
chapter 2, to determine associations between various circulating markers of the 
systemic inflammatory response, or scores and ratios described in the literature, 
and CSS and OS. 
  
 
3.3 Systematic review and meta-analysis results 
2542 results were obtained from the initial search. After review of the titles for 
relevance, abstract review, removal of duplicates and non-English language 
papers, and application of the inclusion and exclusion criteria, 30 studies were 
included in the final review as shown in the PRISMA diagram (Figure 3-1). 18 
studies were suitable for inclusion in meta-analysis.  
 
Figure 3-1. PRISMA flow diagram.  Fig.1 PRISMA flow diagram detailing the process of study 
selection. 
 
3.3.1 The prognostic role of preoperative WCC and its components 
Table 3-1 to Table 3-6 summarise the findings of four studies which investigated 
the WCC or its individual components(122-125). They range from a small 
retrospective cohort study of 350 patients(122) to a large epidemiological study 
which included little detail regarding tumour pathology in its report(123). One 
study analysed each inflammatory marker as a continuous variable while the others 
selected set thresholds for analysis. None of the studies reported a significant 
association with survival or cancer recurrence. For WCC and its components there 
were insufficient studies for meta-analysis. 
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Table 3-1. The prognostic role of preoperative WCC. Papers which investigated the prognostic role of preoperative White Cell Count. Rec = recurrences, 
CDs = cancer deaths, NCDs = non cancer deaths, UV =univariate, MV = multivariate. 
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2288 494 deaths All stages Lum A 48.9% 












Table 3-2. The prognostic role of preoperative neutrophils.  Papers which investigated the prognostic role of preoperative neutrophils. Rec = recurrences, 
UV =univariate, MV = multivariate. 
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Table 3-3. The prognostic role of preoperative lymphocytes.  Papers which investigated the prognostic role of preoperative lymphocytes. Rec = 















2014 Turkey Retrospective 
cohort 
350 48 deaths,  
59 rec (14 local 





ER+ 55.4%  


















2015 China Retrospective 
cohort 
2000 326 deaths All primary 















Table 3-4. The prognostic role of preoperative monocytes. Papers which investigated the prognostic role of preoperative monocytes. Rec = recurrences, 
UV =univariate, MV = multivariate. 
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Table 3-5. The prognostic role of preoperative eosinophils. Papers which investigated the prognostic role of preoperative eosinophils. Rec = recurrences, 
UV =univariate, MV = multivariate.  
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Table 3-6. The prognostic role of preoperative basophils. Papers which investigated the prognostic role of preoperative basophils. Rec = recurrences, UV 





3.3.2 The prognostic role of preoperative platelets 
Three studies investigating the prognostic role of the platelet count met the 
inclusion criteria (Table 3-7). ER positive disease predominated in these studies, 
particularly in the largest study where 91% of its participants had ER positive 
disease(126). This and a smaller study(127) which used thresholds for analysis 
(>400g/L and 350g/L respectively) reported a significant independent association 
between high platelets and worse cancer outcomes, whilst the smallest study, 
which analysed platelets as a continuous variable, reported no association(122). 
There were again insufficient studies for meta-analysis.
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Table 3-7. The prognostic role of preoperative platelets. Papers which investigated the prognostic role of preoperative platelets. Rec = recurrences, CDs 
= cancer deaths, UV =univariate, MV = multivariate. 
 
3.3.3 The prognostic role of preoperative NLR  
Eighteen papers were included which investigated the relationship of the NLR to 
outcome in operable breast cancer (Table 3-8). All the cohorts were dominated by 
ER positive disease, except one study which included exclusively ER negative 
disease(128). All but 5 of them(122, 129-132) (one of which analysed NLR as a 
continuous variable) reported a significant association between high NLR and at 
least one of the cancer outcomes studied. Thresholds used ranged from 1.93-5. 
Therefore, following the overall meta-analysis for the different outcomes, sub-
analyses were carried out for different thresholds, where the number of studies 
allowed. 
 











2013 US Retrospective 
cohort 
437  74 deaths All stages  ER+ 76.2% 
ER- 23.8% 
 










2013 Korea Retrospective 
cohort 



















2014 Belgium Retrospective 
cohort 





















2014 Turkey Retrospective 
cohort 
350 48 deaths, 
59 rec (14 local 







ER+ 55.4%  
ER- 37.7%  
 














2014 Japan Retrospective 
cohort 






















2014 S. Korea Retrospective 
cohort 




received NAC  
 












2014 Turkey Retrospective 
cohort 























2014 Austria Retrospective 
cohort 






Lum B 34.9% 
Basal 9.7% 
HER2 4.2% 








2014 China Retrospective 
cohort 





Lum A 57.9% 





















2015 S Korea Retrospective 
cohort 
3116 Data not given All primary 
operable  
Lum A 58.8% 




















2015 Malaysia Retrospective 
cohort 
































2015 China Retrospective 
cohort 
487 73  All primary 
operable 
Lum A 12.7% 
Lum B 50.1% 
HER2 12.1% 
TNBC 19.3% 








2015 China Retrospective 
cohort 























2015 Austria Retrospective 
cohort 
247 95 rec All early stage 
who underwent 
neoadj therapy 














2016 Austria Retrospective 
cohort 


























2016 China Retrospective 
cohort 



















2017 Brazil Retrospective 
cohort 
2288 494 deaths All stages Lum A 48.9% 
























2017 Japan Retrospective 
cohort 












Table 3-8. The prognostic role of preoperative NLR. Papers which investigated the prognostic role of preoperative neutrophil-lymphocyte ratio. Rec = 
recurrences, CDs = cancer deaths, Lum = luminal, UV =univariate, MV = multivariate. 
 
 
8 studies used an outcome of DFS(128, 135-138, 141-143), with a total of 5169 
patients and 1355 events (one study did not publish event data). This showed a 
significant association of NLR with DFS (pooled HR 1.87, 95% CI 1.59-2.20, 
p<0.00001). Heterogeneity was minimal (I2=0% p=0.58) (Figure 3-2a).  
When the same analysis was carried out for overall survival, there were 9 eligible 
studies(122, 124, 128, 133, 135, 137, 138, 142, 143) with 7860 patients and 1148 
deaths. Pooled HR in this case was higher (HR 2.04, 95% CI 1.46-2.83, p<0.0001). 
However, there was substantial heterogeneity (I2=67%, p=0.002) (Figure 3-2b).  
Four studies using an outcome of CSS were included in the meta-analysis(129, 134, 
136, 139). There were 2010 patients with 191 cancer deaths. There was a 
significant effect shown (HR 2.46, 95% CI 1.27-4.76, p=0.007). There was 
substantial heterogeneity between the studies (I2=67%, p=0.003) (Figure 3-2c). 
3.3.3.1 Subgroup analysis of the relationship between NLR and DFS by 
threshold used 
Four studies which used a threshold of 1.9-2.9 and an outcome measure of DFS 
were included in a further meta-analysis(136, 137, 141, 142). This showed NLR to 
be a significant prognostic factor for worse DFS (HR 2.24, 95% CI 1.62-3.11, 
p<0.001). There was minimal heterogeneity between these studies (I2=0%) (Figure 
3-2a).  
Four studies used a threshold of 3-5 and an outcome of DFS. At this threshold also, 
high NLR was significantly associated with poorer DFS (pooled HR 1.76, 95% CI 
1.46-2.13, p<0.001, I2=0%). 
3.3.3.2 Subgroup analysis of the relationship between NLR and OS by 
threshold used 
Meta-analysis was carried out for 4 studies which used a threshold of 3-3.9 and an 
outcome measure of OS(122, 128, 133, 135). Total number of patients was 1556 
with 388 deaths. This showed a significant effect association with OS (HR 1.96, 95% 
CI 1.04-3.66, p=0.04). There was considerable heterogeneity between studies 
(I2=82%, p=0.0010) (Figure 3-2b).  
 
Further meta-analysis was carried out for 3 studies which used a threshold of 4-5 
and an outcome of OS(124, 138, 143). Again, a significant association was shown 










Figure 3-2. Forrest plots of NLR studies. Forrest plots of studies which investigated the neutrophil-
lymphocyte ratio with an outcome measure of a) disease free survival oredered by threshold used, b) 
overall survival ordered by threshold, c) cancer specific survival (all used a threshold of 2-2.5). 
 
3.3.4 The prognostic role of preoperative dNLR  
Three papers also investigated the effect of dNLR (derived NLR, defined as the 
neutrophil count divided by the WCC-neutrophils)(124, 138, 143). Only one of 
these reported a statistically significant independent association with worse DFS, 
when dNLR >3(143). Meta-analysis for these 3 studies showed a significant 
association of elevated dNLR with OS (HR 1.70, 95% CI 1.39-2.08, p<0.0001). There 
was minimal heterogeneity between studies (I2=0%) (Figure 3-3). 
 
Author Year Country Study type Patients Outcomes Cancer 
stage 
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Table 3-9. The prognostic role of preoperative dNLR. Papers which investigated the prognostic role of preoperative derived neutrophil-lymphocyte ratio. 




Figure 3-3. Forrest plot for dNLR. Forrest plot of studies which investigated the derived neutrophil-lymphocyte ratio with an outcome measure of overall 
survival.
 
3.3.5 The prognostic role of preoperative PLR  
Eight studies investigated the prognostic value of the PLR (Table 3-10). These 
cohorts were all made up of predominately ER positive disease, except for one 
whose cohort was 100% ER negative disease(128). Thresholds used ranged from 
107.64 to 300. Two studies using a threshold of >185(133, 140), and one larger 
study using a threshold of PLR>300(124), reported high PLR to be a significant 
independent predictor of worse survival.  
Five studies(122, 124, 128, 129, 133) used a range of thresholds but all used OS as 
the outcome measure, so were included in the meta-analysis. There were 4186 
patients and 986 deaths). A significant association with OS was shown (HR 1.55, 
95% CI 1.04-2.30, p=0.03), but there was substantial heterogeneity between 
studies (I2=68%, p=0.01) (Figure 3-4). 
 
 
Figure 3-4. Forrest plot for PLR. Forrest plot of studies which investigated the platelet-lymphocyte 
ratio with an outcome measure of overall survival.
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Table 3-10. The prognostic role of preoperative PLR. Papers which investigated the prognostic role of preoperative platelet-lymphocyte ratio. Rec = 
recurrences, CDs = cancer deaths, Lum = luminal, UV =univariate, MV = multivariate. 
 
3.3.6 The prognostic role of preoperative LMR  
Four studies investigated the role of the LMR in operable breast cancer (Table 
3-11). Three of the studies comprised patients with predominantly ER positive 
disease(132, 142, 144) while the largest cohort was made up of 63% ER negative 
disease(125). Thresholds used for analysis ranged 3.8-4.8. The only study to report 
a significant association with cancer outcomes evaluated a cohort of 542 locally 
advanced patients, who received neoadjuvant chemotherapy, and reported that 
LMR>4.25 was an independent prognostic factor for improved DFS(144). There 
were insufficient studies with the same outcome measure to carry out meta-
analysis for LMR. 
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Table 3-11. The prognostic role of preoperative LMR.  Papers which investigated the prognostic role of preoperative lymphocyte-monocyte ratio. Rec = 
recurrences, Lum = luminal, UV =univariate, MV = multivariate. 
  
 
3.3.7 The prognostic role of preoperative CRP 
Five papers were identified which met our inclusion criteria (Table 3-12). One of 
these was a large epidemiological study which did not report extensive detail 
regarding tumour pathology(123) but the other 4 were dominated by ER positive 
disease. In all but one small study, an association between high CRP and worse 
cancer outcomes was reported. Thresholds used ranged from 3.25-10mg/L. 
Three of the studies(123, 145, 146) were included in a meta-analysis for CRP and 
overall survival, with a total of 9816 patients and 1896 deaths. There was a non-
significant association for elevated CRP with OS (HR 1.34, 95% CI 0.86-2.09, 
p=0.19). There was considerable heterogeneity between studies (I2=82%, p=0.004) 
(Figure 3-5a).  
A separate meta-analysis was carried out for the same studies with the outcome 
measure of CSS. There were a total of 986 cancer deaths.  Again, a non-significant 
relationship was observed (HR 1.33, 95% CI 0.90-1.96, p=0.16). Heterogeneity was 
slightly less for this outcome measure but still substantial (I2=63%, p=0.07) (Figure 
3-5b). 
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Table 3-12. The prognostic role of preoperative CRP. Papers which investigated the prognostic role of preoperative C-reactive protein. Rec = recurrences, 







Figure 3-5. Forrest plot for CRP. Forrest plot of studies which investigated CRP with an outcome measure of a) overall survival and b) cancer specific 
survival. 
 
3.3.8 The prognostic role of preoperative albumin 
Five studies were identified, four investigating preoperative albumin with 
thresholds of 35-43g/L, and one investigating the albumin to globulin ratio (Table 
3-13). The three which reported data regarding tumour receptors were heavily 
dominated by ER positive disease. All of the studies reported a significant 
association between low albumin and cancer outcomes, using thresholds between 
35 and 43g/L.   
Three studies(123, 145, 148) were entered into the meta-analysis, with a total of 
9331 patients and 1725 deaths.  This showed a significant association of albumin 
with OS (HR 1.73, 95% CI 1.01-2.99, p=0.05). There was substantial heterogeneity 
between studies (I2=77%, p=0.001) (Figure 3-6).
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Table 3-13. The prognostic role of preoperative albumin. Papers which investigated the prognostic role of preoperative albumin. Rec = recurrences, CDs 
= cancer deaths, NCDs = non cancer deaths, UV =univariate, MV = multivariate. 
 
 
Figure 3-6. Forrest plot for albumin. Forrest plot of studies which investigated albumin with an outcome measure of overall survival.
 
3.3.9 The prognostic role of other markers of systemic 
inflammation 
Three papers evaluated other systemic markers of inflammation. Wulanansih et 
al(123) reported haptoglobin >1.4g/L to be an independent significant prognostic 
factor for worse OS and CSS. In addition to the role of albumin, as outlined above, 
Liu et al(148) analysed other liver function tests and showed LDH>469IU/L and 
total bilirubin >0.2mg/dL to be independently related to worse OS. Watt et al(151) 
investigated the neutrophil platelet score (NPS, made up of score 0-2 for 
combination of elevated platelets and elevated neutrophils) in a variety of cancers 
and reported that this was significantly associated with OS and CSS in the breast 
cancer cohort of 1921 on Kaplan Meier analysis. 
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Author Year Country Study type Patients Outcomes Cancer 
stage 
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Table 3-14. The prognostic role of other preoperative inflammatory markers. Papers which investigated the prognostic role of other preoperative inflammatory 




3.4 Pilot study results 
3.4.1 Patient cohort 
Of 451 patients in the FJ cohort, all had preoperative biochemistry available for 
CRP and albumin analysis and 439 had preoperative full blood count results 
available. Clinicopathological data for the FJ cohort can be found in chapter 2. 
All patients had outcome data for overall survival but 3 patients had no cause of 
death data available so CSS analysis was carried out for 448 patients for 
biochemistry data and 436 patients for haematology data. There were 77 breast 
cancer deaths and 100 non breast cancer deaths. 
 





































3.4.2 Individual circulating markers of the systemic inflammatory 
response 
Median neutrophil count was 4.29 (1.49-14.34) Median lymphocyte count was 
1.64 (0.40-4.18). Median monocyte count was 0.48 (0.17-1.48). Median platelet 
count was 265 (89-617). Median albumin was 43 (31-52). Median CRP was 6 (1-




a) b) c)  
d) e) f)  
Figure 3-8. Distribution of values for individual circulating markers of the systemic inflammatory response.  Histograms illustrating the distribution of 
preoperative values for a) neutrophils, b) lymphocytes, c) monocytes, d) platelets, e) albumin and f) CRP in the cohort. 
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ROC curve analysis was carried out to derive thresholds for survival analysis. 
From this, a threshold of 43g/L was obtained for albumin (incidentally also 
corresponding to the median) and will be used in all further analysis, but no 
clear threshold was derived for the other components listed above (Figure 3-9, 
Figure 3-10). Therefore the median was used to divide each of the other 
components into high and low groups for analysis. Exploratory work (data not 
shown) demonstrated no greater prognostic power if the components were 
divided by tertiles instead.   
Using these thresholds, 219 (49.9%) patients had high neutrophils, 217 (49.4%) 
had high lymphocytes, 213 (48.5%) had high monocytes, 219 (49.9%) had high 
platelets, 227 (50.3%) had low albumin and 108 (23.9%) had a high CRP. High is 
defined as a value greater than the median meaning that, where a number of 
patients had the median value for that component, there were fewer than 50% 
of patients in the high group. 
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a) b) c)  
d)             e)             f)   
Figure 3-9. ROC curves for individual markers of the systemic inflammatory response and CSS. ROC curves with an outcome of cancer specific survival for a) 
neutrophils (AUC 0.489), b) lymphocytes (AUC 0.446), c) monocytes (AUC 0.475), d) platelets (AUC 0.448), e) albumin (AUC 0.410) and f) CRP (AUC 0.507). 
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a) b) c)  
d)     e)        f)   
Figure 3-10. ROC curves for individual markers of the systemic inflammatory response and OS. ROC curves with an outcome of OS for a) neutrophils (AUC 
0.589), b) lymphocytes (AUC 0.470), c) monocytes (AUC 0.549), d) platelets (AUC 0.472), e) albumin (AUC 0.390) and f) CRP (AUC 0.524).
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3.4.2.1 Association between individual markers and CSS 
On univariate analysis, albumin <43g/L was significantly associated with worse 
CSS (HR 2.69, 95% CI 1.65-4.37, p<0.001). There was no association between 
neutrophils (HR 0.93, 95% CI 0.59-1.46, p=0.751), lymphocytes (HR 0.68, 95% CI 
0.43-1.08, p=0.103), monocytes (HR 1.13, 95% CI 0.71-1.78, p=0.608), platelets 
(HR 0.75, 95% CI 0.48-1.19, p=0.223) or CRP (HR 1.10, 95% CI 0.59-1.70, p=0.996) 
and CSS (Figure 3-11). 
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a) b) c)  
d) e) f)  
Figure 3-11. Association between individual markers of the systemic inflammatory response and CSS.  Kaplan Meier graphs illustrating the relationship 
between cancer specific survival and a) neutrophils (p=0.751), b) lymphocytes (p=0.100), c) monocytes (p=0.607), d) platelets (p=0.222), e) albumin (p<0.001) and f) 
CRP (p=0.996)   
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3.4.2.2 Association between individual markers and OS 
On univariate analysis, albumin <43g/L was significantly associated with worse 
OS (HR 2.09, 95% CI 1.54-2.83, p<0.001). There was no association between 
neutrophils (HR 1.28, 95% CI 0.95-1.72, p=0.103), lymphocytes (HR 0.89, 95% CI 
0.66-1.19, p=0.425), monocytes (HR 1.26, 95% CI 0.94-1.69, p=0.127), platelets 
(HR 0.85, 95% CI 0.63-1.14, p=0.285) or CRP (HR 1.08, 95% CI 0.77-1.52, p=0.649) 




a) b) c)  
d) e) f)  
Figure 3-12. Association between individual markers of the systemic inflammatory response and OS.Kaplan Meier graphs illustrating the relationship between 
overall survival and a) neutrophils (p=0.101), b) lymphocytes (p=0.424), c) monocytes (p=0.126), d) platelets (p=0.283), e) albumin (p<0.001) and f) CRP (p=0.649). 
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3.4.2.3 Association between individual markers and survival in ER positive 
and ER negative disease 
Neutrophils were not associated with CSS in either ER positive (HR 1.19, 95% CI 
0.69-2.04, p=0.534) or ER negative disease (HR 0.50, 95% CI 0.21-1.20, p=0.121), 
though the Kaplan Meier curve suggested a possible trend to worse CSS for 
patients with low neutrophils in ER negative disease (Figure 3-13). However, 
high neutrophils were significantly associated with worse OS in ER positive 
disease (HR 1.46, 95% CI 1.04-2.05, p=0.028), but not in ER negative disease (HR 
0.87, 95% CI 0.47-1.59, p=0.641) (Figure 3-14). 
Low albumin was associated with worse CSS in both ER positive (HR 2.41, 95% CI 
1.36-4.25, p=0.002) and ER negative (HR 3.73, 95% CI 1.46-9.56, p=0.006) 
disease, and with worse OS in ER positive (HR 1.99, 95% CI 1.41-2.82, p<0.001) 
and ER negative (HR 2.48, 95% CI 1.32-4.66, p=0.005) disease. 
None of the other individual factors analysed were significantly associated with 













Figure 3-13. Association of neutrophils and albumin with CSS by ER status. Kaplan Meier 
graphs illustrating the association of neutrophils and albumin with CSS in ER positive (a) 














Figure 3-14. Association of neutrophils and albumin with OS by ER status. Kaplan Meier 
graphs illustrating the association of neutrophils and albumin with OS in ER positive (a) neutrophils, 




3.4.2.4 Associations of albumin with clinicopathological characteristics 













































































































































Table 3-15. Association between preoperative albumin and other clinicopathological factors. 
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3.4.3 Scores and ratios of circulating markers of the systemic 
inflammatory response 
Next, scores and ratios made up of different combinations of the individual 
markers of the systemic inflammatory response, previously described in the 
literature, were analysed. These were the NLR, PLR, LMR and mGPS. Median NLR 
was 2.58 (0.71-14.67), median PLR was 163.27 (40.84-751.52) and median LMR 
was 3.53 (0.78-8.76). Distribution of values for these ratios is shown in Figure 
3-15. 396 (87.8%) patients had a mGPS of 0, 51 (11.3%) had a mGPS of 1 and 4 
(0.9%) had a mGPS of 2.  
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a) b) c)  
Figure 3-15. Distribution of values for ratios of markers of the systemic inflammatory response. Histograms illustrating the distribution of preoperative values for 





For NLR, PLR and LMR, ROC curves were constructed to identify thresholds to 
allow division of groups for survival analysis (Figure 3-16, Figure 3-17). If these 
did not demonstrate a clear threshold, Kaplan Meier analysis of tertiles was 
performed. The ROC derived threshold for NLR was 2.5, which happens to 
correspond to the median. For further analysis patients were grouped into low 
NLR (<2.5) or high NLR (>2.5) groups. Neither ROC nor tertile analysis identified 
a clear threshold for PLR so the median was used to divide patients into low PLR 
(<163) or high PLR (>163) groups. For LMR, the ROC curve did not clearly 
demonstrate one specific point. Kaplan Meier analysis of tertiles suggested that 
the cutoff for the lowest tertile would be a suitable threshold for division, and 
this number did correspond to one of the points furthest from the diagonal line 
on the ROC curve. Therefore, patients were divided into low (<2.98) or high 





a) b) c)  
Figure 3-16. ROC curve analysis for ratios of circulating markers of the systemic inflammatory response and CSS. ROC curves with an outcome of CSS for 
preoperative a) NLR (AUC 0.546), b) PLR (AUC 0.512) and c) LMR (AUC 0.462). 
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a)      b)       c)    
Figure 3-17. ROC curve analysis for ratios of circulating markers of the systemic inflammatory response and OS. ROC curves with an outcome of OS for 
preoperative a) NLR (AUC 0.607), b) PLR (AUC 0.502) and c) LMR (AUC 0.433).
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3.4.3.1 Associations between scores/ratios and CSS 
None of NLR (high v low: HR 1.34, 95% CI 0.85-2.12, p=0.211), LMR (high v low: 
HR 0.85, 95% CI 0.53-1.37, p=0.511), PLR (high v low: HR 1.14, 95% CI 0.72-1.79, 
p=0.579) or mGPS (1v0: HR 1.09, 95% CI 0.54-2.19, p=0.804; 2v0: HR 3.20, 95% CI 










Figure 3-18. Association between ratios/scores of markers of the systemic inflammatory 
response and CSS. Kaplan Meier graphs illustrating the relationship between cancer specific 
survival anda) NLR (p=0.209), b) LMR (p=0.510), c) PLR (p=0.578) and d) mGPS (p=0.470).  
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3.4.3.2 Associations between scores/ratios and OS 
High NLR (high v low: HR 1.64, 95% CI 1.21-2.22, p=0.001), low LMR (high v low: 
HR 0.67, 95% CI 0.49-0.90, p=0.008) and high mGPS (1 v 0: HR 1.13, 95% CI 0.72-
1.76, p=0.600; 2 v 0: HR 7.40, 95% CI 2.71-20.25, p<0.001) were all significantly 
associated with worse OS on univariate analysis. PLR was not significantly 










Figure 3-19. Association between ratios/scores of markers of the systemic inflammatory 
response and OS. Kaplan Meier graphs illustrating the relationship between overall survival anda) 
NLR (p=0.001), b) LMR (p=0.008), c) PLR (p=0.772) and d) mGPS (p<0.001).
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Associations between scores/ratios and survival in ER positive and ER 
negative disease 
High NLR was significantly associated with worse CSS and OS in ER positive (CSS: 
HR 1.78, 95% CI 1.02-3.11, p=0.042; OS: HR 1.87, 95% CI 1.32-2.66, p<0.001) but 
not ER negative disease. Neither LMR nor mGPS were significantly associated 
with CSS but low LMR and high mGPS were associated with worse OS in both ER 
positive (LMR high v low: HR 0.70, 95% CI 0.50-0.99, p=0.044; mGPS 2v0: HR 
6.95, 95% CI 1.70-28.44, p=0.007) and ER negative disease (LMR high v low: HR 
0.54, 95% CI 0.29-1.01, p=0.053; mGPS 2v0: HR 5.39, 95% CI 1.25-23.17, 
p=0.024). PLR was not significantly associated with CSS or OS in either subgroup 





Figure 3-20. Association between NLR and CSS by ER status. Kaplan Meier graphs illustrating 


















Figure 3-21. Associations between NLR, LMR and mGPS and OS by ER status. Kaplan Meier 
graphs illustrating the association of NLR, LMR and mGPS with OS in ER positive ( a) NLR, 
p<0.001; c) LMR, p=0.042; e) mGPS, p=0.007) and ER negative disease ( b)NLR, p=0.708; d) 





3.4.3.4 Multivariate analysis 
Individual components or ratios/scores significantly associated with either 
survival outcome on univariate analysis were entered into the multivariate 
analysis controlling for other known prognostic clinicopathological factors. 
Ratios/scores with a component in common were not entered into the same 
analysis. Low albumin was independently associated with worse CSS and OS. 
mGPS was also independently associated with worse OS but NLR and LMR were 
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1.36 (1.00-1.86) 







     0.475  0.606   
Table 3-16. Multivariate analysis. Multivariate Cox regression survival analysis of individual markers or ratios/scores of markers of the systemic inflammatory 
response and CSS or OS, controlling for other known prognostic clinicopathological factors. Markers which were significantly associated with survival on univariate 
analysis were included in the models. Ratios/scores which shared common components were not included in the same model.   
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3.4.3.5 Associations between NLR and LMR and clinicopathological 
characteristics 
Older age was significantly associated with high NLR and low LMR. There were no 















































































































































































































The results of the present systematic review in operable breast cancer showed 
that the majority of studies examined systemic inflammatory markers in ER 
positive disease. Of the markers examined, the NLR and albumin were shown to 
have consistent prognostic value, although the thresholds used were variable. 
Similarly, the pilot study showed a prognostic role for albumin, NLR and LMR in 
the cohort of primary operable breast cancer with mature follow up. Therefore, 
it would appear that the presence of a systemic inflammatory response has 
prognostic value in patients with primary operable breast cancer. 
The marker studied most extensively, NLR, consistently showed prognostic value 
regardless of threshold used. This finding is in agreement with a large meta-
analysis of 100 studies of the NLR in all cancer types, (152) and a meta-analysis 
of the NLR in all stages of breast cancer(153). The pilot study in the FJ cohort 
showed an association between NLR and both CSS and OS in ER positive but not 
ER negative disease. Most studies in the meta-analysis were dominated by ER 
positive disease. No clinical or pathological characteristic was consistently 
shown across studies to be associated with raised NLR. The present pilot study 
reported an association with older age.   
The NLR is a ratio made up of the absolute neutrophil count divided by the 
absolute lymphocyte count.  It is not clear whether it is the neutrophil or 
lymphocyte component of this ratio which is the most significant in terms of its 
prognostic role though the fact that the PLR, which also involves the lymphocyte 
count, showed a weaker prognostic effect in this context suggests that it may be 
the neutrophil count which has the greatest role to play in primary operable 
breast cancer with a majority of ER positive disease. This is supported by the 
fact that the present study reported an association between neutrophils and OS 
in ER positive disease. Previous work in various cancers has shown elevated 
neutrophils to significantly predict worse outcomes(154-156)whereas the value 
of low lymphocytes appears to be less clear(157, 158). Mechanisms by which 
neutrophils promote tumour progression include the remodelling of the 
extracellular matrix aiding tumour cell migration and angiogenesis, the release 
of cytokines, chemokines and reactive oxygen species, and the suppression of T 
cells (119, 159, 160). On the other hand, lymphocytes fulfil a cytotoxic, tumour-
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suppressing role (161, 162). The combination of the two in a ratio is felt to 
result in a magnified and more stable prognostic factor than a single blood cell 
count. The dNLR was initially described by Proctor el al for use when only the 
white cell and neutrophil counts were available, such as in chemotherapeutic 
trial databases(163). This has been less extensively studied but again showed 
prognostic value on meta-analysis, though less marked than the NLR. 
Albumin was consistently associated with prognosis across all studies, although 
this was most frequently with overall survival rather than cancer-specific 
outcomes in the literature. In the pilot study it was associate with both OS and 
CSS in ER positive and ER negative disease. Low albumin has been shown to be a 
prognostic factor for worse survival in a number of cancers (164). Several 
mechanisms to explain this have been proposed. These include its role as an 
antioxidant and as a transporter of common carcinogens (165). Studies have 
previously demonstrated inhibition of growth of the oestrogen responsive human 
breast cancer cell line MCF-7 by albumin (166, 167).  
NLR/dNLR, PLR and albumin are all markers of the systemic inflammatory 
response. It was interesting that the other marker of systemic inflammatory 
response which has consistently shown prognostic value in other cancers(168-
172), CRP, did not have a significant prognostic effect in either the meta-
analysis or pilot study. Studies show variable results regarding the significance of 
CRP in primary operable breast cancer and there is certainly no consensus 
regarding a threshold. The study most suggestive of its prognostic value uses 
hsCRP (with a threshold of 3.24mg/L) which may not be routinely available in all 
institutions. As early as 1977, Coombes et al reported that CRP was commonly 
abnormal in metastatic breast cancer, but rare in localised disease(173), and 
this may explain the lack of prognostic effect seen in this review of primary 
operable breast disease. Similarly, whilst investigating potential markers of 
response to endocrine therapy in breast cancer, Williams et al reported a 13% 
rate of elevated CRP in stage 3 breast cancer, which rose to 53% in stage four 
cancer, further supporting this point(174). Interestingly, there were no studies 
which met our criteria which investigated mGPS, a combined score of CRP and 
albumin which has been widely validated as a prognostic marker in several 
cancers. Studies have shown CRP(175) and mGPS(176) to be prognostic in 
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metastatic breast cancer but evidence in this present review of early-stage 
breast cancer is limited. Proctor et al(177) did demonstrate an association 
between mGPS and CSS in a cohort of 1853 breast cancer patients (within a 
larger study of all cancer types) but this was an unselected cohort with limited 
availability of staging data. The present study did provide evidence for an 
association between high mGPS and OS, and a score of 2 does appear to convey 
greater prognostic power than low albumin alone. 
Both the use of NLR and albumin, as described in the studies in this review, have 
potential limitations in clinical practice. The studies which investigated albumin 
used thresholds which ranged 35-43g/L, which are within the normal range, and 
therefore of questionable clinical utility. This was also the case in the pilot 
study, where ROC curve analysis identified the median value, 43g/L, as the most 
suitable threshold despite this being in the normal range and meaning that 
nearly half of the patients would fall into the low albumin category. The use of 
ROC curves and then, if no suitable threshold was found, carrying out analysis in 
tertiles before resorting to using the median was done with the aim of avoiding 
the situation of having half of the patients in either group. Resorting to using the 
median, having not identified a threshold using the prior two methods, tends to 
suggest that the factor being analysed is not prognostic anyway, but in the case 
of albumin it is unfortunate from a clinical utility point of view that the ROC 
curve identified the median as the most prognostic threshold.  
There was variability in the threshold found to be significant in the studies which 
investigated NLR. Lower values were often used in Asian studies when compared 
to Western ones and this may reflect population differences in levels of 
inflammation. Previous studies have demonstrated ethnic variability in levels of 
inflammation(178-180). Therefore, no consensus has been reached regarding a 
threshold which could be recommended to stratify prognosis in clinical settings 
globally. In this meta-analysis there was no relationship seen between NLR 
threshold used and hazard ratio obtained. NLR is a ratio and therefore has 
limitations in clinical practice in that it is possible to have a neutrophil count 
and a lymphocyte count both within the normal range, and still have an elevated 
NLR, particularly when a lower threshold is used. It could therefore be argued 
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that a combined score, which increases with each abnormal value, would be 
more consistently clinically relevant than a ratio.  
Some studies carried out sub-analysis for different disease stages. Wen et al(125) 
found that an elevated monocyte count was an independent significant 
prognostic factor in stage II-III disease but not stage I. Similarly, Koh et al(137) 
found that elevated NLR was a significant prognostic factor in stage III and IV 
disease but not stage II. It may be that in very early-stage breast cancer the 
inflammatory response is less marked making systemic markers of inflammation 
less important to prognosis in these early stages. Alternatively, given the better 
outcome (fewer events) in primary operable breast cancer, it may be that the 
studies to date have been relatively under powered.  
Breast cancer is a heterogeneous disease and the different histological types and 
molecular subtypes behave differently in terms of progression and response to 
treatment(181, 182). Despite this, the majority of studies have investigated the 
prognostic role of inflammatory markers in cohorts of all operable breast cancer. 
This means, inevitably, that most studies are reported on cohorts with a 
majority of ER positive disease. Limited studies did carry out sub-analysis for 
different subtypes. Subgroup analysis for molecular subtypes in NLR studies was 
conflicting. The findings of several studies support the finding of our pilot study 
that NLR is associated with prognosis in luminal/ER positive disease(124, 134, 
139, 143). The reasons for it to be prognostic in ER positive but not ER negative 
disease are not clear. One theory could be that ER positive tumours tend to be 
less inflammatory in general than ER negative tumours and therefore, when 
inflammation does exist, it is a particularly poor prognostic sign. Alternatively, it 
may just be that in the case of this small pilot study, the ER negative cohort was 
underpowered to detect a difference. This theory is supported by the fact that 
some studies have reported NLR to be prognostic in ER negative subtypes(128, 
139-142). Studies which carried out subtype analysis for PLR also reported 
varying results(124, 129, 140, 147). Therefore, as only limited studies have 
investigated these markers within different subtypes, there is insufficient data 




The studies included in the review and meta-analysis are a heterogeneous group. 
Many of them are retrospective studies, with the inherent problems of missing 
data, loss to follow up and potential confounding factors that may result. These 
issues are shared by the present pilot study. Some studies excluded patients with 
systemic inflammatory conditions as potential confounders while others did not. 
A few studies selected patients with a certain type of adjuvant or neoadjuvant 
therapy whereas most are not selected in terms of treatment. Study size varies 
greatly between smaller local cohorts of a few hundred patients to large 
population studies in the thousands. The latter may have the advantage of 
greater statistical power but may not have as detailed and complete data 
regarding tumour and patient characteristics and treatment.  
Therefore, a pilot studied was conducted on patients from within the host 
centre, which has the advantage of assessing whether the findings of the meta-
analysis are present in the host population but shares the issues of retrospective 
studies and limited patient numbers. Consistent with the results of the meta-
analysis, an association between survival and both NLR and albumin was 
observed, as well as LMR.  
In conclusion, current evidence suggests a potential role for preoperative serum 
inflammatory markers, which are readily available, in delineating prognosis in 
primary operable breast cancer, particularly as regards NLR, PLR, LMR and 
albumin. However, their precise role in clinical practice remains unclear. 
Further work is warranted to ascertain reproducible thresholds and to ascertain 
in which subtypes they may be of most value. Large prospective studies would 
be required to achieve this aim. As currently there is no consensus on thresholds 
for clinical use, and given the timelines that would be required for a large 
prospective study, the following chapters of this thesis will instead move on to 
investigate the role of the local inflammatory response in primary operable 





4 The role of the local inflammatory infiltrate in 
primary operable breast cancer 
4.1 Introduction 
The findings of the previous chapter suggested a possible prognostic role for 
markers of the systemic inflammatory response in primary operable breast 
cancer, although it was acknowledged that there are difficulties in identifying a 
suitable threshold for clinical use and this was accompanied by the observation 
that systemic inflammation is not a predominant feature of early-stage breast 
cancer. Therefore, in primary operable breast cancer, the question arises as to 
whether the local inflammatory response to the tumour may play a more 
important role in terms of prognosis or therapeutic targets.  
It is now well recognised that the tumour microenvironment has a significant 
role in the progression of cancer, of which immune cells are a significant 
component. Increasing evidence supports a role for certain inflammatory cells in 
suppressing tumour growth, for instance through direct cytotoxicity, while for 
others they may promote tumour growth through secretion of various cytokines, 
chemokines and pro-angiogenic factors(63).  
The Klintrup-Makinen scoring system was reported in 2005 as a method to 
classify the inflammatory reaction to a tumour(183). It is a four-point system 
using H&E-stained tissue which incorporates the overall inflammatory reaction at 
the invasive margin of the tumour. Using this score, high grade inflammation at 
the invasive margin has been consistently reported to be associated with 
improved survival in colorectal cancer(183, 184). However, its role in breast 
cancer is at present unknown. 
Other methods, including IHC, allow assessment of specific inflammatory cell 
types in and around the tumour, such as CD4+ helper T lymphocytes and CD8+ 
cytotoxic T lymphocytes. Different subsets of tumour-infiltrating lymphocytes 
(TILs) have shown varying prognostic roles in different cancers(64, 185-187). In 
breast cancer, evidence to date suggests that TILs are associated with 
favourable prognosis in HER2 positive and triple negative breast cancers, as well 
as improved response to neoadjuvant therapies(188). However, some studies 
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have reported an association between certain subtypes of CD4+ T lymphocytes 
and poorer prognosis in breast cancer(64, 189).   
The aim of this study was to evaluate the prognostic role of the local 
inflammatory infiltrate, assessed by the KM score, in primary operable breast 
cancer, with the hypothesis that a higher KM score would be associated with 
improved prognosis. A secondary aim was to assess the relationship of KM score 
to specific TIL subsets.   
4.2 Materials and methods 
4.2.1 Patient cohort 
For this study, both the 1800 and FJ cohorts were used, with characteristics as 
described in chapter 2. Both cohorts were used for Klintrup-Makinen scoring and 
analysis, but only the 1800 cohort was used for further analysis related to 
lymphocyte subsets as TMAs were only available for this cohort. 
4.2.2 Slide staining and scanning 
4.2.2.1 Klintrup-Makinen score 
A single full section slide was cut from surplus tissue blocks, stained with H&E 
and scanned into Slidepath software as described in chapter 2. 
4.2.2.2 Inflammatory cell markers 
TMAs for the 1800 cohort were stained in triplicate using the 
immunohistochemistry technique described in chapter 2. Antibodies for CD4 and 
CD8 were used as markers of helper T and cytotoxic T lymphocytes respectively, 
and the slides were scanned into Slidepath software, as detailed in chapter 2. 
4.2.3 Scoring 
Each slide was scored for Klintrup-Makinen score and each core was scored for 
CD4 and CD8 positive lymphocytes using the methods described in chapter 2.  
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4.2.4 Molecular subtyping 
Ki67 scoring was available for the 1800 cohort but not for the FJ cohort. For this 
reason, in this combined cohort, full molecular subtyping could not be carried 
out. Instead, surrogate receptor subtypes were used for analysis, namely 
ER+/HER2-, ER+/HER2+, ER-/HER2+ and ER-/HER2- subgroups. 
4.2.5 Statistical analysis 
Analysis of associations with clinicopathological characteristics and with cancer 
specific survival was carried out as described in chapter 2. This analysis was 
carried out initially in the full cohort, then in the ER positive and ER negative 
cohorts separately, and subsequently in the 4 individual receptor subtypes. 
4.3 Results 
4.3.1 Patient cohort 
1195 patients who underwent surgery for primary operable breast cancer and 
who had a full section H&E-stained slide suitable for assessing Klintrup-Makinen 
grade were in included in the study. 1191 patients had full survival data 
available. Median follow up was 158 months (28-183) during which time there 





Figure 4-1. Formation of the cohort. Flow diagram showing exclusions from the original cohort 
and numbers included in the final analysis.  
Patients with clinical information 
available. 
n=1301 
Patients with H&E-stained slide 
available for analysis. 
n=1211 
No excess tissue block available for H&E 
staining. 
n=90 
Patients scored for Klintrup-Makinen. 
n=1195 
Available H&E slide not suitable for 
Klintrup-Makinen scoring. 
n=16 
Eligible to be entered into survival 
analysis. 
n=1191 
Incomplete survival data. 
n=4 
Eligible to be entered into ER subgroup 
survival analysis. 
n=1188 
Missing oestrogen receptor (ER) data. 
n=3 
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4.3.2 Klintrup-Makinen score 
Examples of the 4 different Klintrup-Makinen scores are shown below in Figure 
4-2. 298 (24.9%) tumours had KM score 0, 589 (49.3%) had KM 1, 238 (19.9%) had 









Figure 4-2. Klintrup-Makinen score. Images of breast tumour tissue, stained with H&E, at 20x 
magnification illustrating examples of a) KM 0 – no inflammatory infiltrate at the invasive tumour 
edge, b) KM 1 – patchy inflammatory infiltrate at the invasive tumour edge, c) KM 2 – a continuous 
layer of inflammatory cells at the invasive tumour edge, and d) KM3 – a ‘cup’ of inflammatory 




Figure 4-3. Distribution of KM scores. Bar chart illustrating the distribution of Klintrup-Makinen 
scores within the cohort. 
 
4.3.3 Association between KM score and CSS 
In the full cohort, KM score was significantly associated with CSS (p=0.003). 
However, this association was not straightforward in that patients with both the 
lowest and highest KM scores had the best CSS while those with a score of 2 had 
the worst CSS (score 1 v 0: HR 1.46, 95% CI 1.02-2.07, p=0.037; score 2 v 0: HR 
1.98, 95% CI 1.34-2.92, p=0.001; score 3 v 0: HR 0.92, 95% CI 0.46-1.83, 
p=0.807). 
When subgroup analysis was carried out, overall KM score was not significantly 
associated with CSS in ER positive (p=0.116) or ER negative disease (p=0.082). 
However, in ER positive disease a score of 2 was significantly associated with 
worse CCS than a score of 0 (score 1 v 0: HR 1.17, 95% CI 0.80-1.72, p=0.409; 
score 2 v 0: HR 1.70, 95% CI 1.04-2.78, p=0.035; score 3 v 0: HR 0.68, 95% CI 
0.24-1.90, p=0.464) but in ER negative disease, whilst there was a trend to 
scores of 1 and 2 having a worse prognosis, this did not reach statistical 
significance (score 1 v 0: HR 6.68, 95% CI 0.92-48.52, p=0.060; score 2 v 0: HR 
6.92, 95% CI 0.95-50.46, p=0.056; score 3 v 0: HR 3.77, 95% CI 0.45-31.32, 









Figure 4-4. KM score and CSS. Kaplan Meier graphs to illustrate the relationship between Klintrup-Makinen score and cancer specific survival in a) the full cohort, 
(n=1191, p=0.003), b) ER positive disease (n=830, p=0.116), c) ER negative disease (n=358, p=0.082). 
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Overall, KM score was not significantly associated with CSS in any of the 4 
receptor subtypes (Figure 4-5). Although the pattern of the Kaplan Meier curves 
suggested the possibility of some variability in terms of which KM scores confer a 
more favourable prognosis in different subtypes, none of these relationships 
were statistically significant in ER+/HER2- (score 1 v 0: HR 1.24, 95% CI 0.79-
1.95, p=0.342; score 2 v 0: HR 1.62, 95% CI 0.90-2.91, p=0.108; score 3 v 0: HR 
0.63, 95% CI 0.19-2.06, p=0.442), ER+/HER2+ (score 1 v 0: HR 0.70, 95% CI 0.27-
1.82, p=0.466; score 2 v 0: HR 0.97, 95% CI 0.34-2.80, p=0.954; score 3 v 0: HR 
0.47, 95% CI 0.06-3.78, p=0.480), ER-/HER2+ (score 1 v 0: HR 0.44, 95% CI 0.06-
3.43, p=0.431; score 2 v 0: HR 0.35, 95% CI 0.05-2.79, p=0.324; score 3 v 0: HR 
0.12, 95% CI 0.01-1.91, p=0.132) and ER-/HER2- disease (HRs and 95% CIs 
incalculable, score 1 v 0: p=0.88; score 2 v 0: p=0.878; score 3 v 0: 









Figure 4-5. KM score and CSS by receptor subtype. Kaplan Meier graphs to illustrate the 
relationship between Klintrup-Makinen score and cancer specific survival in each of the molecular 
subtypes. a) ER+/HER2- (n=645, p=0.257), b) ER+/HER2+ (n=86, p=0.799), c) ER-/HER2+ (n=86, 




On multivariate analysis controlling for known prognostic clinicopathological 
factors, KM score was not independently associated with cancer specific survival 
in the whole cohort (Table 4-1).  
 Univariate analysis Multivariate analysis 


























































































Table 4-1. Multivariate survival analysis. Table showing KM score and other clinicopathological 
factors entered into the multivariate analysis for association with cancer specific survival. 
Significant p values are highlighted in bold. 
4.3.4 Association of KM score with clinicopathological 
characteristics 
Higher KM score was associated with younger age, higher tumour grade, ER 
negativity and HER2 positivity. Tumours with a KM score of 1 or 2 were more 
likely to be of ductal type, have larger tumours and have nodal involvement 
















































































































































Table 4-2. Associations between KM score and clinicopathological characteristics. Table 
describing the associations between Klintrup-Makinen score and important clinicopathological 
characteristics in primary operable breast cancer. 
 
4.3.5 Associations between KM score and individual TIL subtypes 
Frequency of both CD4+ and CD8+ TIL subtypes increased with increasing KM 
score (Table 4-3). 
 Klintrup-Makinen score p 











































Table 4-3. Associations between KM score and individual TIL subtypes. Table detailing the 
associations between KM score and both CD4+ and CD8+ TIL subtypes. 
4.3.6 Associations between individual TIL subtypes and CSS 
When the inflammatory cell subtypes were analysed individually, low CD8+ 
lymphocyte infiltrate was associated with worse CSS (medium v low: HR 0.78, 
95% CI 0.48-1.26, p=0.307; high v low: 0.33, 95% CI 0.18-0.61, p<0.001). There 







Figure 4-6. Association between TIL subtypes and CSS. Kaplan Meier graphs to illustrate the 
relationship between CSS and a) CD4+ lymphocytes (n=695, p=0.213) and b) CD8+ lymphocytes 
(n=371, p=0.001). 
The individual TIL subtypes were then analysed within each KM score. As might 
be expected, no individual cell type was significantly associated with CCS in 
patients with KM0. In patients with KM1 (p=0.025) or KM3 (p=0.039), only high 
CD8+ T lymphocytes were significantly associated with improved CSS. However, 
in patients with KM2, CD4+ lymphocytes and CD8+ lymphocytes were both 
significantly associated with CSS. Within this group, medium levels of CD4+ 
lymphocytes (overall p=0.021; medium v low: HR 1.88, 95% CI 0.80-4.37, 
p=0.145; high v low: HR 0.80, 95% CI 0.33-1.91, p=0.612) and lower CD8+ 
lymphocytes (medium v low: HR 0.84, 95% CI 0.31-2.26, p=0.731; high v low: HR 





Figure 4-7. The relationship between TIL subtypes and CSS in KM2 patients. Kaplan meier 
graphs to illustrate the relationship with CSS of a) CD4+ TILs (n=172, p=0.017) and b) CD8+ TILs 





In this study it was observed that inflammatory infiltrate at the invasive tumour 
edge, as measured using the Klintrup Makinen grade, is associated with CSS in 
primary operable breast cancer, though this was not independent of other known 
prognostic factors. This association is not straight-forward in that patients with 
the highest and lowest KM scores have better CSS than those with intermediate 
scores. These intermediate scores (KM1 and 2) were associated with larger 
tumours and nodal involvement. Higher KM score was associated with higher 
numbers of each of the individual TIL subtypes in this study (CD4+ and CD8+ T 
lymphocytes). Low CD8+ TILs were associated with worse CSS. 
There is very little in the published literature regarding the use of the Klintrup 
Makinen scoring system for assessment of local inflammatory infiltrate in breast 
cancer. One smaller study (n=461) reported no significant association between 
KM score and CSS (p=0.069) but the authors divided patients into 2 groups for 
analysis, weak (0-1) versus strong (2-3) and therefore the more complex 
relationship with CSS observed in this study would have been hidden with good 
and poor prognostic groups combined together and cancelling each other 
out(78). The KM score has been much more widely studied in other cancer types, 
particularly colorectal cancer, in which it was first described(183). A number of 
studies have reported improved survival outcomes in colorectal cancer with 
higher KM score. A recent meta-analysis reported improved DFS, OS and CSS with 
higher KM score in colorectal cancer(184) A small study reported improved 
survival in patients with oesophageal cancer with higher KM score on univariate 
analysis but this did not reach significance on multivariate analysis 
(p=0.055)(190). No association was seen in a small study of KM in bladder 
cancer(191). 
It is not clear why worse outcomes in intermediate KM groups is observed in this 
breast cancer study, rather than the positive correlation with outcome seen in 
colorectal cancer. It may be that it is due to the individual inflammatory cell 
types that make up the inflammatory infiltrate as the KM does not distinguish 
between them. However, in this study each of the individual cell types measured 
using IHC increased with increasing KM score. It may be that the ratios of 
different cell types change despite them increasing overall in number. There are 
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also a number of other inflammatory cell types not measured in this study as its 
focus was on T lymphocytes. It was not possible to reliably calculate ratios in 
this study as scoring for individual cell types had been carried out at different 
times by different people. Additionally, it was carried out on TMAs and therefore 
is more reflective of TIL numbers than inflammatory cells at the invasive tumour 
edge, which the KM assesses. It would be desirable to carry out multiplex IHC on 
full section slides to more reliably assess the components of the infiltrate 
measured by the KM score. 
Another measure of the tumour inflammatory infiltrate which has been more 
extensively covered in the breast cancer literature is measurement of tumour-
infiltrating lymphocytes. TILs have been reported to be a favourable prognostic 
factor in breast cancer(63, 66, 192-194). A 2015 review and meta-analysis 
reported that total TILs (intraepithelial and stromal) was associated with 
improved prognosis(66). However, most recent studies report on stromal TILs 
only(193, 195). This practice is in line with standardised methodology for the 
assessment of TILs by pathologists proposed initially by an International TILs 
Working Group in 2014(196) and then updated in 2017 by the renamed 
International Immuno-Oncology Biomarkers Working Group(197), citing evidence 
that assessment of intra-tumoural TILs does not add to the prognostic utility of 
stromal TILs and that the latter is more straightforward and reproducible on 
H&E-stained slides. This study used total TIL numbers to be consistent with 
methodology as the CD8+ TILs had been scored this way previously. While most 
studies have scored stromal TILs throughout the tumour stroma, one study 
measured total and peripheral sTILs separately and found peripheral sTILs to be 
associated with survival but not total sTILs(195). This measurement of peripheral 
sTILs at the invasive tumour edge is probably more reflective of the infiltrate 
scored by the KM score, so this observed association is interesting in comparison 
to the KM results in this study. Studies have also reported a predictive role for 
TILs as higher TILs are associated with higher pCR rates(66, 198-200). Variation 
in the prognostic and predictive role of TILs depending on molecular subtype has 
been reported, particularly that they have an association with outcome in triple 




The advantage of this method of assessing TILs, as well as the KM score, is that 
they both only require a single H&E-stained full section slide. The disadvantage 
however is that they do not differentiate between the different lymphocyte 
subtypes which make up the infiltrate. There is evidence that different 
lymphocyte subtypes have pro-tumour or anti-tumour actions and it may be that 
the balance between the actions of these different subtypes partially explains 
the pattern of survival association seen with our KM data. In our cohort, high 
CD8+ T lymphocytes were associated with improved CSS. This is in keeping with 
the findings of numerous other studies(64-66) and is consistent with their 
cytotoxic action against tumour cells(201). In our study, CD8+ TILs were 
consistently associated with improved CSS within the different KM scores. 
Overall, no association between CD4+ T lymphocytes and CSS was observed in 
this study, though there was an association in patients with a KM score of 2. This 
is contrary to another study which reported an association with worse cancer 
outcomes(64). However, it may be due to the more complex roles of CD4+ T 
lymphocytes with some acting as helper cells, promoting the anti-tumour 
response, and some acting as Treg cells promoting an immunosuppressive 
environment in which the tumour can grow(201). This is supported by the 
complex association with CSS observed in KM2 tumours, mirroring the association 
of KM with CSS where intermediate numbers are associated with the worst CSS. 
It should also be noted that CD4 can also be expressed by monocytes and 
macrophages(202, 203). 
In summary, this study has observed a non-independent association between 
Klintrup Makinen score and CSS, with those patients with intermediate scores 
having worse outcomes. This is likely to reflect the complex interactions 
between the tumour and the various inflammatory cells which make up the 
inflammatory infiltrate. The clinical utility of this score in breast cancer is 
therefore in doubt, particularly when compared to measurement of TILs which 
has been much more widely validated as a prognostic and predictive marker in 
breast cancer studies, particularly in triple negative and HER2-enriched breast 
cancer, and for which there is standardised methodology. Better understanding 
of the roles of and interactions between the various immune cells in the tumour 
microenvironment will be crucial in developing effective breast cancer 
therapies. This includes progressing our understanding of the more common 
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subtypes but also further investigating the role of less common subtypes such as 
FoxP3+ and γδT lymphocytes. Work related to these subtypes is ongoing in our 
lab.  
Although the KM score may have limited clinical utility in breast cancer, the use 
of a single H&E slide is a considerable advantage for a prognostic score in view 
of its simplicity and low cost. Therefore, the next chapter of this thesis will go 
on to investigate other features of the tumour and tumour microenvironment 
which are assessable on a single H&E slide and which have been reported to have 





5 Tumour necrosis, tumour budding and tumour-
stroma percentage in primary operable breast 
cancer 
5.1 Introduction 
Significant advances in breast cancer diagnosis and treatment over recent 
decades have been associated with improvements in survival rates from the 
disease, with breast cancer mortality rates in the UK falling by 22% over the last 
decade(204). Despite this, breast cancer remains the second highest cause of 
cancer death in females in the UK, accounting for approximately 31 deaths per 
day in 2014-2016(204). Consequently, ongoing work is required to identify new 
prognostic markers and novel therapeutic targets.  
Breast cancer is a heterogeneous disease, made up of several different subtypes 
which are associated with different prognosis and recognised to behave 
differently (205). There are currently no targeted systemic treatments for triple 
negative breast cancer. Patients with oestrogen receptor (ER) positive disease 
receive endocrine therapy, but the more precise benefit of chemotherapy in ER 
positive patients is yet to be determined. While genomic assays are currently 
used to aid this decision, their role is under constant refinement and these 
assays are relatively expensive (115, 116, 206).  Therefore, there is a need to 
establish further prognostic tests, ideally using methods already available in 
clinical practice. 
The tumour microenvironment and its constituent parts, including fibroblasts, 
tumour-associated stroma and various immune cells, are increasingly recognised 
to have varied and complex roles in the progression and dissemination of cancer 
(55, 207). Multiple measures of components of the tumour microenvironment 
such as tumour necrosis, tumour budding and tumour-stroma percentage (TSP) 
have shown prognostic value in a number of solid tumours (67-73, 78-80, 208-
224). In breast cancer, only one small study has reported an independent 
association between necrosis and CSS(72) while one historical study found 
necrosis to be associated with tumour size but was not independently 
prognostic(73). Three studies have reported an association between high tumour 
budding and lymph node metastases, lymphovascular invasion and poorer 
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outcomes(78-80). However, these are small studies with 148, 160 and 474 
patients respectively. They each use a different threshold to define high 
budding, and molecular subtype analysis is limited by the low patient numbers. 
Similarly, 3 smaller studies have reported an association between high TSP and 
poorer outcomes in breast cancer, particularly in TNBC(72, 212, 213). The aim of 
the present study was to validate, in a larger cohort of patients with mature 
follow up, these previously reported associations with the hypothesis that 
tumour necrosis, high tumour budding and high TSP would all be associated with 
poorer CSS but that these associations may vary in the different molecular 
subtypes and may not be independent of each other. This is with a view to 
establishing whether these features might have a prognostic role in clinical 
practice and in which group of patients they could be useful.   
5.2 Materials and methods 
5.2.1 Patient cohort 
For this study, both the 1800 and the FJ cohorts were used, with characteristics 
as described in chapter 2. 
5.2.2 Full section slide staining and scanning 
A single full section per patient was cut from surplus tissue blocks, H&E stained 
and scanned into Slidepath software as described in chapter 2. 
5.2.3 Scoring for tumour necrosis, tumour budding and TSP 
Each slide was scored for tumour necrosis, tumour budding and TSP as described 
in chapter 2. 
5.2.4 Molecular subtyping 
Ki67 scoring was available for the 1800 cohort but not for the FJ cohort. For this 
reason, in this combined cohort, analysis could not be carried out within the 
formal molecular subtypes. Subtype analysis was instead carried out in 
ER+/HER2-, ER+/HER2+, ER-/HER+ and ER-/HER2- subgroups. 
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5.2.5 Statistical analysis 
Analysis of associations with clinicopathological characteristics and with cancer 
specific survival was carried out as described in chapter 2. This analysis was 
carried out initially in the full cohort, then in the ER positive and ER negative 
cohorts separately, and subsequently in the 4 ER/HER2 receptor subtypes. 
Finally, all of this analysis was repeated in the ductal cancers only, as different 
pathological subtypes are known to behave differently and ductal cancers are 
the most common pathological subtype. This ductal analysis is included in the 
appendices.  
5.3 Results 
5.3.1 Patient cohort 
1188 patients who underwent surgery for primary operable breast cancer and 
had a score for all three markers were included in the study. 1084 (91.2%) 
patients had ductal tumours, 498 (41.9%) had grade 3 tumours and 490 (41.2%) 
had axillary lymph node involvement. 649 (54.6%) cancers were pathological 
Tumour stage 1 (pT1), 498 (41.9%) were pT2 and 40 (3.4%) were pT3. 826 (69.5%) 
tumours were ER positive, 173 (14.6%) were HER2 positive and HER2 status was 
unavailable for 131 patients. Median follow up was 158 months (26-183). Over 




Figure 5-1. Formation of the cohort. Flow diagram showing exclusions from the original cohort 
and numbers included in the final analysis, by receptor subtype.  
Patients with clinical information 
available.  
n=1301 
Patients with H&E-stained slide 
available for analysis. 
n=1211 
Patients scored for all 3 components. 
n=1188 
Eligible to be entered into survival 
analysis. 
n=1184 
Eligible to be entered into ER subgroup 
survival analysis. 
n=1181 
No excess tissue block available for H&E 
staining. 
n=90 
Available H&E slide not suitable for 
scoring for 1 or more component 
(necrosis, TSP and/or budding). 
n=23 
Incomplete survival data. 
n=4 
Missing oestrogen receptor (ER) data. 
n=3 
Eligible to be entered into ductal-only 
survival analysis. 
n=1077 


















5.3.2 Tumour necrosis 
700 (58.9%) patients had no or low (<25%) necrosis and 488 (41.1%) patients had 
high necrosis (>25%). 
  
Figure 5-2. Examples of tumour necrosis. Area of necrosis arrowed. Images of breast tumour 
tissue stained with H&E at 20x and 40x magnification. 
5.3.2.1 Associations with cancer specific survival  
In the full cohort, high necrosis was associated with worse CSS (10yr CSS 72% 
high necrosis v 87% no necrosis, p<0.001; HR 2.26, 95%CI 1.74-2.94, p<0.001). 
High necrosis was associated with worse CSS in both ER positive (10yr CSS 73% 
high necrosis v 87% no necrosis, p<0.001; HR 2.03, 95% CI 1.46-2.82, p<0.001) 
and ER negative disease (10yr CSS 70% v 87%, p<0.001; HR 2.77, 95%CI 1.54-4.98, 







Figure 5-3. The relationship between tumour necrosis and CSS in primary operable breast 
cancer. Kaplan Meier survival graphs for CSS in patients with high compared to low necrosis in a) 
the full cohort (n=1184, p<0.001), b) ER positive disease (n=823, p<0.001), and c) ER negative 
disease (n=358, p<0.001). 
In ER+/HER2- disease, high necrosis was associated with worse CSS (10yr CSS 87% 
v 73%, p<0.001; HR 1.97, 95% CI 1.36-2.86, p<0.001). This was also the case in 
ER+/HER2+ disease (10yr CSS 76% v 61%, p=0.037; HR 2.24, 95% CI 1.00-5.02, 
p=0.049) and ER-/HER2- disease (10yr CSS 87% v 71%, p=0.003; HR 2.75, 95% CI 
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1.35-5.59, p=0.005), but not in ER-/HER2+ cancers (10yr CSS 72% v 67%, p=0.733; 









Figure 5-4. The relationship between tumour necrosis and CSS in primary operable breast 
cancer, by receptor subtype. Kaplan Meier survival graphs for CSS in patients with high 
compared to low necrosis in a) ER+/HER2- disease (n=643, p<0.001), b) ER+/HER2+ disease 
(n=86, p=0.043), c) ER-/HER2+ disease (n=87, p=0.675), and d) ER-/HER2- disease (n=238, 
p=0.004).  
5.3.2.2 Associations with clinicopathological characteristics 
High tumour necrosis was associated with younger age (p=0.001), ductal subtype 
(p<0.0001), larger tumour size (p<0.001), higher tumour grade (p<0.001), nodal 
(p=0.008) and HER2 positivity (p<0.001), ER negativity (p<0.001) and a higher 
Klintrup Makinen (KM) score (p<0.001) (Table 5-1). In smaller cohorts of patients 
for whom these markers were available, necrosis was associated with high CD4 
lymphocytes (n=675, p<0.001) and high CD68 cells (a marker for macrophages, 
n=369, p<0.001).  
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Table 5-1. Associations between tumour necrosis and clinicopathological characteristics. 
Table detailing the associations between tumour necrosis and other clinicopathological 
characteristics. ER – oestrogen receptor, TSP – tumour-stroma percentage. Significant p values 




5.3.3 Tumour budding 
The median highest bud count was 11 (0-45). The distribution of highest bud 
counts is illustrated below. 
 
Figure 5-5. Budding count distribution. Histogram showing the distribution of highest bud counts 
within the whole cohort. 
900 (75.9%) tumours had low budding (highest bud count <20) and 288 (24.1%) 
had high budding. The threshold of 20 buds had been determined as the most 
prognostic in a previous smaller study(78) but ROC curve analysis supported the 








17.50 0.396 0.285 
18.50 0.383 0.269 
19.50 0.362 0.252 
20.50 0.336 0.218 
21.50 0.200 0.166 
22.50 0.170 0.141 
Figure 5-6. ROC curve analysis for highest budding count. ROC curve plotting sensitivity 
against 1-specificity of highest budding count for the outcome of CSS. Point furthest away from the 
diagonal line marked with a dotted line. Relevant coordinates highlighted in the table, confirming 20 




An example of tumour budding is shown in below. 
 
Figure 5-7. Example of tumour budding. Individual tumour bud arrowed. Image of breast cancer 
tissue stained with H&E at a) 20x magnification and b) 40x magnification. 
5.3.3.1 Associations with CSS 
In the full cohort, patients with high tumour budding had worse CSS than those 
with low tumour budding (10yr CSS 72% v 83%, p<0.001; HR 1.69, 95%CI 1.29-
2.22, p<0.001).  This effect on CSS was negated in the ER positive cohort (10yr 
CSS 79% high budding v 84% low budding, p=0.143; HR 1.33, 95%CI 0.94-1.89, 
p=0.102) but potentiated in the ER negative cohort (10yr CSS 49% high budding v 







Figure 5-8. The relationship between tumour budding and CSS in primary operable breast 
cancer. Kaplan Meier survival graphs for CSS in patients with high compared to low tumour 
budding in a) the full cohort (n=1184, p<0.001), b) ER positive disease (n=823, p=0.101), and c) 
ER negative disease (n=358, p<0.001). 
High budding was not significantly associated with CSS in either ER+/HER2- (10yr 
CSS 84% v 82%, p=0.689; HR 1.14, 95% CI 0.77-1.69, p=0.509) or ER+/HER2+ 
disease (10yr CSS 74% v 61%, p=0.220; HR 1.64, 95% CI 0.72-3.76, p=0.241). High 
budding was associated with worse CSS in ER-/HER2+ cancers, (10yr CSS 76% v 
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36%, p=0.003; HR 3.38, 95% CI 1.56-7.32, p=0.002) and in ER-/HER2- cancers 









Figure 5-9. The relationship between tumour budding and CSS in primary operable breast 
cancer, by receptor subtype. Kaplan Meier survival graphs for CSS in patients with high 
compared to low tumour budding in a) ER+/HER2- disease (n=643, p=0.508), b) ER+/HER2+ 
disease (n=86, p=0.235), c) ER-/HER2+ disease (n=87, p=0.001), and d) ER-/HER2- disease 
(n=238, p=0.001).  
5.3.3.2 Associations with clinicopathological characteristics 
High tumour budding was associated with lobular subtype (p<0.001), lower 
tumour grade (p<0.001), nodal (p<0.0001) and ER positivity (p=0.001), high TSP 
(p<0.001) and lower KM score (p=0.001)(Table 5-2). In those patients where the 
markers were available, high budding was associated with low CD4+ lymphocytes 




 Tumour budding p 
 Low (<20 buds) 
n=900 (75.9%) 







































































































































Table 5-2. Associations between tumour budding and clinicopathological characteristics.  




5.3.4 Tumour-stroma percentage 
The median TSP was 40 (0-90). The distribution of TSP across the cohort is 
illustrated below. 
 
Figure 5-10. TSP distribution. Histogram showing the distribution of TSP within the whole cohort.  
 
Patients were divided into high (>50%) and low (<50%) TSP groups at the 50% 
threshold as previously described(212, 218). ROC curve analysis supported the 







35.00 0.562 0.546 
42.50 0.421 0.356 
47.50 0.417 0.351 
52.50 0.366 0.279 
57.50 0.362 0.270 
62.50 0.119 0.093 
 
Figure 5-11. ROC curve for TSP.  ROC curve plotting sensitivity against 1-specificity of TSP for 
the outcome of CSS. Point furthest away from the diagonal line marked with a dotted line. Relevant 
coordinates highlighted in the table, confirming TSP of 50% as an appropriate threshold for division 





833 (70.1%) tumours had low TSP and 355 (29.9%) had high TSP. Examples of 





Figure 5-12. Examples of low and high TSP. a) Low TSP, b) high TSP. Images of breast tumour 
tissue stained with H&E at 20x magnification.  
5.3.4.1 Associations with CSS 
In the full cohort, patients with high TSP had worse CSS compared to those with 
low TSP (10yr CSS 77% v 82%, p=0.006; HR 1.42, 95%CI 1.09-1.86, p=0.010). In ER 
positive disease TSP was not significantly associated with CSS (10yr CSS 81% high 
TSP v 83% low TSP, p=0.440, HR 1.22, 95%CI 0.87-1.71, p=0.259). In ER negative 
disease high TSP was associated with worse CSS (10yr CSS 65% v 79%, p=0.005, 







Figure 5-13. The relationship between TSP and CSS in primary operable breast cancer. 
Kaplan Meier survival graphs for CSS in patients with high compared to low TSP in a) the full 
cohort (n=1184, p=0.009), b) ER positive disease (n=823, p=0.258), and c) ER negative disease 
(n=358, p=0.002).  
High TSP was not significantly associated with CSS in ER+/HER2- cancers (10yr 
CSS 84% v 80%, p=0.216; HR 1.40, 95% CI 0.96-2.06, p=0.083) or ER+/HER2+ 
cancers (10yr CSS 69% v 75%, p=0.620; HR 0.75, 95% CI 0.28-2.01, p=0.569). High 
TSP was associated with worse CSS in ER-/HER2+ cancers (10yr CSS 75% v 56%, 
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p=0.043; HR 2.24, 95% CI 1.05-4.79, p=0.037) and ER-/HER2- cancers (10yr CSS 









Figure 5-14. The relationship between TSP and CSS in primary operable breast cancer, by 
receptor subtype. Kaplan Meier survival graphs for CSS in patients with high compared to low 
TSP in a) ER+/HER2- disease (n=643, p=0.081), b) ER+/HER2+ disease (n=86, p=0.568), c) ER-
/HER2+ disease (n=87, p=0.032), and d) ER-/HER2- disease (n=238, p=0.015). 
5.3.4.2 Associations with clinicopathological characteristics 
High TSP was associated with nodal positivity (p=0.048) and high budding 
(p<0.001) but lower tumour grade (p<0.001) and a lower Klintrup-Makinen (KM) 
score (p<0.001)(Table 5-3). In the patients where these markers were available, 
high budding was associated with low CD4+ lymphocytes (n=679, p=0.022), low 














































































































































Table 5-3. Associations between TSP and clinicopathological characteristics.  Table detailing 
the associations between TSP and other clinicopathological characteristics.  
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5.3.5 Multivariate survival analysis 
Multivariate Cox regression survival analysis was carried out for tumour necrosis, 
budding and TSP along with other known prognostic factors. In ER positive 
disease, the only one of the 3 features which was significantly associated with 
CSS independent of other prognostic factors was tumour necrosis. However, in 
ER negative disease, all 3 were significantly associated with CSS independent of 
the other factors (Table 5-4).  
Factor ER positive ER negative 

































































Table 5-4. Multivariate survival analysis of necrosis, tumour budding, TSP and other known 
prognostic pathological factors.  Multivariate cox regression survival analysis for prognostic 
factors (p<0.05 on univariate analysis) for CSS in ER positive and ER negative primary operable 
breast cancer. 
5.3.6 A combined score of tumour necrosis and tumour budding 
5.3.6.1 Creation of the score 
Budding and TSP were combined into a single score (0=both components low, 
1=either one component high, 2=both components high). 517 (43.5%) patients 
had a score of 0, 566 (47.6%) had a score of 1, and 105 (8.8%) had a score of 2. 
5.3.6.2 Associations with CSS 
In the full cohort, a higher necrosis-budding score was associated with worse CSS 
(10yr CSS 87% v 80% v 50%, p<0.001; score 1 v 0: HR 1.65, 95% CI 1.23-2.23, 
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p=0.001; score 2 v 0: HR 4.71, 95% CI 3.26-6.79, p<0.001). In ER positive disease, 
a score of 2 was significantly associated with worse CSS compared to those with 
a score of 0 (10yr CSS 87% v 82% v 60%, p<0.001; score 1 v 0: HR 1.41, 95% CI 
0.99-2.01, p=0.059; score 2 v 0: HR 3.09, 95% CI 1.92-4.96, p<0.001). In ER 
negative disease, a higher necrosis-budding score was associated with worse CSS 
(10yr CSS 90% v 78% v 33%, p<0.001; score 1 v 0: HR 2.64, 95% CI 1.26-5.55, 







Figure 5-15. The relationship between the necrosis-budding score and CSS in primary 
operable breast cancer. Kaplan Meier survival graphs for CSS in patients with a necrosis-budding 
score of 2 compared to 1 compared to 0 in a) the full cohort (n=1184, p<0.001), b) ER positive 
disease (n=823, p<0.001), and c) ER negative disease (n=358, p<0.001). 
In ER+/HER2- cancer, a score of 2 was significantly associated with worse CSS 
than a score of 0 (10yr CSS 86% v 84% v 61%, p<0.001; score 1 v 0: HR 1.17, 95% 
CI 0.78-1.76, p=0.448; score 2 v 0: HR 2.82, 95% CI 1.65-4.82, p<0.001). In 
ER+/HER2+ cancer, a score of 1 was significantly associated with worse CSS than 
a score of 2 (10yr CSS 80% v 62% v 59%, p=0.048; score 1 v 0: HR 2.77, 95% CI 
1.09-7.07, p=0.033; score 2 v 0: HR 2.67, 95% CI 0.85-8.43, p=0.094). In ER-
/HER2+ cancers, there was an overall association between high combined 
necrosis-budding score and worse CSS (10yr CSS 72% v 77% v 26%, p=0.002; score 
1 v 0: HR 0.81, 95% CI 0.23-2.81, p=0.735; score 2 v 0: HR 3.60, 95% CI 0.99-
13.10, p=0.052). In ER-/HER2- cancers, a higher combined score was associated 
with worse CSS (10yr CSS 90% v 77% v 38%, p<0.001; score 1 v 0: HR 2.90, 95% CI 












Figure 5-16. The relationship between the necrosis-budding score and CSS in primary 
operable breast cancer, by receptor subtype. Kaplan Meier survival graphs for CSS in patients 
with a necrosis-budding score of 2 compared to 1 compared to 0 in a) ER+/HER2- disease (n=643, 
p<0.001), b) ER+/HER2+ disease (n=86 p=0.066), c)ER-/HER2+ disease (n=87, p<0.001), and d) 
ER-/HER2- disease (n=238, p<0.001). 
5.3.6.3 Associations with clinicopathological characteristics 
A high necrosis-budding score was significantly associated with ductal cancer 
(p=0.022), larger tumour size (p<0.001), higher tumour grade (p<0.001), nodal 
positivity (p<0.001), ER and PR negativity (p<0.001, p<0.001), HER2 positivity 


































































































































































Table 5-5. Associations between the necrosis-budding score and clinicopathological 
characteristics.  Table detailing the associations between the necrosis-budding score and 
clinicopathological characteristics. 
5.3.7 A combined score of tumour necrosis and TSP 
5.3.7.1 Creation of the score 
Necrosis and TSP were combined into a single score (0=both components low, 
1=either one component high, 2=both components high). 477 (40.2%) patients 
had a score of 0, 579 (48.7%) had a score of 1, and 132 (11.1%) had a score of 2. 
5.3.7.2 Associations with CSS 
In the full cohort, an increasing combined necrosis-TSP score was associated 
with worse CSS (10yr CSS 87% v 79% v 62%, p<0.001; score 1 v 0: 1.70, 95% CI 1.2-
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2.31, p=0.001; score 2 v 0: 3.63, 95% CI 2.50-5.25, p<0.001). Higher combined 
score was associated with worse CSS in both ER positive (10yr CSS 87% v 80% v 
67%, p=0.001; score 1 v 0: HR1.56, 95% CI 1.09-2.22, p=0.015; score 2 v 0: HR 
2.85, 95% CI 1.70-4.77, p<0.001) and ER negative disease (10yr CSS 87% v 77% v 
58%; score 1v 0: HR 2.10, 95% CI 1.06-4.16, p=0.033; score 2 v 0: HR 4.54, 95% CI 







Figure 5-17. The relationship between the necrosis-TSP score and CSS in primary operable 
breast cancer. Kaplan Meier survival graphs for CSS in patients with a necrosis-TSP score of 2 
compared to 1 compared to 0 in a) the full cohort (n=1184, p<0.001), b) ER positive disease 
(n=823, p<0.001), and c) ER negative disease (n=358, p<0.001). 
For those with ER+/HER2- cancer, a higher combined score was associated with 
worse CSS (10yr CSS 88% v 81% v 65%, p=0.001; score 1 v 0: HR 1.52, 95% CI 1.01-
2.29, p=0.044; score 2 v 0: HR 3.24, 95% CI 1.86-5.66, p<0.001). In ER+/HER2+ 
cancer, there was no significant association between the combined score and 
CSS (10yr CSS 76% v 63% v 74%, p=0.169; score 1 v 0: HR 2.10, 95% CI 0.88-5.01, 
p=0.095; score 2 v 0: HR 1.27, 95% CI 0.27-5.97, p=0.765). Similarly, in ER-
/HER2+ cancers, the combined score was not significantly associated with CSS 
(10yr CSS 74% v 75% v 55%, p=0.116; score 1 v 0: HR 0.89, 95% CI 0.25-3.24, 
p=0.862; score 2 v 0: HR 2.07, 95% CI 0.60-7.21, p=0.252). In ER-/HER2- disease, 
a score of 2 was significantly associated with worse CSS than a score of 0(10yr 
CSS 87% v 77% v 56%, p=0.001; score 1 v 0: HR 2.15, 95% CI 0.95-4.85, p=0.065; 












Figure 5-18. The relationship between the necrosis-TSP score and CSS in primary operable 
breast cancer, by receptor subtype. Kaplan Meier survival graphs for CSS in patients with a 
necrosis-TSP score of 2 compared to 1 compared to 0 in a) ER+/HER2- disease (n=643, p<0.001), 
b) ER+/HER2+ disease (n=86, p=0.220), c) ER-/HER2+ disease (n=87, p=0.091), and d) ER-
/HER2- disease (n=238, p<0.001).  
5.3.7.3 Associations with clinicopathological characteristics 
A high necrosis-TSP score was significantly associated with ductal tumours 
(p<0.001), larger tumour size (p<0.001), higher tumour grade (p<0.001), nodal 
positivity (p=0.001), ER and PR negativity (p<0.001, p<0.001), HER2 positivity 


































































































































































Table 5-6. Associations between the necrosis-TSP score and clinicopathological 
characteristics. Table detailing the associations between the necrosis-TSP score and 
clinicopathological characteristics. 
5.3.8 A combined score of tumour budding and TSP 
5.3.8.1 Creation of the score 
Budding and TSP were combined into a single score (0=both components low, 
1=either one component high, 2=both components high). 665 (56.0%) patients 
had a score of 0, 403 (33.9%) had a score of 1, and 120 (10.1%) had a score of 2. 
5.3.8.2 Associations with CSS 
In the full cohort, a higher combined budding-TSP score was associated with 
worse CSS (10yr CSS 84% v 77% v 71%, p<0.001; score 1 v 0: HR 1.58, 95% CI 1.19-
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2.08, p=0.001; score 2 v 0 HR 2.02, 95%CI 1.38-2.97, p<0.001). In ER positive 
disease, a score of 2 was associated with worse CSS compared to a score of 0 
(10yr CSS 83% v 85% v 74%, p=0.110; score 1 v 0: HR 0.99 95% CI 0.69-1.44, 
p=0.976; score 2 v 0: HR 1.70, 95%CI 1.09-2.66, p=0.021). In ER negative disease, 
a higher combined budding-TSP score was associated with worse CSS (10yr CSS 
86% v 59% v 56%, p<0.001; score 1 v 0 HR 3.28, 95%CI 2.09-5.15, p<0.001; score 2 







Figure 5-19. The relationship between the budding-TSP score and CSS in primary operable 
breast cancer. Kaplan Meier survival graphs for CSS in patients with a budding-TSP score of 2 
compared to 1 compared to 0 in a) the full cohort (n=1184, p<0.001), b) ER positive disease 
(n=823, p=0.046), and c) ER negative disease (n=358, p<0.001).  
In ER+/HER2- disease, a score of 2 was significantly associated with worse CSS 
(10yr CSS 83% v 85% v 74%, p=0.211; score 1v 0: HR 1.00, 95% CI 0.66-1.52, 
p=0.989; score 2 v 0: HR 1.66, 95% CI 1.00-2.75, p=0.050). In ER+/HER2+ disease, 
the combined budding-TSP score was not significantly associated with CSS (10yr 
CSS 73% v 66% v 68%, p=0.792; score 1 v 0: HR 1.26, 95% CI 0.52-3.05, p=0.605; 
score 2 v 0: HR 1.15, 95% CI 0.33-4.02, p=0.833). In ER-/HER2+ cancers, higher 
combined score was associated with worse CSS (10yr CSS 84% v 58% v 29%, 
p=0.002; score 1 v 0: HR 3.25, 95% CI 1.27-8.31, p=0.014; score 2 v 0: HR 9.12, 
95% CI 2.74-30.35, p<0.001). In ER-/HER2- cancers, a score of 1 was associated 
with worse CSS than a score of 0 (10yr CSS 85% v 56% v 70%, p<0.001; score 1 v 0: 













Figure 5-20. The relationship between the budding-TSP score and CSS in primary operable 
breast cancer, by receptor subtype. Kaplan Meier survival graphs for CSS in patients with a 
budding-TSP score of 2 compared to 1 compared to 0 in a) ER+/HER2- disease (n=643, p=0.110), 
b) ER+/HER2+ disease (n=86, p=0.871), c) ER-/HER2+ disease (n=87, p<0.001), and d) ER-
/HER2- disease (n=238, p<0.001).  
5.3.8.3 Associations with clinicopathological characteristics 
A high budding-TSP score was significantly associated with lobular tumour type 
(p=0.018), larger tumour size (p=0.015), lower tumour grade (p<0.001), nodal 



































































































































































Table 5-7. Associations between the budding-TSP score and clinicopathological 
characteristics. Table detailing the associations between the budding-TSP score and 
clinicopathological characteristics. 
5.3.9 A combined score of tumour necrosis, tumour budding and 
TSP 
5.3.9.1 Creation of the score 
Necrosis, budding and TSP were combined into a single score (0=all components 
low, 1=any one component high, 2=any two components high, 3=all components 
high). 372 (31.3%) patients had a score of 0, 543 (45.7%) score 1, 231 (19.4%) 
score 2 and 42 (3.5%) had a score of 3. 
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5.3.9.2 Associations with CSS  
In the full cohort, a higher score was significantly associated with worse CSS 
(10yr CSS 87% v 83% v 70% v 44%, p<0.001; score 1 v 0: HR 1.42, 95% CI 0.10-2.01, 
p=0.053; score 2 v 0: HR 2.79, 95% CI 1.94-4.03, p<0.001; score 3 v 0: HR 5.61, 
95% CI 3.35-9.40, p<0.001). In ER positive disease, a score of 3 was significantly 
associated with worse CSS compared to a score of 0 (10yr CSS 86% v 84% v77% 
v50%, p<0.001; score 1 v 0: HR 1.22, 95% CI 0.82-1.82, p=0.324; score 2 v 0: HR 
1.77, 95% CI 1.13-2.79, p=0.013; score 3 v 0: HR 4.24, 95%CI 2.23-8.07, p<0.001). 
In ER negative disease, a score of 2 or 3 was significantly associated with worse 
CSS compared to a score of 0 (10 year CSS 92% v 81% v 57% v 36%, p<0.001; score 
1 v 0: HR 2.71, 95% CI 1.06-6.92, p=0.037; score 2 v 0: HR 7.42, 95% CI 2.92-







Figure 5-21. The relationship between the necrosis-budding-TSP score and CSS in primary 
operable breast cancer. Kaplan Meier survival graphs for CSS in patients with a necrosis-
budding-TSP score of 3 compared to 2 compared to 1 compared to 0 in a) the full cohort (n=1184, 
p<0.001), b) ER positive disease (n=823, p<0.001), and c) ER negative disease (n=358, p<0.001).  
In ER+/HER2- disease, a score of 3 was significantly associated with worse CSS 
than a score of 0 (10yr CSS 86% v 85% v 80% v 45%, p<0.001; score 1 v 0: HR 1.17, 
95% CI 0.74-1.84, p=0.506; score 2 v 0: HR 1.51, 95% CI 0.90-2.55, p=0.122; score 
3 v 0: HR 4.90, 95% CI 2.46-9.75, p<0.001). In ER+/HER2+ cancers, the combined 
score was not significantly associated with CSS (10yr CSS 79% v 67% v 59% v 75, 
p=0.181; score 1 v 0: HR 2.17, 95% CI 0.79-5.97, p=0.135; score 2 v 0: HR 2.72, 
95% CI 0.91-8.10, p=0.073; HR 1.23, 95% CI 0.15-10.23, p=0.849). In ER-/HER2+ 
cancers, there was no significant association between the combined score and 
CSS (score 1 v 0: HR 0.55, 95% CI 0.11-2.74, p=0.467; score 2 v 0: HR 1.91, 95% CI 
0.43-8.40, p=0.393; score 3 v 0: HR 4.92, 95% CI 0.95-25.51, p=0.058). In ER-
/HER2- disease, a higher combined score was associated with worse CSS (10yr 
CSS 93% v 80% v56% v 45%, p<0.001; score 1 v 0: HR 3.42, 95% CI 1.04-11.27, 
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p=0.043; score 2 v 0: HR 9.06 95% CI 2.73-30.12, p<0.001; score 3 v 0 HR 10.46, 









Figure 5-22. The relationship between the necrosis-budding-TSP score and CSS in primary 
operable breast cancer, by receptor subtype. Kaplan Meier survival graphs for CSS in patients 
with a necrosis-budding-TSP score of 3 compared to 2 compared to 1 compared to 0 in a) 
ER+/HER2- disease (n=643, p<0.001), b) ER+/HER2+ disease (n=86, p=0.268), c) ER-/HER2+ 
(n=87, p=0.001), and d) ER-/HER2- disease (n=238, p<0.001).  
As stratification of risk in patients with ER positive lymph node negative disease 
is of particular clinical interest, we further analysed the combined necrosis-
budding-TSP score in this group of patients. In this cohort of 479 patients, a 
score of 2 or 3 was significantly associated with worse CSS (10yr CSS 95% v 91% v 
82% v 58%; score 1 v 0: HR 1.62, 95% CI 0.80-3.28, p=0.185; score 2 v 0: HR 3.58, 




Figure 5-23. The relationship between the necrosis-budding-TSP score and CSS in primary 
operable ER positive, node negative breast cancer. Kaplan Meier survival graphs for CSS in 
patients with a necrosis-budding-TSP score of 3 compared to 2 compared to 1 compared to 0, in 
ER positive, node negative breast cancer (n=429, p<0.001).  
5.3.9.3 Associations with clinicopathological characteristics 
A high combined necrosis-budding-TSP score was associated with ductal subtype 
(p=0.008), larger tumour size (0.018), nodal (p<0.001) and HER2 positivity 
(p=0.001), ER negativity (p<0.001) and higher KM score (p<0.001)(Table 5-8).  
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Table 5-8. Associations between the combined necrosis-budding-TSP score and 
clinicopathological characteristics. Table showing associations between the necrosis-budding-
TSP score and other known prognostic clinicopathological characteristics. 
5.3.10 Multivariate survival analysis for the combined 
necrosis-budding-TSP score 
A summary of the univariate survival analysis in ER positive and ER negative 
disease for each of the individual factors and each of the combined scores 





Factor ER positive ER negative 




















































































































































































































































Table 5-9. Univariate survival analysis of the relationship between various 
clinicopathological characteristics, including the combined scores, and CSS in primary 
operable breast cancer. Univariate analysis for each of the combined scores and other known 
prognostic clinicopathological characteristics for an outcome of CSS in the ER positive and ER 
negative cohorts.  
Of the individual factors and combined scores investigated in this chapter, the 
necrosis-budding-TSP score had the highest prognostic power on univariate 
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analysis. Therefore, multivariate Cox regression survival analysis was carried out 
for this score with other prognostic clinicopathological factors. The score was 
significantly associated with CSS, independent of other factors, in both ER 
positive and ER negative disease (Table 5-10). 
Factor ER positive ER negative 















































1 component high 
2 components high 

























Table 5-10. Multivariate survival analysis of the necrosis-budding-TSP score and other 
known prognostic pathological factors. Multivariate cox regression survival analysis for 
prognostic factors (p<0.05 on univariate analysis), including the necrosis-budding-TSP score, for 
CSS in ER positive and ER negative primary operable breast cancer. 
 
5.4 Discussion 
The present chapter involving over 1000 patients confirms the hypothesis that 
necrosis, tumour budding and TSP have prognostic value in primary operable 
breast cancer.  All 3 features have independent prognostic value in ER negative 
breast cancer, whilst necrosis also has prognostic value in ER positive disease.  A 
combined score of necrosis, budding and TSP shows particular prognostic power 
in both ER positive and ER negative disease. 
The present study observed that tumour necrosis is associated with worse CSS in 
both ER positive and ER negative disease. There is little in the literature 
regarding the prognostic value of tumour necrosis in breast cancer, however 
these results are in keeping with one smaller study which reported reduced CSS 
in patients with tumour necrosis(72). The association of necrosis with poor 
prognosis in other cancers has been reported, including bladder(69), renal(70, 
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222), lung(71) and colorectal(67).  One study in colorectal cancer reported 
necrosis to be associated with worse outcomes, though this was not independent 
of systemic and local inflammation, and therefore the authors suggest that the 
role of necrosis is related to its effect on tumour-related inflammation(68). 
Similarly, a large but much older cohort of breast cancer patients reported 
necrosis to be prognostic for survival on univariate analysis but this was not 
independent of inflammatory cell reaction and known prognostic tumour 
pathological features(73). In support of this, the present study observed an 
association between necrosis and high KM score but necrosis was prognostic 
independent of KM score using Cox regression analysis. It would be interesting, 
in further work going forward, to determine the associations between necrosis 
and specific immune cell subtypes. In this study we observed an association 
between necrosis and high CD4+ lymphocytes and CD68+ macrophages but this 
analysis could only be carried out in a much smaller subgroup of patients who 
had had tissue stained for CD4, CD8 and CD68. Larger studies with a broader 
range of cell markers are required. 
The present data has observed that high tumour budding is also associated with 
worse CSS in primary operable breast cancer, and this is potentiated in ER 
negative disease. In addition, the current study validates, in a much larger 
cohort of patients, results previously reported for tumour budding in smaller 
cohorts of breast cancer(78-80). Tumour budding has been more extensively 
studied in other solid tumours and has been reported to be associated with 
worse cancer outcomes in pancreatic(216, 219), oesophageal(208, 211), 
lung(215, 225), oral squamous(210, 221), and colorectal(209, 217, 223, 224, 226) 
cancers. In colorectal cancer, whilst budding reporting is not yet in routine use 
worldwide, the International Tumour Budding Consensus Conference 2016 agreed 
a single international evidence-based method for tumour budding assessment 
and reporting, and proposed that the method should be incorporated into 
colorectal cancer guidelines and staging systems (77). Tumour budding has since 
been included in the College of American Pathologists guidelines as a feature for 
reporting in colorectal cancer(75).  
Several mechanisms have been proposed regarding the role of tumour budding in 
cancer growth and dissemination. Budding is observed as a detachment of a 
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small number of tumour cells at the invasive tumour edge and characteristically 
these buds show reduced E-cadherin, the cell-cell adhesion molecule. Some 
evidence suggests that tumour buds may be in a partial epithelial-mesenchymal 
transition (EMT) state(74)(Figure 5-24). There is a potential role for the tumour 
stroma in establishing a pro-budding microenvironment(75), which is supported 
by the association between TSP and budding in the present study.   
 
Figure 5-24. Epithelial-mesenchymal transition. Diagram illustrating the process of epithelial-
mesenchymal transition. In the epithelial state, tight junctions, adherens junctions and e-cadherin 
maintain cell-cell adhesion. In the mesenchymal state these are lost and migratory potential is 
much stronger. Diagram adapted from that in a paper by Leggett et al(227).  
TSP was also associated with worse CSS overall, particularly in ER negative 
patients in the current study. This observation is in accordance with findings of 
previous studies in breast cancer that also reported TSP to have higher 
prognostic power in triple-negative tumours(212, 213). High TSP has also been 
reported to be associated with worse cancer outcomes in colorectal cancer(214, 
218, 220). Components of the tumour-associated stroma can promote tumour 
progression by secretion of growth factors, cytokines and chemokines. These 
promote cancer cell motility, invasion, resistance to apoptosis, and 
metastases(228-233). They can also regulate the immune environment to an 
immunosuppressive, pro-tumourigenic role, and the tumour stroma has been 
shown to have a role in resistance to systemic therapies in breast cancer(228, 
234). Cancer-associated fibroblasts can induce EMT(228), again providing a 
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potential explanation for the association between TSP and tumour budding 
observed in the present study. It is interesting to note, with this in mind, that 
women with high mammographic density breasts (associated with stromal 
collagen-deposition) have a higher risk of breast cancer(235) and that these 
tumours differ in terms of cytokine profile and neutrophil recruitment(236).  
Given that each of these three factors (necrosis, budding and TSP) were 
independently associated with worse CSS, they were used in combination to see 
if a combined score would have additional prognostic value. The combined score 
of necrosis, budding and TSP had the greatest prognostic power, compared to 
the combined scores involving only two of these factors. It is interesting to note 
that, although the only individual factor associated with CSS in ER positive 
disease was necrosis, which therefore is likely to be the main contributor to the 
prognostic power of the score in this cohort, the combined score did still have 
additional prognostic power compared to necrosis alone.  
The necrosis-budding-TSP score stratifies ER negative patients into four 
prognostic groups. It therefore has potential in clinical practice, alongside other 
established prognostic tumour pathological factors, for risk stratification of 
patients and therefore to aid discussions around therapeutic options, particularly 
for patients at high risk from treatment toxicities. With the current move within 
the breast surgical community to do less surgery in the axilla, the prognostic 
information from axillary lymph nodes, often used by oncologists to guide 
treatment decisions such as post-mastectomy radiotherapy, may become less 
frequently available, adding to the potential for use of this score in clinical 
practice(45).  
Excitingly, this combined score also identifies a high-risk group of patients with 
ER positive, node negative disease and this may prove useful in decisions 
regarding chemotherapy for these patients. The advantage of the combined 
score, over the genomic assays currently in use in this context, is that the only 
requirement is visual assessment of an H&E slide. Thus it would be cheaper and 
more readily available for use worldwide. Finally, in the ER positive cohort, it is 
interesting to note that a score of 3 on the Kaplan Meier graph diverges around 
the 5 year mark (CSS for those with a score of 3 drops from 78% at 5 years to 50% 
at 10 years), which is when a number of these patients would have stopped their 
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endocrine therapy. This suggests another potential clinical use for this score, in 
identifying patients who may benefit from extended endocrine therapy(51, 237).  
Limitations to the present study include retrospective data collection and that it 
is a cohort of patients from up to 20 years ago when management of breast 
cancer was different, and therefore there is a question as to whether these 
results remain applicable in the context of modern treatment regimen. In 
particular, as this work was carried out on tissue from full resection specimens, 
it is unclear at present how the prognostic score described could be applied in 
the setting of neoadjuvant treatment decision-making. Assessment of 
intratumoral budding on core biopsies has been described(79) but much more 
work would be required to evaluate scoring of all 3 features on core biopsy 
specimens, whether their prognostic power was maintained in this setting, and 
relevance to neoadjuvant treatment decisions. The issue of a historical dataset 
is weighed against the long follow up period, which is important in breast cancer 
studies as recurrence can occur many years down the line. In view of the timing 
of patient accrual to the study, we do not have full HER2 data for all patients 
and therefore could not carry out detailed analysis within the full molecular 
subtypes. Work is ongoing to create a tissue microarray for these patients to 
allow HER2 and Ki67 scoring, and subsequently more detailed subtype analysis, 
to be carried out. 
In conclusion, a combined score of tumour necrosis, tumour budding and TSP 
shows promise as an inexpensive and readily-available prognostic tool in both ER 
positive and ER negative operable breast cancer. It requires further validation in 
other, more recent cohorts, ideally in other regions and with full molecular 
subtyping. Tumour budding in particular appears to have prognostic power in ER 
negative breast cancer but what budding represents in currently unknown. This 




6 The relationship between tumour budding and 
specific gene signatures: a pilot study 
6.1 Introduction 
The findings in the previous chapter provide evidence that necrosis, TSP and 
tumour budding are associated with worse CSS in ER negative breast cancer. Of 
the 3 features, tumour budding was the strongest prognostic feature in ER 
negative disease in this cohort. Therefore, in this chapter, further investigation 
into tumour budding is carried out. 
As described in the previous chapter, tumour budding represents a phenotype 
defined in recent colorectal cancer studies as the detachment of buds of 1-5 
tumour cells from the main tumour(238-241). It has been implicated in EMT and 
development of metastases in several cancers including colorectal, pancreatic, 
oesophageal, lung, head and neck and breast(74), but there is at present little 
understanding of what this phenotype represents. In this chapter, the aim was to 
investigate genomic signatures associated with the high budding phenotype in ER 
negative disease. In view of the suggestion that budding represents a partial EMT 
state, the hypothesis was that genes associated with EMT would also be 
associated with high budding. A better understanding of the genomic, 
transcriptomic and protein pathways associated with the budding phenotype may 
identify potential therapeutic targets against this aggressive phenotype. 
TempOSeq is a targeted sequencing technology based on probe 
hybridisation(242, 243). Advantages of the technique include the absence of the 
requirement for RNA extraction, the lack of sensitivity to RNA fragmentation 
when tissue is formalin fixed and paraffin embedded, and its reproducibility in 
FFPE compared to frozen specimens is much higher than that associated with 
RNAseq when RNA has been extracted from the tissue using traditional 
methods(242, 243). Therefore, this technology can be used to profile gene 
expression from an area of <2mm2 of the FFPE H&E-stained sections available for 
our cohort. In this chapter a small pilot study is carried out, using this 
technique, to investigate the difference in genomic signatures between ER 
negative cancers with high tumour budding compared to those with no or low 
budding, and to evaluate the TempOSeq technique in this setting.  
176 
 
6.2 Materials and methods 
6.2.1 Cohort selection 
Due to financial constraints, only 50 sections could be submitted for RNA 
sequencing, so this study was carried out as a pilot study of 25 high budding 
tumours and 25 no/low budding controls. The 1800 cohort was used as this was 
the cohort for which tissue blocks were still available to our lab. Only patients 
with ER negative disease were included. They were ordered from highest 
‘highest bud count’ to lowest ‘highest bud count’ (please refer to chapter 5). 
Due to the time since the original formation of this cohort, tissue blocks for 
every patient were not available. Therefore, the high budding cohort was 
formed by working down the list from the highest bud count patient pulling 
tissue blocks until 25 high budding patients with tissue blocks were identified. 
The control cohort was formed in a similar manner, working from the lowest 
budding count upwards (Figure 6-1). 
6.2.2 Slide preparation 
Tissue sections were cut and fixed as described in chapter 2, prior to transfer to 
Bioclavis. Sections were labelled with the TMA ID only, to maintain anonymity 
but to allow data to be linked back to the master database. 
6.2.3 RNA sequencing using TempOSeq® 
RNA sequencing was carried out at Bioclavis using the protocol detailed in 
chapter 2. Samples which appeared to have become saturated during 
amplification were diluted and re-amplified. They were given a suffix of _diluted 
in the database. 
6.2.4 Data analysis 
6.2.4.1 Unbiased analysis 
Initial analysis was carried out by Bioclavis using the Temp0SeqR data analysis 
program (BioSpyder technologies, USA). Assay performance metrics were 
calculated using positive and negative controls. One sample from the high 
budding cohort was removed prior to analysis because it had a per mapping rate 
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too close to the negative control (Figure 6-1, Figure 6-2). Heatmaps were 
constructed and principle component analysis was carried out to identify any 
clustering of samples. Differential expression analysis was carried out using MA 
plots. The remainder of the analysis was carried out by EM using log2 fold 
change and adjusted p value data for each of the 22357 genes analysed, using 
Microsoft® Office Excel 16 (Microsoft, Redmond, WA, USA). Genes with a 
statistically significant fold change (adjusted p<0.10) in the high budding 
compared to low budding tumours were identified. 
6.2.4.2 Biased analysis 
A second stage of analysis was carried out to investigate whether genes 
associated with certain other tumour features/properties were also associated 
with high tumour budding. In view of the hypothesis that tumour budding may be 
related to EMT, an EMT-related gene signature reported in the literature was 
investigated to identify whether any of these genes were associated with tumour 
budding. Similarly, as the results in chapter 5 reported that high budding is 
associated with high grade, Klintrup-Makinen grade and TSP, gene signatures 
reported in the literature for proliferation, inflammation/immunity and stroma 
were also investigated. Any gene with a log2 fold change of 2 or more in either 
direction was considered to be of interest in this pilot study, regardless of p 




6.3.1 The cohort 
Of the 276 patients with ER negative breast cancer, 61 had high tumour budding, 
of which 25 with tissue blocks available were identified.  
 
Figure 6-1. Selection of the cohorts for analysis. Flow chart showing how the cohort of 25 high 









No ER status 
n=4 
High tumour budding (>20 buds) 
n=61 
Low tumour budding (<20 buds) 
n=212 
No budding status 
n=3 
Tissue available 
(Highest bud count 21- 36) 
n=25 
Tissue available 
(Highest bud count 0-8) 
n=25 
No tissue available 
(before n=25 target 
reached) 
n=29 
No tissue available 
(before n=25 target 
reached) 
n=66 
Too close to 
negative control 
n=1 
Patients included in final 
analysis 
n=24 





Quality control metrics were met for all samples but one, which was excluded 
from further analysis because of its per mapping rate. 
 
Figure 6-2. Dendrogram of Temp0Seq samples. Dendrogram showing samples which had 
Temp0Seq carried out. One sample with a per mapping rate close to the negative controls (outlined 
in red) was excluded from further analysis. 
There was no significant difference in clinicopathological features between the 
high budding and the control cohorts. 



























































































Table 6-1. Clinicopathological characteristics of the cohorts. Clinicopathological 




When principle component analysis was carried out for all of the samples, no 
clear clustering of the high budding samples was observed. 
 
Figure 6-3. Principle component analysis. Scatter plot showing no clear clustering of high 
budding samples on principle component analysis. 
However, when the top 20 or the top 50 genes were analysed (determined by 
ranking the adjusted p values), clustering of high budding samples was observed, 
though there was little separation between the groups. 
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Figure 6-4. Principle component analysis and heat map of top 20 genes. Principle component analysis and heat map of the top 20 differentially expressed genes 
in high budding tumours compared to low budding tumours, when ranked by adjusted p value.  
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Figure 6-5. Principle component analysis and heat map of top 50 genes.Principle component analysis and heat map of the top 50 differentially expressed genes in 
high budding tumours compared to low budding tumours, when ranked by adjusted p value
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6.3.3 Differential gene expression 
On MA plot analysis of the whole genome, 5 genes were differentially expressed, 
namely ODAM, LMNTD1, RFX5, TBX22 and JUNB (Figure 6-6). Despite the low 
sample size, each of these had statistical significance with adjusted p values 
<0.05. An additional 4 genes were significantly associated with high tumour 
budding when significance was defined as p<0.10, namely C7orf65, DEFA3, 
TSPO2 and FEV (Table 6-2). In view of the small sample size, all 9 of these genes 
were felt to be of interest. JUNB was overexpressed in high budding tumours 
while the other 8 genes were under-expressed when compared to no/low 









Gene Log2 fold change Adjusted p value 
ODAM_10470 -21.67390508 5.08E-10 
LMNTD1_16950 -6.327795415 0.001981035 
RFX5_5817 -0.957331392 0.005303307 
TBX22_18996 -6.266009835 0.019374302 
JUNB_3476 1.133353948 0.045423795 
C7orf65_26215 -4.981285379 0.07858763 
DEFA3_34006 -3.458724686 0.07858763 
TSPO2_87465 -5.446552656 0.079250702 
FEV_89925 -4.599240538 0.079250702 
Table 6-2. Genes associated with high budding. Table to show genes significantly associated 
with high tumour budding (adjusted p<0.10) with log 2 fold change (negative value = gene under-
expressed in high budding samples, positive value = gene over expressed in high budding 
samples).   
 
Figure 6-7. Log2 fold changes of genes associated with high tumour budding. Genes 
significantly (adjusted p<0.10) associated with high tumour budding. Negative log2 fold change 




















The top 20 under-expressed genes when ordered by log2fold change, regardless 
of adjusted p value, are shown in Table 6-3 and Figure 6-8. 
Gene Log2 fold change Adjusted p value 
CXorf51A_28526 -5.469168841 0.137760652 
CACNA2D3_10872 -5.495757679 0.411760366 
AK7_14244 -5.497712438 0.274411945 
B3GNT6_16482 -5.522703217 0.624087369 
MUC5AC_33972 -5.603885245 0.753514367 
SMR3A_25046 -5.666009126 0.28611906 
OR2A5_24846 -5.69576121 0.411760366 
OR2T33_28562 -5.717346908 0.411933075 
IQCF6_18544 -5.753724239 0.742692709 
ABCG2_25072 -5.759850284 0.476318603 
RPL10L_21828 -5.788856054 0.382662613 
FLJ45513_15717 -5.800807318 0.137760652 
SERPINB12_15476 -5.870567158 0.137760652 
LGALS16_12287 -5.950707368 0.411760366 
NEUROD1_21767 -5.988195633 0.137760652 
GIMD1_18976 -6.159071965 0.224803823 
TBX22_18996 -6.266009835 0.019374302 
LMNTD1_16950 -6.327795415 0.001981035 
CLDN20_89808 -6.369118435 0.186675354 
ODAM_10470 -21.67390508 5.08E-10 
Table 6-3. Top 20 downregulated genes. 20 downregulated genes with highest log2 fold change, 
regardless of adjusted p value. P values <0.10 are highlighted in bold. 
 
Figure 6-8. Top 20 under-expressed genes. The top 20 under-expressed genes in high budding 
tumours, ranked by log2 fold change regardless of adjusted p value. 
The top 20 over-expressed genes when ordered by log2fold change, regardless of 



















Gene Log2 fold change Adjusted p value 
TMEM80_12837 4.857853809 0.722280467 
MMP27_26120 4.468012524 0.751797539 
TSLP_15791 4.315909273 0.753514367 
DEFB132_13526 4.146491249 0.224803823 
IGSF22_87763 4.126676816 0.741406955 
LGALS9C_33893 4.044036848 0.842257468 
CLEC3A_89796 4.040631403 0.476318603 
KRT13_90016 3.923890453 0.671678235 
SKP1_92580 3.917842063 0.796037379 
OR13C8_26182 3.914452784 0.886439732 
KCNK18_18748 3.885310945 0.759464518 
IL12A_16427 3.850510942 0.771821104 
GAGE12H_33626 3.813749585 0.826923871 
CLEC12B_12546 3.758917401 0.796037379 
ANXA10_10678 3.733644368 0.886439732 
CCDC197_88898 3.692522362 0.797471532 
PSG4_25648 3.679085901 0.551401805 
ZNF577_13278 3.668203113 0.841522977 
SERPINA2_18838 3.652173389 0.90766013 
ZNF257_12562 3.638369425 0.769561568 
Table 6-4. Top 20 upregulated genes. 20 upregulated genes with highest log2 fold change, 
regardless of adjusted p value. None had p<0.10. 
 
Figure 6-9. Top 20 over-expressed genes. The top 20 over-expressed genes in high budding 
tumours, ranked by log2 fold change regardless of adjusted p value. 
6.3.4 EMT-associated gene expression 
As tumour budding has been hypothesised to be related to EMT, EMT associated 
genes were investigated for their association with tumour budding. The top 20 
EMT-associated genes as reported by Zhao and colleagues(244) were selected for 




















of an adjusted p value <0.10 or a log2 fold change of >2 in either direction 
(Table 6-5, Figure 6-10). 
Gene Log2 fold change Adjusted p value 
SMAD2_87442 -0.452939559 0.497826542 
ERBB2_88307 1.008340544 0.821898969 
SMAD7_12470 0.323588783 0.852885718 
ILK_28806 -0.247318142 0.867154666 
SMAD4_6563 0.557366798 0.882828754 
ZEB2_23804 0.309804472 0.893189103 
CTNNB1_1633 -0.223141521 0.941573573 
SNAI1_24734 -0.542307579 0.949082394 
EPAS1_16750 0.392035561 0.952696439 
ZEB1_7834 1.030299905 0.973028805 
MET_4125 1.196778837 0.973028805 
IGF1R_3254 -0.224919614 0.973541439 
HIF1A_2945 -0.240403247 0.974907314 
SMAD3_6562 0.172699357 0.977577551 
TWIST1_20872 0.259923553 0.981902443 
AKT1_210 0.192725573 0.981928361 
CDH1_1186 0.191330577 0.99417153 
EGFR_2063 -0.01669307 0.99963455 
SNAI2_24257 0.039971503 0.99963455 
TGFB1_27949 -0.052067202 0.99963455 
Table 6-5. Top 20 EMT-associated genes. None of the top 20 EMT-associated genes were 
significantly associated with tumour budding. 
 
Figure 6-10. Top 20 EMT-associated genes. Differential expression of the top 20 EMT-

























6.3.5 Proliferation-associated gene expression 
As tumour grade was associated with tumour budding in the previous chapter, 
proliferation-associated genes were investigated for their relationship with 
tumour budding. When the genes in the proliferation signature described by 
Whitfield and colleagues(245) were investigated, none were associated with high 
tumour budding either by the definition of an adjusted p value <0.10 or a log2 
fold change of >2 in either direction. The top 20 over or under-expressed genes 
by log2 fold change are shown in Table 6-6 and Figure 6-11 below. 
Gene Log2 fold change Adjusted p value 
CCNE1_1070 0.678180781 0.985609972 
MCM6_20957 -0.694336338 0.943562789 
MYB_4387 -0.701375987 0.90766013 
NASP_16246 -0.705365677 0.216058692 
CTPS1_1637 -0.730483094 0.973028805 
CDC25C_19441 -0.762438101 0.937246645 
CCNB1_1053 -0.76561175 0.933863281 
PLK1_5203 -0.830012122 0.782518966 
DDX11_13416 -0.831243629 0.794354392 
BIRC5_709 -0.835264684 0.969543647 
MKI67_28355 -0.882138149 0.86676989 
PCNA_4987 -0.953452259 0.923181684 
PRIM1_26195 -0.99540237 0.963299143 
CDC7_19277 -1.028263705 0.854708164 
CKS2_92658 -1.127034735 0.794420592 
MCM4_4075 -1.128666354 0.538745025 
FEN1_2387 -1.165960135 0.616891593 
TYMS_21327 -1.250112629 0.285286658 
CENPF_1252 -1.330196597 0.654022047 
RRM2_25733 -1.5905154 0.652488961 
Table 6-6. Top 20 proliferation-associated genes. None of the top 20 proliferation-associated 
genes were significantly associated with tumour budding 
 
Figure 6-11. Top 20 proliferation-associated genes. Differential expression of the top 20 


















6.3.6 Inflammation-associated gene expression 
In the previous chapter, tumour budding was associated with inflammatory cell 
infiltrate (Klintrup Makinen grade). Therefore, inflammation-associated genes 
were investigated for their association with tumour budding. A 17 gene immunity 
signature reported by Yang and colleagues(246) was selected for investigation. 
None of the genes were associated with high tumour budding either by the 
definition of an adjusted p value <0.10 or a log2 fold change of >2 in either 
direction (Table 6-7, Figure 6-12). 
Gene Log2 fold change Adjusted p value 
APOBEC3G_11453 0.893210897 0.987131933 
CD52_13919 0.27300838 0.979645955 
CD2_12308 0.22581409 0.994963222 
PTPRC_5605 -0.026939881 0.99963455 
GZMK_88700 -0.124475363 0.99963455 
PRKCB_17133 -0.300826428 0.981134553 
CORO1A_1507 -0.321342479 0.95861623 
LCK_21336 -0.345390724 0.971033723 
CD3D_1127 -0.50031214 0.949624064 
CXCL9_88188 -0.549216484 0.969543647 
CD27_87841 -0.6885763 0.893189103 
GZMA_88696 -0.761682536 0.783113889 
HLA-DMA_27315 -0.848189727 0.852514812 
IL2RG_15624 -0.885880944 0.92493824 
CCL5_24896 -1.327594711 0.725985453 
SH2D1A_20738 -1.454421351 0.933863281 
CCR2_88510 -1.744589821 0.59940306 
Table 6-7. Immunity-associated genes. None of the 17 immunity-associated genes were 
significantly associated with tumour budding 
 
Figure 6-12. Immunity-associated genes. Differential expression of 17 immunity-associated 





















6.3.7 Stromal-associated gene expression 
As TSP was associated with budding in the previous work, stromal-associated 
genes were investigated for their association with tumour budding. The top 20 
genes (by adjusted p value) in a stromal gene signature described in breast 
cancer by Winslow and colleagues(247) were selected for investigation. None 
were associated with tumour budding either by the definition of an adjusted p 
value <0.10 or a log2 fold change of >2 in either direction (Table 6-8, Figure 
6-13). 
Gene Log2 fold change Adjusted p value 
SFRP2_13438 1.014523743 0.258785 
MMP2_4213 0.894817655 0.864873 
COL1A2_20081 0.847423878 0.436128 
DCN_27099 0.809936235 0.780617 
POSTN_20868 0.706350757 0.71678 
VCAN_20627 0.698025242 0.551402 
DPT_26697 0.674431459 0.790799 
COL6A3_13292 0.638170904 0.637922 
MMP2_27519 0.635171355 0.583813 
COL1A1_1466 0.602504943 0.782467 
LUM_17157 0.547305097 0.795848 
DCN_27098 0.534879101 0.826924 
DCN_1779 0.451157342 0.939316 
CTSK_10977 0.430861127 0.848861 
CDH11_23329 0.398191959 0.904628 
IGLV6-57_89187 0.372736537 0.999635 
IGHA1_88367 -0.052550726 0.999635 
IGKV1-5_3282 -0.257571765 0.999635 
IGLJ3_91164 -0.284814175 0.999635 
LOC652493_3838 -0.374086124 0.98561 
CCL19_88586 -0.401966663 0.969544 
IL7R_3347 -0.479979314 0.977862 
Table 6-8. Stroma-associated genes. None of the stroma-associated genes studied were 




Figure 6-13. Stroma-associated genes. Differential expression of the top 20 proliferation-

























This exploratory pilot study of 50 ER negative breast tumours has identified 9 
genes associated with tumour budding which warrant further investigation, 
namely ODAM, LMNTD1, RFX5, TBX22, JUNB, C7orf65, DEFA3, TSPO2 and FEV. 
ODAM (Odontogenic ameloblast associated protein) showed the greatest 
differential expression in this cohort, with under-expression by a log2 fold 
change of -21.7 in high budding tumours compared to no/low budding tumours. 
ODAM is a constituent protein of calcifying epithelial odontogenic, glandular and 
epithelial tissues(248). It is a tight-junction protein which contributes to cell 
adhesion. There is evidence for a regulatory role in breast cancer 
tumourigenesis. In vitro studies of triple negative MDA-MB-231 breast cancer 
cells reported that ODAM expression resulted in increased rates of apoptosis, 
increased adhesion to extracellular matrices, increased cell aggregate 
formation, reduced cell proliferation (also in MCF-7) reduced migration and 
invasiveness(249). In vivo, ODAM expression in MDA-MB-231 tumours was 
associated with greatly reduced tumour growth and greatly reduced pulmonary 
metastatic disease. The tumours had reduced Ki-67 expression and higher levels 
of caspase-3. The authors of the study suggest that the regulatory effects of 
ODAM may in part be due to inhibition of Runx2(249). Nuclear ODAM expression 
has been reported to be associated with improved 5 year survival in breast 
cancer patients(250). 
Under expression of LMNTD1 (lamin tail domain-containing protein 1) was also 
significantly associated with high tumour budding (log2 fold change -6.32, 
p=0.002). There is very limited literature related to the role of LMNTD1 in 
normal or cancer cells. It is however considered to be part of the Pas1c1 gene 
which is a locus on chromosome 6 which has been implicated in lung cancer in 
mice(251-253). 
Under expression of RFX5 (Regulatory factor X5) was significantly associated with 
high tumour budding (log2 fold change -0.96, p=0.005). It is a transcriptional 
activator which has a role in lymphocyte development and, in particular, 
transcription of the alpha and beta chains of MHC class II(254, 255). This finding 
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therefore may be relevant to the finding in the previous chapter of an 
association between tumour budding and KM grade. 
Under-expression of TBX22 (T-box transcription factor 22) was associated with 
high tumour budding (log2 fold change -6.27 p=0.019). The gene encodes a T-
box-containing transcription factor, a family of transcription factors which are 
involved in developmental processes. Mutations in this gene are implicated in X-
linked cleft palate(256) and therefore the bulk of available research into this 
gene is in that field. There is little available literature regarding the role of this 
gene in cancer. One small Iranian study of colorectal cancers did report it as one 
of the 10 most amplified markers(257). Conversely, an earlier American study 
reported TBX22 to be one of the most frequently deleted genes in colorectal 
cancer(258). Its role in tumourigenesis is currently unknown. 
The only gene to be significantly overexpressed in tumours with high budding 
was JUNB (Transcription factor jun-B) (log2fold change 1.13, p=0.045). In normal 
cells it is thought to be a growth-arrest mediator with a negative effect on 
proliferation(259). A recent study in breast cancer reported over-expression of 
JUNB in circulating tumour cells and in metastases when compared to the 
primary tumour and has reported its association with poor prognosis(260). 
Studies have suggested a critical role for JUNB in EMT(261, 262). Another has 
demonstrated induction of JUNB in response to kinase inhibitors and therefore 
has suggested a role for the gene in the development of chemotherapy 
resistance(263). Similarly, it has been implicated as an oncogene in NSCLC(264). 
Conversely, in other malignancies such as lymphoma, it is postulated to be an 
anti-oncogene(265). 
The other 4 genes significantly under-expressed (when p<0.10 rather than 0.05) 
in high budding tumours were the uncharacterised C7orf65 (Chromosome 7 Open 
Reading Frame 65), DEFA3 (Defensin Alpha 3) which encodes a protein found in 
the microbicidal granules of neutrophils(266), TSPO2 (Translocator Protein 2) 
which binds cholesterol and mediates its redistribution during 
erythropoiesis(267), and FEV (Fifth Ewing Variant) which is a member of the ETS 
transcription family and functions as a transcription repressor(268). There is very 
limited published literature relating to these genes in cancer. 
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In summary, 9 genes were significantly associated with tumour budding in our 
study, but 2 are of particular interest in the context of the published literature. 
Under-expression of ODAM may lead to reduced cell adhesion and increased 
migration and invasiveness, resulting in the identifiable phenotype of tumour 
budding. Over-expression of JUNB may be significant in the EMT process thought 
to be strongly related to budding, and the high expression levels in CTCs and 
metastases compared to the primary tumour, reported in the literature, support 
its role in the process of EMT, budding and metastases development. 
Despite the identification of differential expression of these genes, clear 
clustering of genes in high budding patients was not observed. There are several 
possible reasons for this. There may have been signal dilution as full sections of 
tumour were used, rather than just analysing the invasive edge where budding 
takes place. Secondly, it may be that a transient signal occurs which is gone by 
the time the tumour displays the high budding phenotype. Another possible 
explanation is that the budding phenotype is not controlled at the gene 
transcription level but further downstream in cell signalling pathways. 
Furthermore, the very small numbers in the study will have limited the power of 
the study to detect significant differences and may explain why no significant 
findings resulted from the biased analysis. 
In conclusion, this small pilot study has identified 9 genes which merit further 
investigation in relation to tumour budding in ER negative breast cancer, with 
ODAM and JUNB of particular interest. It has validated the use of the TempOSeq 
technique in this context and these results should be validated in larger cohorts. 








7 IL6 and the IL6 receptor in primary operable 
breast cancer. 
7.1 Introduction 
Thus far, this thesis has examined the relationships between cancer outcomes 
and markers of the systemic inflammatory response, the local inflammatory 
infiltrate, and specific phenotypic features of the tumour and tumour 
microenvironment. As examples, the neutrophil-lymphocyte ratio, TILs and 
specifically CD8+ T lymphocytes, and tumour budding have been observed to be 
associated with CSS. The question therefore arises as to what may link the 
observed prognostic association of certain inflammatory cells with the poor 
prognostic associations observed with certain tumour phenotypic features such 
as necrosis and budding. Cell signalling pathways link external stimuli such as 
cytokines within the tumour microenvironment with signalling pathways and 
hence gene expression in tumour cells. 
The IL6/JAK/STAT3 pathway is one such pathway. As described in chapter 1, the 
JAK/STAT3 pathway can be stimulated by numerous ligands, including IL-6. Il-6 
binds to the IL6 receptor (IL6R) which may be either membrane-bound or soluble 
and induces homodimerization of gp130. Receptor-associated JAKs are then 
activated and can phosphorylate each other as well as allowing 
autophosphorylation by phosphorylating the intracellular portion of their 
receptors and other signalling proteins such as STAT3 when in the cytoplasm, 
permitting STAT3 dimerisation and its translocation to the nucleus where it can 




Figure 7-1. Initiation of the IL6/JAK/STAT3 pathway.  Diagram illustrating the first stage of the 
Il6/JAK/STAT3 pathway. IL6 binds with the IL6 receptor leading to activation of JAKs which 
phosphorylate each other and phosphorylate tyrosine residues of the membrane-bound receptor. 
Il-6 is a cytokine with numerous and varied functions including roles in 
metabolism, haematopoiesis, organ development, immune and inflammatory 
responses(269). It is produced by immune cells, fibroblasts and various tumour 
cells(270-272). In classical signalling it binds to the membrane-bound IL6R, 
which is only expressed by certain cells in the body including hepatocytes and 
certain immune cells such as macrophages, neutrophils and CD4+ T cells(269). 
Signal transduction is then mediated by gp130. In the alternative pathway, 
termed trans-signalling, IL-6 binds to soluble IL6R (sIL6R) and these complexes 
then have the potential to activate all cells due to the ubiquitous expression of 
gp130(273). In its most simplistic view, classical signalling has generally been 
accepted as having anti-inflammatory and regenerative roles whereas trans-
signalling has been ascribed a pro-inflammatory role(273). The true situation is 
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In cancer, a role for IL6 in progression and metastatic spread has been 
recognised(270, 274-277) due to its actions within the tumour 
microenvironment(275). IL6/IL6R/gp130 blockade is therefore a potential 
therapeutic option in cancer and various agents have been investigated in 
certain cancers(270), though rarely in breast cancer to date. However, a number 
of studies have investigated the role of IL6 in breast cancer. An association 
between high serum levels of IL6 and poorer prognosis has been reported(270, 
274, 278-281). A degree of dependence on IL6 for growth and progression has 
been observed in breast cancer, particularly in HER2+ and triple negative 
subtypes(282). IL6 is secreted both by the breast cancer cells themselves and by 
cells within the tumour microenvironment such as CAFs and mesenchymal stem 
cells(277, 283-286). IL6 has also been implicated in treatment resistance(287-
289). It is therefore important to develop our understanding of the actions of 
IL6/IL6R/gp130 in breast cancer as it may represent a promising therapeutic 
target. 
With the evidence above in mind, for the present study it was postulated that 
high expression of IL6 and Il6R would be associated with poorer CSS. Whether IL6 
is predominantly expressed in the tumour cells or stromal cells is of interest to 
try to understand the mechanisms driving tumour growth, The study aimed to 
describe the expression and distribution of IL6 and IL6R in tumour cells and in 
the stroma, their associations with each other, with other features of the 
tumour and tumour microenvironment, and with cancer outcomes in primary 
operable breast cancer.       
7.2 Materials and methods 
7.2.1 Patient cohort 
The 1800 cohort was used for this study as tissue blocks were available for 
cutting of a previously constructed TMA. Patient characteristics are detailed in 
chapter 2.  
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7.2.2 IL6 expression 
7.2.2.1 RNA scope 
Due to the secreted nature of IL6, previous efforts in the lab to stain and 
quantify IL6 expression in cells using IHC were unsuccessful. Therefore for this 
study, RNA scope, which assesses mRNA expression rather than protein 
expression, was used to stain fresh TMA slides. The technique is described in 
chapter 2. TMAs were stained in triplicate. 
7.2.2.2 Quantifying expression 
Stained slides were scanned and subsequently analysed using HALO™ Image 
Analysis Software, as described in chapter 2, to quantify probe expression of 
both IL6 and the housekeeper gene. A normalised ratio (IL6/HK ratio) was 
formed as described in chapter 2 and used in the analysis. 
7.2.3 IL6R expression 
7.2.3.1 TMA slide staining and scanning 
TMAs were stained in triplicate for IL6R using the IHC technique and antibody 
detailed in chapter 2. They were scanned into Slidepath software as previously 
described. 
7.2.3.2 Scoring for IL6R expression 
Each TMA core was scored by the author using the weighted histoscore method 
described in chapter 2. Cores which were assessed visually to have >20% of the 
core missing were not scored. As the IL6 receptor can be membrane-bound or 
soluble, IL6R expression in tumour cells was scored separately for membranous 
and cytoplasmic expression. A separate score was also given for expression in 
stromal cells (differentiation between membranous and cytoplasmic expression 
in these smaller cells was not reliably possible at 20x magnification). 
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7.2.4 Molecular subtyping 
ER, PR, HER2 and Ki67 profiling had previously been carried out in the lab for 
this cohort. This data was used to divide the cohort into the four main molecular 
subtypes of breast cancer, as detailed in chapter 1, for subgroup analysis. 
7.2.5 Statistical analysis 
Initial analysis using ROC curves and division into tertiles and at the median was 
carried out to determine the optimum threshold for division into high and low 
expression groups for further analysis. Analysis of associations with 
clinicopathological characteristics and with cancer specific survival was carried 
out as described in chapter 2. This analysis was carried out initially in the full 
cohort, then in the ER positive and ER negative cohorts separately, and 
subsequently in the 4 individual molecular subtypes. 
7.3 Results 
7.3.1 Formation of the cohort for IL6 analysis 
Of 850 patients in the cohort, 702 had at least one core assessable for tumour 
and stromal counts of IL6, while 649 had at least one assessable core for tumour 
and stromal HK gene probe counts. 645 had calculable tumour IL6/HK ratios and 




Figure 7-2. Formation of the IL6 cohort. Flow diagram to illustrate the number of patients within the 1800 cohort with at least 1 core which was assessable for IL6 
and the housekeeper gene for tumour expression and separately for stromal expression. The numbers available for subgroup analysis by ER status and by molecular 
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7.3.2 IL6 expression 
On initial visual inspection of the stained TMA slides, IL6 staining was often 
present in clusters which could be both in the tumour and the stroma, while in 









Figure 7-3. TMA cores stained for IL6.  Images of TMA cores stained using the RNA scope 
technique for IL6. a) and b) demonstrate clustering of staining while c) and d) display sparser 
staining. 
The median IL6/HK ratio in tumour was 0.06 (0.00-534.69). Overall, IL6 was 
more highly expressed in stroma with a median IL6/HK ratio of 0.11 (0.00-




Figure 7-4. Expression of IL6 in tumour and stroma.  Box plots illustrating the range of 
expression levels of IL6 in tumour compared to stroma. Extreme outliers are not shown due to the 
scale which would be required. Median expression in stroma was higher than that in tumour 
(p<0.001). 
 





Figure 7-5. Expression of IL6 in tumour by molecular subtype.  Box plots illustrating the 
expression of IL6 in tumour in the 4 molecular subtypes. There was no significant difference 
between the subtypes (p=0.205). 
Overall there was no significant difference in stromal IL6 expression between the 
molecular subtypes (p=0.070) (Figure 7-6). However, when the two subtypes 
were directly compared, triple negative tumours had significantly higher stromal 




Figure 7-6. Stromal expression of IL6 by molecular subtype.  Box plots to illustrate the 
expression of IL6 in stroma in the different molecular subtypes. There was no significant difference 
between the subtypes (p=0.070). 
 
There was a strong positive correlation between tumour and stroma IL6/HK ratio 







Figure 7-7. Tumour versus stromal IL6 scatterplots. Scatterplots to illustrate the correlation of tumour and stromal IL6/HK ratios, a) includes all cases as at large 
scale, b) uses a much smaller scale and excludes the major outliers to more clearly illustrate the majority of tumours with lower expression.
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7.3.3 The relationship between IL6 and CSS 
To determine thresholds to use in further analysis, ROC curves were constructed 





Figure 7-8. ROC curves for IL6 and CSS. ROC curves illustrating the relationships between CSS 
and a) tumour IL6/HK ratio (AUC 0.539), b) stromal IL6/HK ratio (AUC 0.515). 
As no clear threshold was identified from the ROC curves, exploratory analysis 
using Kaplan Meier curves and divisions at the median, into tertiles and into 
quartiles was carried out. This identified division into tertiles as the optimum 
grouping for further survival analysis. Division points for stromal IL6/HK ratio 
tertiles were 0.07 and 0.18. Tumour IL6/HK ratio was divided at 0.09 which 
defined the highest tertile. 
7.3.3.1 IL6 and CSS in the full cohort 
When the whole cohort was analysed, high tumour IL6/HK ratio (>0.09) was 
significantly associated with worse CSS (HR 1.45, 95% CI 1.02-2.05, 
p=0.037)(Figure 7-9). There was no association between stromal IL6/HK ratio 
and CSS (medium v low: HR 1.00, 95% CI 0.65-1.52, p=0.985; high v low: HR 1.09, 





Figure 7-9. Association of tumour IL6 with CSS. Kaplan Meier graphs illustrating the relationship 
between the tumour IL6/HK ratio and CSS, a) divided into tertiles (low <0.04, medium 0.04-0.08, 






Figure 7-10. Association of stromal IL6 with CSS. Kaplan Meier graphs illustrating the 
relationship between the stromal IL6/HK ratio and CSS. IL6/HK is divided into tertiles (low <0.07, 
medium 0.07-0.17, high >0.18), n=649, p=0.888. 
7.3.3.2 IL6 and CSS by ER status 
When analysed separately, there was no significant association observed 
between tumour IL6/HK ratio and CSS in either ER positive (HR 1.50, 95% CI 
0.96-2.36, p=0.077) or ER negative disease (HR 1.32, 95% CI 0.77-2.27, p=0.317). 
Similarly, no association was observed between stromal IL6/HK ratio and CSS in 
ER positive (Medium v low: HR 0.78, 95% CI 0.45-1.37, p=0.388; high v low: HR 
1.02, 95% CI 0.60-1.74, p=0.946) or ER negative disease (Medium v low: HR 1.22, 





Figure 7-11. Tumour IL6 and CSS by ER status. Kaplan Meier graphs to illustrate the 
relationship between tumour IL6/HK ratio and CSS in a) ER positive disease (n=446, p=0.075) and 










Figure 7-12. Stromal IL6 and CSS by ER status. Kaplan Meier graphs to illustrate the 
relationship between stromal IL6/HK ratio and CSS in a) ER positive disease (n=445, p=0.589) and 
b) ER negative disease (n=203, p=0.846). 
7.3.3.3 IL6 and CSS by molecular subtype 
When analysed individually, there was no association observed between tumour 
IL6/HK ratio and CSS in luminal A (HR 1.51, 95% CI 0.77-2.95, p=0.227), luminal B 
(HR 1.55, 95% CI 0.72-3.34, p=0.264), HER2-enriched (HR 1.45, 95% CI 0.59-3.56, 









Figure 7-13. Tumour IL6 and CSS by molecular subtype.  Kaplan Meier graphs to illustrate the 
relationship between tumour IL6/HK ratio and CSS in a) luminal A (n=296, p=0.224), b) luminal b 




Similarly, there was no association observed between stromal IL6/HK ratio and 
CSS in luminal A (medium v low: HR 1.07, 95% CI 0.46-2.52, p=0.876; high v low: 
HR 1.37, 95% CI 0.58-3.20, p=0.474), luminal B (medium v low: HR 0.73, 95% CI 
0.26-2.08, p=0.560; high v low: HR 1.03, 95% CI 0.44-2.38, p=0.952), HER2-
enriched (medium v low: HR 1.43, 95% CI 0.44-4.70, p=0.552; high v low: HR 
1.56, 95% CI 0.51-4.78, p=0.433) or triple negative breast cancer (medium v low: 










Figure 7-14. Stromal IL6 and CSS by molecular subtype.  Kaplan Meier graphs to illustrate the 
relationship between stromal IL6/HK ratio and CSS in a) luminal A (n=295, p=0.730), b) luminal b 
(n=99, p=0.806), c) HER2-enriched (n=58, p=0.720) and d) triple negative breast cancer (n=128, 
p=0.905). 
7.3.4 Formation of the cohort for IL6R analysis 
678 patients had one or more core assessable for cytoplasmic and membranous 
IL6R expression. 642 patients had one or more cores which were assessable for 




Figure 7-15. Formation of the IL6R cohort.  Flow diagram to illustrate the number of patients within the 1800 cohort with at least 1 core which was assessable for 
IL6R expression in the tumour membrane and cytoplasm, and separately in the stroma. The numbers available for subgroup analysis by ER status and by molecular 
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7.3.5 IL6R expression 
No nuclear IL6R expression was observed. Cytoplasmic, membranous and stromal 
expression were present. Examples of slides stained for IL6R expression using IHC 
are shown below (Figure 7-16). 
 
Figure 7-16. Examples of IL6R staining. TMA cores stained using IHC for IL6 receptor: a) breast 
core with moderate cytoplasmic and moderate and strong membranous staining at 10x 
magnification with an inset at 40x magnification, b) breast core with weak cytoplasmic staining, c) 
true positive core (control, liver) at 10x magnification, d) true negative core at 10x magnification. 
 
Highest IL6R expression was in the cytoplasm. Median weighted histoscore was 
105 (0-300) for cytoplasmic IL6R expression, 0 (0-150) for membranous 
expression and 55 (0-202.50) for stromal expression. Expression of IL6R in each 









Figure 7-17. Histograms of IL6R expression. Histograms to illustrate IL6R expression in a) tumour cell cytoplasm, b) tumour cell membrane and c) stromal cells. 
 
 
Figure 7-18. Boxplots of IL6R expression. Boxplots to illustrate the expression of IL6R in tumour cell cytoplasm, tumour cell membrane and stromal cells. The 
highest IL6R expression was observed in cytoplasm (p<0.001).
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In the molecular subtypes, highest cytoplasmic IL6R expression was in the HER2-
enriched subtype (p=0.003). 
 
Figure 7-19. Boxplots of cytoplasmic IL6R expression within molecular subtypes. Boxplots to 
illustrate cytoplasmic IL6R expression within the different molecular subtypes. Highest expression 
is observed in the HER2-enriched subtype (p=0.003). 
There was no significant difference in membranous or stromal IL6R expression 
observed between the molecular subtypes. 
 
 
Figure 7-20. Boxplots of membranous IL6R expression within molecular subtypes. Boxplots 




Figure 7-21. Boxplots of stromal IL6R expression within molecular subtypes. Boxplots to 
illustrate stromal IL6R expression within the different molecular subtypes (p=0.399). 
 
A moderate significant correlation between stromal and cytoplasmic IL6R 
expression was observed (Pearson correlation coefficient 0.472, p<0.001) but no 
significant correlation was observed between stromal and membranous IL6R 








Figure 7-22. Tumour and stromal IL6R expression correlation. Scatter plots to illustrate a) a positive correlation between stromal and tumour cytoplasmic IL6R 




7.3.6 The relationship between IL6R and CSS 
ROC curves for cytoplasmic, membranous and stromal expression of IL6R were 
constructed with an outcome of CSS to determine suitable thresholds to use in 
survival analysis going forward.  No threshold was identified for cytoplasmic 
expression.   A mean WHS of 2.5 was derived for membranous IL6R and a mean 
WHS of 82 for stromal IL6R.  The median was used to divide patients into high 









Figure 7-23. ROC curves of IL6R expression and CSS.  ROC curves to show the relationship with CSS of IL6R expression in a) tumour cytoplasm (AUC 0.511), b) 
tumour cell membrane (AUC 0.554) and c) stromal cells (AUC 0.531). 
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7.3.6.1 Cytoplasmic IL6R expression and CSS 
No significant association was observed between cytoplasmic IL6R expression and 
CSS when analysed divided at the median (HR 1.12, 95% CI 0.81-1.55, p=0.486) 
or into tertiles (medium v low: HR 1.37, 95% CI 0.93-2.01, p=0.113; high v low: 
HR 1.05, 95% CI 0.69-1.58, p=0.829) (Figure 7-24). This remained the case when 
analysed in sub-cohorts of ER positive or ER negative disease or within the 4 





Figure 7-24. The relationship between cytoplasmic IL6R expression and CSS.Kaplan meier 
graphs to illustrate the relationship between cytoplasmic IL6R expression and CSS when divided a) 
at the median (p=0.486) or b) into tertiles (p=0.224). 
7.3.6.2 Membranous IL6R expression and CSS 
When the whole cohort was analysed, high membranous IL6R expression (mean 
WHS>2.5) was associated with significantly worse CSS (HR 1.90, 95% CI 1.31-2.77, 
p=0.001). This was the case both in ER positive (HR 1.94, 95% CI 1.19-3.18, 
p=0.008) and ER negative disease (HR 1.86, 95% CI 1.04-3.32, p=0.037). 
 
Figure 7-25. The relationship between membranous IL6R expression and CSS. Kaplan meier 
graph to illustrate the relationship between membranous IL6R expression and CSS in the full 







Figure 7-26. The relationship between membranous IL6R expression and CSS by ER status. 
Kaplan meier graphs to illustrate the relationship between membranous IL6R expression and CSS 
in a) ER positive (n=466, p=0.007) and b) ER negative disease (n=211, p=0.034). 
When analysed within the molecular subtypes, high membranous IL6R expression 
was significantly associated with worse CSS in luminal A disease (HR 3.40, 95% CI 
1.74-6.65, p<0.001) but not the other 3 subtypes (luminal B: HR 0.86, 95%CI 
0.33-2.25, p=0.759; HER2-enriched: HR 1.99, 95% CI 0.78-5.12, p=0.152; TNBC: 









Figure 7-27. The relationship between membranous IL6R expression and CSS by molecular 
subtype. Kaplan meier graphs to illustrate the relationship between membranous IL6R expression 
and CSS in a) luminal A (n=294, p<0.001), b) luminal B (n=117, p=0.759), c) HER2-enriched 
(n=67, p=0.143) and d) triple negative breast cancer (n=133, p=0.118). 
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7.3.6.3 Stromal IL6R expression and CSS 
When the whole cohort was analysed, high stromal IL6R expression (mean 
WHS>82) was associated with significantly worse CSS (HR 1.44, 95% CI 1.02-2.05, 
p=0.041). However, there was no statistically significant difference when 
analysed by ER status (ER+: HR 1.54, 95% CI 0.97-2.43, p=0.065; ER-: HR 1.65, 
95% CI 0.94-2.90, p=0.082). 
 
Figure 7-28. The relationship between stromal IL6R expression and CSS. Kaplan meier graph 






Figure 7-29. The relationship between stromal IL6R expression and CSS by ER status. 
Kaplan meier graphs to illustrate the relationship between stromal IL6R expression and CCS in a) 
ER positive (n=438, p=0.063) and b) ER negative disease (n=203, p=0.078). 
When analysed within the molecular subtypes, high stromal IL6R was 
significantly associated with worse CSS in luminal A disease (HR 2.23, 95% CI 
1.14-4.38, p=0.019) but not in the other 3 subtypes (luminal B: HR 1.51, 95% CI 
0.70-3.26, p=0.291; HER2-enriched: HR 2.14, 95% CI 0.87-5.24, p=0.096; TNBC: 
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HR 1.30, 95% CI 0.62-2.74, p=0.494), though there was a trend to worse CSS in 









Figure 7-30. The relationship between stromal IL6R expression and CSS by molecular 
subtype. Kaplan meier graphs to illustrate the relationship between stromal IL6R expression and 
CCS in a) luminal A (n=275, p=0.016), b) luminal B (n=109, p=0.287), c) HER2-enriched (n=65, 
p=0.088) and d) triple negative breast cancer (n=128, p=0.492). 
7.3.6.4 Multivariate survival analysis 
On multivariate analysis, controlling for known prognostic clinicopathological 
factors, membranous IL6R was the only site of IL6 or IL6R expression which was 




 Univariate analysis Multivariate analysis 



















































































































































































































0.041  0.330 
Table 7-1. Survival analysis for IL6, IL6R and other prognostic factors. Univariate and 
multivariate Cox regression analysis of the relationship between IL6 expression, IL6R expression, 
other known prognostic clinicopathological factors and CSS. Factors with p<0.05 on univariate 




High tumour IL6 was associated with larger tumours (p=0.050), low CD8+ 
lymphocytes (p=0.028) and high stromal IL6 (<0.001). Low membranous IL6R 
expression was associated with high tumour budding (p=0.031). High stromal 
IL6R expression was associated with KM score (p=0.001), medium levels of CD8+ 
lymphocytes (p=0.023), low CD4+ lymphocytes (p=0.017) and tumour cytoplasmic 















































































































































































































Table 7-2. Associations between tumour IL6 and other clinicopathological factors. Table 















































































































































































































Table 7-3. Associations between membranous IL6R and other clinicopathological factors. 















































































































































































































Table 7-4. Associations between stromal IL6R and other clinicopathological factors. Table 




7.3.8 IL6 and IL6R in combination 
To investigate the relationship of different combinations of IL6 expression and 
IL6R expression site with disease outcome, scores were created for each 
combination of tumour or stromal IL6 and each of the 3 IL6R receptor sites in the 
study. When both factors were high there was a significant association with 
worse CSS with all the possible combinations except stromal IL6 and cytoplasmic 
IL6R, on univariate analysis. However, on multivariate analysis controlling for 
known prognostic clinicopathological factors, the only combination 
independently associated with worse CSS was tumour IL6 and membranous IL6R.  
Combined score Univariate analysis Multivariate analysis 
HR (95% CI) p HR (95% CI) p 
































































































































Table 7-5. Associations between combined IL6 and IL6R expression scores and CSS. Table 
showing univariate and multivariate Cox regression analysis for the association between various 
scores combining different IL6 and IL6R expression sites and CSS. For the multivariate analysis, 
scores with p<0.005 were individually (ie. Not alongside another of the scores) entered into a 
multivariate model with other significant clinicopathological factors detailed in similar analysis 




Figure 7-31. The relationship between a combined score of tumour IL6 and membranous 
IL6R expression and CSS. Kaplan meier graph illustrating the relationship between a combined 




This study describes the pattern of IL6 and IL6R expression in a cohort of primary 
operable breast cancers. Higher IL6 expression in stroma compared to tumour 
was observed and higher stromal expression was observed in the triple negative 
subtype. Cytoplasmic IL6R expression was generally higher than membranous 
expression but when high membranous expression was present there was a 
significant association with worse CSS, particularly when this was combined with 
high tumour IL6. 
The observation that IL6 expression is higher in TNBC is in keeping with some 
previous research. The triple negative cell line MDA-MB-231 produces IL-6 while 
the ER positive cell line MCF-7 does not(290-292). One tissue study reported 
overexpression of multiple cytokines, including IL-6, in ER negative breast 
cancer(279). This study used a multiplexed flow cytometry method and 
therefore did not distinguish between the position of the IL6 in the tumour or 
the stroma. Similarly, in a large genomic study, IL6 expression was reported to 
be high in TNBC but not in the other molecular subtypes(293). The higher 
stromal expression observed in this study may represent secretion by immune 
cells and CAFs in the stroma, which have been shown to express high levels of 
IL6 in human breast cancer(284), and reflect the more inflammatory nature of 
triple negative breast cancer compared to the other molecular subtypes. It is 
interesting to note the positive correlation observed between tumour and 
stromal IL6 expression. In contrast to the above findings, an early small study 
reported an association between ER positivity and IL6, with a positive 
correlation between the levels of ER and IL6 staining(294). However, its 
measurement of IL6 staining was specifically in tumour cells rather than stroma 
or both. In the present study no association between ER status and tumour IL6 
was observed.  
It was observed that membranous IL6R expression on tumour cells was associated 
with worse CSS independently of other prognostic factors, suggesting that the 
classical signalling pathway is important in tumour progression. The association 
with worse CSS was particularly marked in patients who had tumours with both 
high membranous IL6R and high tumour IL6 expression. This was particularly the 
case in luminal A disease. This is suggestive of a positive feedback loop whereby 
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the tumour secretes IL6 which stimulates its own growth and progression via the 
membranous IL6R receptor and JAK/STAT3 signalling. This is supported by 
previous work showing that STAT3 activation in tumour cells leads to increased 
production of IL6(295). Evidence regarding the direct effect of IL6 on tumour 
growth is mixed with studies reporting growth inhibitory(292, 296) and growth 
stimulating effects(285, 297). Mechanisms which have been suggested for its 
pro-tumour effects include alteration of the proliferation/apoptosis balance via 
an effect on bcl-2 expression(298) and downregulation of tumour suppressor 
hypermethylated in cancer 1 (HIC1)(299). This conflict suggests the involvement 
of multiple other influencing factors, such as activation of JAK/STAT3, other 
components of the tumour microenvironment and the interplay between other 
cell signalling pathways which IL6 can activate such as the Ras-MAPK, JNK MAPK, 
PI 3-K-Akt and MEK-ERK5 pathways. This is supported by our study in that tumour 
IL6 was associated with worse CSS but this was not independent of other 
prognostic factors. The ability of IL6 to initiate JAK/STAT3 signalling via classical 
signalling would appear to be important.  
On molecular subtype analysis, this association was only significant in luminal A 
disease. This could simply be because of the higher sample numbers for this 
subtype, providing more statistical power. However, it is in keeping with 
previous evidence that ER positive tumours are more sensitive to stimulation by 
IL6. It has been postulated that this may be due to the longstanding higher 
exposure of ER negative breast cancer cells to IL6(274). Another reason proposed 
is that it could be due to difference in IL6R expression with one cell line study 
reporting that ER positive cells predominantly express sIL6R while in ER negative 
breast cancer cells the transmembrane receptor predominates(292), but this was 
not observed in our study. Interestingly, a large genomic study reported high 
expression of gp130 in luminal A breast cancers but not the other molecular 
subtypes(293). It is also of interest that IL6 has been reported to increase 
oestrogen levels(300, 301) and this therefore may be another mechanism by 
which IL6 stimulates tumour progression in ER positive disease. 
It is interesting to note the inverse association between membranous IL6R 
expression and tumour budding, given that both are reported in this thesis as 
poor prognostic features. IL6 has been shown to induce EMT in ER positive cell 
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lines (302) but the finding in this study raises the possibility that once the 
budding phenotype is established, stimulation by IL6 may become less 
important.  
The association between high tumour IL6, high membranous IL6R and worse CSS 
observed in this study suggests that therapies which target IL6/IL6R may be 
beneficial in some patients, particularly those with high-risk ER positive disease 
or those who have developed resistance to endocrine therapies. As detailed in a 
review by Heo et al, a number of molecules which target IL6, IL6R or gp130 are 
available(272). Many of these have shown anti-inflammatory and antitumoural 
activity in vitro. Several have been approved or are the subject of ongoing trials 
in autoimmune diseases such as rheumatoid arthritis, systemic lupus and 
Castleman’s disease, providing evidence for their safety in clinical use. Few have 
undergone clinical trials for cancer, one rare example is the trial of siltuximab in 
melanoma. Most of the cancer work to date is preclinical and there have been 
very few studies either in the pre-clinical or clinical setting involving breast 
cancer. The IL6 inhibitor 6a inhibits STAT3 phosphorylation in IL-6 stimulated 
MDA-MB-231 cells(303). The IL6R inhibitor tocilizumab inhibited tumour growth 
in trastuzumab-resistant breast cancer cell lines in mouse models(289). Although 
adverse effects including infection, cardiovascular toxicity and gastrointestinal 
perforation have been reported with IL6/IL6R inhibitors, their safe use in certain 
inflammatory diseases supports further investigation of their potential role in 
breast cancer.  
Limitations of our study include the small patient numbers in the less common 
molecular subtypes which limit the possibility of identifying significant 
associations in these groups. Numbers available for final analysis were also 
limited due to the number of TMA cores which were incomplete or completely 
floated off during the staining process, perhaps due to the age of the tissue. The 
nature of TMAs also means that only a tiny section of the tumour is observed and 
at a single point in time so it may not account for tumour heterogeneity and 
changes in the tumour as it progresses. This single point in time analysis also 
makes it difficult to conclude with certainty whether membranous IL6R 
expression observed represents the membrane-bound IL6R and therefore 
activation of the classical signalling pathway or whether it actually represents 
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sIL6R which has formed a complex with IL6 and subsequently bound to the 
membrane. On the other hand, one advantage of using the RNA scope method to 
identify IL6 is that it detects the RNA message, and therefore we can be more 
confident that the IL6 is being produced by the cells in the site it is observed. 
However, it could also be argued that this message may not be translated to IL6 
protein synthesis and secretion as other processes and pathways may interfere 
and therefore, we may not have a truly accurate recording of the amount of IL6 
present.  
In summary, the present study has observed higher stromal IL6 expression in 
TNBC, suggesting that stromal cells such as CAFS and immune cells in this 
particularly inflammatory tumour type secrete IL6. However, no association 
between stromal IL6 and CSS was observed. Overall and in luminal A cancer, high 
membranous expression of IL6R, particularly when combined with high tumour 
IL6 expression, was associated with worse CSS. This may represent a positive 
feedback loop driving tumour progression, possibly via the classical signalling 
pathway. Therefore, further investigation of the role of IL6 and the IL6R in 
breast cancer is warranted as treatments which target both of these proteins are 





8 JAK1 and JAK2 in primary operable breast 
cancer. 
8.1 Introduction 
Findings in the previous chapter suggest a role for IL6 and IL6R in the progression 
of primary operable breast cancer. IL6 can stimulate several different cell 
signalling pathways but this thesis focuses on the IL6/JAK/STAT3 pathway. 
Therefore, to better understand the role of this pathway in breast cancer, this 
chapter will focus further downstream in the pathway, on the Janus kinases 
(JAKs) 1 and 2. 
Four JAKs are known to exist, namely JAKs 1,2, 3 and TYK2(304).They are a 
subgroup of non-receptor tyrosine kinases(304). As previously described, when a 
ligand binds to its receptor (in this case IL6 to IL6R), phosphorylation of JAKs 
occurs at specific tyrosine and serine residues and the JAKs become 
enzymatically active(304). This leads to phosphorylation of STATs. Structurally, 
JAKs are made up of a C terminus on which the kinase domain is located, a 
pseudokinase domain, a SH2 domain and a N terminus which is the part which 
interacts with the intracellular portion of receptors(304). It is the kinase and 
pseudokinase domains which led to the name Janus kinase, after the two-faced 
Roman god Janus(305). Of the 4 JAKs, JAKs 1 and 2 can activate STAT3 in 




Figure 8-1. Phosphorylation of STAT3 by JAK. Diagram illustrating the next stage of the 
Il6/JAK/STAT3 pathway. Activated JAKs phosphorylate tyrosine residues of the IL6R, allowing 
STAT3 to bind. JAKs then phosphorylate STAT3 following which dimerisation of STAT3 occurs.  
JAKs have been extensively studied in immune diseases and haematological 
malignancies and some JAK inhibitors are in clinical use while trials are ongoing 
in others (304, 307, 308). This raises the question as to whether these agents 
may be beneficial in breast cancer. There is limited literature regarding the role 
of JAKs 1 and 2 in breast cancer. In cell line and murine models JAK1 has been 
identified as a pivotal kinase for the activation of STAT3 resulting in increased 
invasiveness(306, 309). However studies of human breast cancer tissue have 
reported lower levels of JAK1 expression in breast cancer compared to normal 
breast tissue(310) and a correlation with improved cancer outcomes and higher 
TILs with higher JAK1 expression(311). These latter results raise the possibility 
that use of JAK1 inhibitors may be counterproductive in breast cancer 
treatment. Cell line studies of JAK2 have reported conflicting results regarding 
its effect on STAT3 activation(312, 313). Elevated JAK2 expression is reported to 














may be implicated in chemotherapy resistance, suggesting JAK2 specific 
inhibition may have a role in breast cancer treatment(314). 
With this limited evidence in mind, for this study it was postulated that, in a 
cohort of patients with primary operable breast cancer, high JAK2 expression 
would be associated with poorer outcomes and, if it is being activated by 
IL6/IL6R, high JAK2 expression would be correlated with high IL6/IL6R 
expression. The study therefore aims to describe the expression of JAK1 and 
JAK2 in primary operable breast cancer and to determine if they are associated 
with cancer outcomes, with specific clinicopathological features and with IL6 
and IL6R expression with a view to better understanding their role within the 
IL6/JAK/STAT3 pathway in primary operable breast cancer. 
8.2 Materials and methods 
8.2.1 Patient cohort 
The 1800 cohort was used for this study as tissue blocks were available for 
cutting of a previously constructed TMA. Patient characteristics are detailed in 
chapter 2.  
8.2.2 TMA slide staining and scanning 
TMAs were stained in triplicate for JAK1 and separately for JAK2 using the 
immunohistochemistry technique and antibody detailed in chapter 2. They were 
scanned into Slidepath software as previously described. 
8.2.3 Scoring for JAK1 and JAK2 expression 
Each TMA core was scored by the author using the weighted histoscore method 
described in chapter 2. Cores which were assessed visually to have >20% of the 
core missing were not scored. For both JAK1 and JAK2, nuclear and cytoplasmic 
expression in tumour cells was scored separately. A separate score was also 
given for expression in stromal cells (differentiation between nuclear and 




8.2.4 Molecular subtyping 
ER, PR, HER2 and Ki67 profiling had previously been carried out in the lab for 
this cohort. This data was used to divide the cohort into the four main molecular 
subtypes of breast cancer, as detailed in chapter 1, for subgroup analysis. 
8.2.5 Statistical analysis 
Initial analysis using ROC curves and division into tertiles and at the median was 
carried out to determine the optimum threshold for division into high and low 
expression groups for further analysis. Analysis of associations with 
clinicopathological characteristics and with cancer specific survival was carried 
out as described in chapter 2. This analysis was carried out initially in the full 
cohort, then in the ER positive and ER negative cohorts separately, and 
subsequently in the 4 individual molecular subtypes. 
8.3 Results 
8.3.1 Formation of the cohort  
577 patients had at least one core which was assessable for tumour cell nuclear 
and cytoplasmic JAK1 staining. 531 had at least one core which was assessable 
for stromal JAK1 expression (Figure 8-2). 
567 patients had at least one core which was assessable for tumour cell nuclear 
and cytoplasmic JAK2 expression. 533 patients had at least one core which was 




Figure 8-2. Formation of the JAK1 cohort. Flow diagram to illustrate the number of patients within the 1800 cohort with at least 1 core which was assessable for 
JAK1 expression in the tumour cell nucleus and cytoplasm, and separately in the stroma. The numbers available for subgroup analysis by ER status and by molecular 
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Figure 8-3. Formation of the JAK2 cohort. Flow diagram to illustrate the number of patients within the 1800 cohort with at least 1 core which was assessable for 
JAK2 expression in the tumour cell nucleus and cytoplasm, and separately in the stroma. The numbers available for subgroup analysis by ER status and by molecular 
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8.3.2 JAK1 expression 
JAK1 was predominantly expressed in tumour cytoplasm but some nuclear 
expression was observed. Examples of TMA cores stained for JAK1 are shown 
below (Figure 8-4).  
 
Figure 8-4. Examples of JAK1 staining. TMA cores stained using IHC for JAK1: a) breast core 
with predominantly moderate and strong cytoplasmic staining at 10x magnification with an inset at 
40x magnification, b) breast core with predominantly weak cytoplasmic staining, c) true positive 
core (control, liver) at 10x magnification, d) true negative core at 10x magnification. 
 
Median WHS for cytoplasmic expression was 101.67 (0-230) compared to 0.33 (0-
61.00) for nuclear expression. Median WHS for stromal cell expression was 1.67 
(0-130.00). Expression of JAK1 in the different locations described is illustrated 









Figure 8-5. Histograms of JAK1 expression. Histograms to illustrate JAK1 expression in a) tumour cell nuclei, b) tumour cell cytoplasm and c) stromal cells. 
 









Figure 8-7. Boxplots of nuclear JAK1 by hormone receptor status. Boxplots to illustrate the 
differences in nuclear JAK1 expression by a) ER status (p=0.646) and b) molecular subtype 
(p=0.003). In both graphs extreme outliers have been excluded to permit an appropriate scale (2 
TNBC cases). 
 
Cytoplasmic expression was highest in ER negative tumours and specifically the 





Figure 8-8. Boxplots of cytoplasmic JAK1 by hormone receptor status. Boxplots to illustrate 











Figure 8-9. Boxplots of stromal JAK1 by hormone receptor status. Boxplots to illustrate the 
differences in stromal JAK1 expression by a) ER status (p=0.879) and b) molecular subtype 
(p=0.017). In both graphs extreme outliers have been excluded to permit an appropriate scale. 
 
There was a moderate positive correlation between nuclear and cytoplasmic 
JAK1 expression (Pearson correlation 0.438, p<0.001). There was a weak positive 
correlation between cytoplasmic and stromal JAK1 expression (Pearson 
correlation 0.127, p=0.003) but there were significant outliers which may affect 









Figure 8-10. Correlation between JAK1 expression sites. Scatter plots to illustrate the correlation between JAK1 expression in different sites: a) nuclear and 
cytoplasmic expression (Pearson correlation 0.438, p<0.001), b) nuclear and stromal expression (Pearson correlation 0.023, p=0.601), c) cytoplasmic and stromal 
expression (Pearson correlation 0.127, p=0.003). 
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8.3.3 The relationship between JAK1 and CSS 
ROC curves were drawn to determine thresholds for division of patients into high 
and low expression groups for further analysis (Figure 8-11). From these, a 
threshold of 0.17 was derived for nuclear JAK1 expression and a threshold of 
0.17 was also derived for stromal JAK1 expression. No threshold could be derived 










Figure 8-11. ROC curves for JAK1 and CSS. ROC curves to illustrate the relationship between CSS and JAK1 expression in a) tumour cell nuclei (AUC 0.480), b) 
tumour cell cytoplasm (AUC 0.508) and c) stromal cells (AUC 0.462).
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8.3.3.1 Nuclear JAK1 expression and CSS 
289 (50.1%) patients had high (mean WHS>0.17) nuclear JAK1 expression. There 
was no significant association between nuclear JAK1 expression and CSS (high v 
low: HR 0.79, 95% CI 0.55-1.14, p=0.209). However, when analysed according to 
ER status, low nuclear expression of JAK1 in tumour cells was significantly 
associated with worse CSS in ER positive disease (high v low: HR 0.60, 95% CI 
0.38-0.95, p=0.029) but not ER negative disease (HR 1.44, 95% CI 0.77-2.68, 
p=0.249) (Figure 8-12). However, when analysed within the molecular subtypes, 
high nuclear expression of JAK1 was significantly associated with worse CSS in 
TNBC (HR 2.65, 95% CI 1.19-5.92, p=0.017) but there was no significant 
association with CSS in the other 3 subtypes (Figure 8-13). The associations in 
ER positive disease and TNBC were not independent of other prognostic variables 









Figure 8-12. The relationship between nuclear JAK1 expression and CSS. Kaplan meier graphs to illustrate the relationship between nuclear JAK1 expression in 











Figure 8-13. The relationship between nuclear JAK1 expression and CSS by molecular 
subtype. Kaplan meier graphs to illustrate the relationship between nuclear JAK1 expression in 
tumour cells and CSS in a) luminal A (n=277, p=0.118), b) luminal B (n=110, p=0.514), c) HER2-
enriched (n=48, p=0.224) and d) triple negative (n=78, p=0.013) breast cancer. 
8.3.3.2 Cytoplasmic JAK1 expression and CSS 
There was no significant association between cytoplasmic JAK1 expression and 
CSS in the full cohort (high v low: HR 1.14, 95% CI 0.79-1.64, p=0.480), ER 
positive (HR 0.87, 95% CI 0.55-1.37, p=0.545) or ER negative disease (HR 1.45, 
95% CI 0.72-2.90, p=0.298)(Figure 8-14). This was also the case when analysed 









Figure 8-14. The relationship between cytoplasmic JAK1 expression and CSS. Kaplan meier graphs to illustrate the relationship between cytoplasmic JAK1 
expression in tumour cells and CSS in a) the full cohort (n=577, p=0.480), b) ER positive disease (n=444, p=0.545) and c) ER negative disease(n=133, p=0.294).  
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8.3.3.3 Stromal JAK1 expression and CSS 
401 (75.5%) patients had high (mean WHS>0.17) stromal expression of JAK1. 
There was no significant association between stromal JAK1 expression and CSS in 
the full cohort (high v low: HR 0.79, 95% CI 0.52-1.20, p=0.265). However, when 
analysed by ER status, low stromal JAK1 expression was significantly associated 
with worse CSS in ER positive (high v low: HR 0.61, 95% CI 0.37-0.99, p=0.047) 
but not ER negative disease (HR 1.55, 95% CI 0.70-3.41, p=0.277)(Figure 8-15). 
This was also the case when analysed in the individual molecular subtypes, 
though there was a trend towards worse CSS with low stromal JAK1 expression in 
luminal A disease (p=0.057)(Figure 8-16). The association in ER positive disease 









Figure 8-15. The relationship between stromal JAK1 expression and CSS. Kaplan meier graphs to illustrate the relationship between stromal JAK1 expression and 












Figure 8-16. The relationship between stromal JAK1 expression and CSS by molecular 
subtype. Kaplan meier graphs to illustrate the relationship between stromal JAK1 expression and 
CSS in a) luminal A (n=254, p=0.057), b) luminal B (n=101, p=0.277), c) HER2-enriched (n=45, 
p=0.457) and d) triple negative (n=72, p=0.423) breast cancer. 
8.3.4 Associations between JAK1 expression and 
clinicopathological characteristics 
As nuclear and stromal JAK1 expression were both associated with cancer 
outcomes, association analysis was carried out for various clinicopathological 
factors.  
High nuclear JAK1 expression was associated with increased age (p=0.032), 
lobular cancers (p=0.022), lower grade tumours (p=0.006) and low CD4+ 
lymphocytes (p<0.001) (Table 8-1). In ER positive disease it was associated with 
low grade (p<0.001) and low CD4+ lymphocytes (p<0.001) whereas in TNBC the 
































































































































































Table 8-1. The association between nuclear JAK1 and clinicopathological characteristics. 
Table detailing the associations between nuclear JAK1 expression and clinicopathological factors. 




High stromal JAK1 expression was associated with smaller tumour size (p=0.012), 
HER2 positivity (p=0.037), high tumour budding (p=0.005) and medium CD8+ 
lymphocyte counts (p=0.023) (Table 8-2). 




























































































































































Table 8-2. The association between stromal JAK1 and clinicopathological characteristics. 
Table detailing the associations between stromal JAK1 expression and clinicopathological factors. 




8.3.5 JAK2 expression 
JAK2 expression was predominantly in the cytoplasm with a median WHS 99.00 
(0-195.00). Very little nuclear JAK2 expression was observed with median WHS 
0.00 (0-22.50). Median WHS for stromal cell JAK2 expression was 20.50 (0-
193.00). Examples of TMA cores stained for JAK2 are show below (Figure 8-17). 
 
Figure 8-17. Examples of JAK2 staining. TMA cores stained using IHC for JAK2: a) breast core 
with predominantly moderate and strong cytoplasmic staining at 10x magnification with an inset at 
40x magnification, b) breast core with predominantly weak cytoplasmic staining, c) true positive 
core (control, colon) at 10x magnification, d) true negative core at 10x magnification. 
 
Expression of JAK2 in the different locations described is illustrated in the 









Figure 8-18. Histograms of JAK2 expression. Histograms to illustrate JAK2 expression in a) tumour cell nuclei, b) tumour cell cytoplasm and c) stromal cells. 
 









Figure 8-20. Boxplots of nuclear JAK2 by hormone receptor status. Boxplots to illustrate the 
differences in nuclear JAK2 expression by a) ER status (p<0.001) and b) molecular subtype 
(p<0.001). In both graphs extreme outliers have been excluded to permit an appropriate scale. 
Cytoplasmic expression was higher in ER positive disease and lowest in the triple 





Figure 8-21. Boxplots of cytoplasmic JAK2 by hormone receptor status. Boxplots to illustrate 





Similarly, stromal expression was higher in ER positive disease and lowest in the 





Figure 8-22. Boxplots of stromal JAK2 by hormone receptor status. Boxplots to illustrate the 
differences in stromal JAK2 expression by a) ER status (p=0.004) and b) molecular subtype 
(p=0.025). 
There was a weak positive correlation between cytoplasmic and stromal JAK2 
expression (Pearson correlation 0.276, p<0.001) (Figure 8-23).  This was the 










Figure 8-23. Correlation between JAK2 expression sites. Scatter plots to illustrate the correlation between JAK2 expression in different sites: a) nuclear and 
cytoplasmic expression (Pearson correlation 0.065, p=0.121), b) nuclear and stromal expression (Pearson correlation -0.001, p=0.985), c) cytoplasmic and stromal 
expression (Pearson correlation 0.276, p<0.001). 
261 
 
8.3.6 The relationship between JAK2 and CSS 
ROC curves were drawn to determine thresholds for division of patients into high 
and low expression groups for further analysis (Figure 8-24). From these, a 
threshold of 0.30 was derived for nuclear JAK2 expression and a threshold of 
70.0 was derived for stromal JAK2 expression. No threshold could be derived 









Figure 8-24. ROC curves for JAK2 and CSS. ROC curves to illustrate the relationship between CSS and JAK2 expression in a) tumour cell nuclei (AUC 0.468), b) 




8.3.6.1 Nuclear JAK2 expression and CSS 
83 (14.6%) patients had high (mean WHS>0.30) nuclear JAK2 expression. There 
was no significant association between nuclear JAK2 expression and CSS in the 
full cohort (high v low: HR 0.61, 95% CI 0.33-1.10, p=0.605). This remained the 
case in ER positive (HR 0.69, 95% CI 0.34-1.39, p=0.293) and ER negative disease 
(HR 0.83, 95% CI 0.26-2.65, p=0.757) (Figure 8-25) and in each of the molecular 









Figure 8-25. The relationship between nuclear JAK2 expression and CSS.  Kaplan meier graphs to illustrate the relationship between nuclear JAK2 expression in 
tumour cells and CSS in a) the full cohort (n=567, p=0.093), b) ER positive disease (n=347, p=0.290) and c) ER negative disease (n=220, p=0.756).   
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8.3.6.2 Cytoplasmic JAK2 expression and CSS 
There was no significant association between cytoplasmic JAK2 expression and 
CSS in the full cohort (high v low: HR 0.94, 95% CI 0.66-1.33, p=0.719), in ER 
positive (HR 0.88, 95% CI 0.54-1.45, p=0.615) or in ER negative disease (HR 1.18, 
95% CI 0.72-1.92, p=0.511)(Figure 8-26). However, when analysed in the 
individual molecular subtypes, high cytoplasmic JAK2 expression was 
significantly associated with worse CSS in triple negative disease (HR 1.83, 95% 
CI 0.99-3.39, p=0.054)(Figure 8-27), but this was not independent of other 









Figure 8-26. The relationship between cytoplasmic JAK2 expression and CSS. Kaplan meier graphs to illustrate the relationship between cytoplasmic JAK2 











Figure 8-27. The relationship between cytoplasmic JAK2 expression and CSS by molecular 
subtype. Kaplan meier graphs to illustrate the relationship between cytoplasmic JAK2 expression 
in tumour cells and CSS in a) luminal A (n=215, p=0.261), b) luminal B (n=95, p=0.389), c) HER2-
enriched (n=68, p=0.097) and d) triple negative (n=140, p=0.049) breast cancer. 
8.3.6.3 Stromal JAK2 expression and CSS 
77 (14.4%) patients had high (mean WHS>70) stromal JAK2 expression. In the full 
cohort, high stromal expression of JAK2 was significantly associated with worse 
CSS (HR 1.65, 95% CI 1.07-2.54, p=0.024), though this was not independent of 
other prognostic factors on multivariate analysis (p=0.347). However, when 
analysed by ER status, high stromal JAK2 expression was only significantly 
associated with CSS in ER negative (HR 2.38, 95% CI 1.29-4.39, p=0.005), not ER 
positive disease (HR 1.41, 95% CI 0.76-2.61, p=0.273)(Figure 8-28). The 
association in ER negative disease was not independent of other prognostic 
factors (p=0.370). When analysed in the molecular subtypes, high stromal JAK2 
expression was significantly associated with worse CSS in both luminal B (HR 
2.88, 95% CI 1.13-7.31, p=0.026) and HER2-enriched (HR 3.37, 95% CI 1.38-8.23, 









Figure 8-28. The relationship between stromal JAK2 expression and CSS. Kaplan meier graphs to illustrate the relationship between stromal JAK2 expression and 











Figure 8-29. The relationship between stromal JAK2 expression and CSS by molecular 
subtype. Kaplan meier graphs to illustrate the relationship between stromal JAK2 expression and 
CSS in a) luminal A (n=194, p=0.404), b) luminal B (n=91, p=0.020), c) HER2-enriched (n=68, 
p=0.005) and d) triple negative (n=133, p=0.238) breast cancer. 
 
On multivariate analysis, the associations between high stromal JAK2 expression 
and worse CSS in luminal B (p=0.003, Table 8-3) and HER2-enriched (p=0.021, 







































Table 8-3. Multivariate analysis for stromal JAK2 expression in luminal B cancer. Table 
detailing the multivariate survival analysis for stromal JAK2 expression in luminal B breast cancer.  


























Table 8-4. Multivariate analysis for stromal JAK2 expression in HER2-enriched cancer. Table 
detailing the multivariate survival analysis for stromal JAK2 expression in HER2-enriched breast 
cancer.  
8.3.7 Associations between JAK2 and clinicopathological 
characteristics 
Cytoplasmic and stromal JAK2 expression were associated with cancer outcomes 
so their associations with clinicopathological characteristics were assessed. 
High cytoplasmic JAK2 expression was significantly associated with ER (p=0.001) 
and HER2 positivity (p=0.010) and high CD8+ lymphocytes (p=0.004) (Table 8-5).   
271 
 




























































































































































Table 8-5. The association between cytoplasmic JAK2 and clinicopathological 
characteristics. Table detailing the associations between cytoplasmic JAK2 expression and 




High stromal JAK2 expression was associated with low CD8+ (p=0.016) and CD4+ 
lymphocytes (p<0.001) (Table 8-6). 




























































































































































Table 8-6. The association between stromal JAK2 expression and clinicopathological 
characteristics. Table detailing the associations between stromal JAK2 expression and 
clinicopathological factors. Statistically significant p values are highlighted in bold. 
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8.3.8 The relationship between JAK1 and JAK2 
To evaluate the relationship between JAK1 and JAK2 expression, association and 
correlation analysis was carried out. High nuclear JAK1 expression was 
associated with high nuclear JAK2 expression (p=0.028) but there were no 
significant associations observed between the other combinations of JAK1 and 
JAK2 expression sites (Table 8-7). 
On correlation analysis, the only significant correlation observed was a very 
weak negative correlation between nuclear JAK1 and cytoplasmic JAK2 
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Table 8-7. The association between JAK1 and JAK2. Tables detailing the associations between JAK1 and JAK2 in their different expression sites. Significant p 
values are highlighted in bold. 
 
Figure 8-30. The correlation between nuclear JAK1 and cytoplasmic JAK2. Scatter plot illustrating the weak negative correlation between nuclear JAK1 and 
cytoplasmic JAK2 (Pearson correlation -0.108, p=0.027). 
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8.3.9 The relationship between JAK1, JAK2 and other 
components of the IL6/JAK/STAT3 pathway 
To evaluate the relationship between JAK1 and JAK2 expression and the 
components of the IL6/JAK/STAT3 pathway studied so far in this thesis, 
association and correlation analysis was carried out. 
8.3.9.1 The relationship between JAK1 and IL6/IL6R expression 
High cytoplasmic JAK1 expression was associated with high cytoplasmic and 
stromal IL6R expression. High stromal JAK1 expression was associated with low 
membranous IL6R expression (Table 8-8). 
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 Nuclear expression p Cytoplasmic expression p Stromal expression p 
Low High Low High Low High 





















































































































Table 8-8. The association between JAK1 and IL6/IL6R. Table detailing the associations between JAK1 expression in different sites and Il6 and IL6R expression. 
Significant p values are highlighted in bold.
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On correlation analysis using continuous variables, the only significant 
correlation identified was a very weak positive correlation between stromal 
JAK1 and IL6R expression but there was a significant outlier which may skew this 
statistic (Figure 8-31). 
 
 
Figure 8-31. The correlation between stromal JAK1 and IL6R expression. Scatter plot to 
illustrate the correlation between stromal expression of JAK1 and IL6R (Pearson correlation 0.110, 
p=0.015). 
 
8.3.9.2 The relationship between JAK2 and IL6/IL6R expression  
High cytoplasmic JAK2 was associated with high cytoplasmic IL6R. High stromal 
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Table 8-9. The association between JAK2 and IL6/IL6R. Table detailing the associations between JAK2 expression in different sites and Il6 and IL6R expression. 




On correlation analysis using continuous variables, weak positive correlations 
were observed between cytoplasmic JAK2 and cytoplasmic and stromal IL6R, and 
between stromal JAK2 and stromal IL6R. A weak negative correlation was 












Figure 8-32. The correlation between JAK2 and IL6R. Scatter plots to illustrate the correlation between a) cytoplasmic JAK2 and IL6R expression (Pearson 
correlation 0.203, p<0.001), b) cytoplasmic JAK2 and stromal IL6R expression (Pearson correlation 0.105, p=0.020), c) stromal JAK2 and membranous IL6R 




In this study the expression of JAK1 and JAK2 and their associations with 
clinicopathological factors, CSS and IL6/IL6R expression have been described. 
JAK1 is predominantly expressed in the cytoplasm but some nuclear expression 
was also observed. Levels of expression varied between the molecular subtypes. 
High nuclear JAK1 expression was associated with improved CSS and lower 
tumour grade in ER+ tumours but with reduced CSS in TNBC. Stromal JAK1 
expression was also associated with improved CSS and smaller tumour size in ER+ 
cancers. Nuclear JAK1 expression was not associated with IL6/IL6R expression 
whereas cytoplasmic JAK1 expression was. Similarly, JAK2 was predominantly 
expressed in the cytoplasm and there was negligible nuclear expression 
observed. Converse to JAK1, stromal JAK2 expression was associated with 
reduced CSS and with lower CD4+ and CD8+ lymphocytes. Cytoplasmic JAK2 
expression was also associated with worse CSS and node positivity in TNBC, as 
well as IL6 and IL6R expression. 
JAK1 was predominantly expressed in the cytoplasm of tumour cells. This is 
consistent with its widely described role in the JAK/STAT3 pathway mediating 
phosphorylation of STAT3 in the cytoplasm in response to cytokine signalling. As 
described in the introduction, binding of cytokines with membrane receptors 
leads to activation of receptor-associated JAKs via trans-phosphorylation which 
then phosphorylate sites on the cytoplasmic region of the receptor providing 
docking sites for STATs and subsequent JAK-mediated STAT3 phosphorylation and 
activation(315). STAT3 translocates into the nucleus where it influences gene 
transcription(82, 83). However, JAK1 expression in the nucleus was also 
observed, more commonly in luminal A cancers and, in this study, it was this 
expression site which was associated with cancer outcomes. Nuclear JAK 
expression has been described previously in the literature(316). Initial studies in 
the late 1990s observed JAK 1 and 2 in the nuclei of CHO cells transfected with 
the GH receptor(317), JAK2 in nuclei of pancreatic islet cells(318), in cultured 
liver cells(319) and in mouse oocytes(320). To the knowledge of the author this 
is the first time that nuclear expression has been reported in breast cancer cells. 
JAKs are too large to freely diffuse between the cytoplasm and nucleus(316) so 
they may travel bound to one of their receptors shown to translocate to the 
nucleus such as growth hormone, prolactin or insulin receptors(316). In diffuse 
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large B-cell lymphoma (DLBCL), a classical nuclear localisation signal on the N 
terminus of JAK1 has been described which can be recognised by importin 
isoforms(321).  
Chromatin has been identified as a nuclear target of JAK1 in this tumour type as 
JAK1 can phosphorylate chromatin on H3Y41 leading to upregulation of the 
protooncogene transcription factor MYC and consequently to transcription of 
numerous genes including MYD88 which activates both the NF-κB and p38 MAP 
kinase pathways(322). In DLBCL nuclear JAK1 was observed to be essential for 
cell survival. This raises the possibility that the mechanism outlined above may 
have a role in TNBC, in which subtype the present study observed an association 
between reduced CSS and high nuclear expression of JAK1. However, the reverse 
was true in ER+ disease suggesting that in these cancers, genomic targets may 
differ such that nuclear JAK1 expression leads to inhibition of cancer cell growth 
and proliferation.  
This association between JAK1 and improved survival is in keeping with the 
findings of a previous small study using human breast cancer tissue which also 
observed an inverse association between JAK1 expression and tumour size, 
lymph node status and TNM stage(311). The authors used a qRT-PCR technique 
to measure mRNA and therefore it is impossible to know the site of JAK1 
expression in their study(311). In addition, one other small human tissue study 
which did, like the present study, use IHC techniques observed high pJAK1 
expression in normal breast tissue compared with adjacent breast cancer tissue 
and low pJAK1 expression was correlated with increased tumour size(310). Both 
of these findings would seem to support the findings of our study that higher 
JAK1 expression is associated with better prognosis, at least in ER+ tumours 
which represent the majority. They also observed an association between high 
pJAK1 expression and ER negative tumours(310) which would be in keeping with 
our findings for cytoplasmic but not nuclear JAK1 expression. Like the first 
study, this one did not report the specific site of the JAK1 expression observed 
so the present study has the advantage over both of these studies in that regard 
and in having a far greater sample size. Conversely, a cell line and murine study 
identified decreased expression of JAK1 in cells whose invasiveness and EMT 
characteristics had been suppressed by low dose radiation, implicating JAK1 in 
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the promotion of these characteristics(309). The primary cell line used in the 
study was the triple negative MDA-MB231 cell line so this would support our 
finding of worse cancer outcomes with high JAK1 expression in our TNBC 
patients. Another cell line study in breast cancer reported evidence that JAK1 is 
key to the oncogenic activation of STAT3 in response to IL6 but this was in a 
HER2 positive cell line(306), in which subtype the present study did not identify 
any significant association with CSS. However, the numbers of the HER2-enriched 
and luminal B subtypes in this cohort are comparatively low so this may be a 
factor. Cytoplasmic JAK1 expression was observed to be higher in the HER2 
enriched subtype.   
Nuclear JAK1 expression was not associated with any of the sites of IL6 or IL6R 
expression and this supports the theory that nuclear JAK1 expression is part of a 
different, non-canonical pathway, activated by other ligands such as growth 
hormone(316). On the other hand, cytoplasmic JAK1 was associated with 
cytoplasmic IL6R suggesting that IL6R signalling via the alternative pathway 
leads to JAK1 activation in accordance with the widely documented sequence of 
the IL6/JAK/STAT3 pathway. However, in our study, neither cytoplasmic IL6R 
nor JAK1 was significantly associated with CSS. It is interesting to note that 
there was no association between membranous IL6R, the site associated with 
CSS in the previous chapter, and JAK1 expression, suggesting that classical IL6 
signalling via the membrane-bound receptor activates a different pathway. 
Cytoplasmic JAK1 was also associated with stromal IL6R which may simply 
reflect IL6 in the tumour microenvironment leading to activation of the 
IL6/JAK/STAT3 pathway in both tumour and stromal cells. 
JAK2 was primarily observed in the tumour cell cytoplasm and there was 
negligible nuclear expression with, in contrast to nuclear JAK1 expression, no 
association with CSS observed. Cytoplasmic JAK2 expression was lower in ER 
negative and particularly TNBC but where expression was high in TNBC, it was 
associated with worse CSS and nodal positivity. It was also associated and 
correlated with cytoplasmic IL6R expression and, in TNBC, with tumour IL6 
expression. Though the association with worse CSS was not independent of other 
prognostic features, including nodal status, these findings raise the possibility 
that, in TNBC, IL6 signalling via the alternative pathway leads to JAK2 activation 
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and subsequent downstream signalling leads to development of tumour cell 
characteristics that lead to nodal and distant metastasis such as cell motility, 
invasiveness, EMT and angiogenesis(323). These findings are in keeping with 
those of other studies which have observed poorer outcomes with tumours that 
express high levels of JAK2. In particular, one study of TNBC reported reduced 
overall and recurrence-free survival in post-chemotherapy patients with JAK2 
amplification(314). In longitudinal specimens they noted that JAK2 was selected 
for during neoadjuvant chemotherapy suggesting a role in chemoresistance. 
However, they identified STAT6 rather than STAT3 as the key downstream target 
of JAK2 in this process(314). In the present study we did not observe a 
significant association between cytoplasmic JAK2 and outcome in ER+ disease 
but a role for JAK2 and STAT3 has recently been reported in tamoxifen 
resistance in cell lines and mouse xenografts(312). There is evidence from 
murine studies that JAK2 activation promotes brain metastasis(324) and the 
IL6/JAK2/STAT3 pathway is also implicated in the growth of stem cell-like breast 
cancer cells(325).  In contrast, two studies which measured JAK2 mRNA levels 
reported reduced recurrence rates with higher JAK2 levels(326, 327). However, 
Miller et al concede that mRNA levels may not reflect JAK2 protein or activated 
JAK2 levels. High mRNA in that study was correlated with TILs suggesting these 
may be important in the improved outcomes, rather than JAK2 in the tumour 
cells themselves(326). 
Stromal JAK1 and JAK2 expression was also observed, predominantly in ER+ 
disease and less in TNBC in the case of JAK2. Differentiation between expression 
within the cytoplasm or nucleus of these cells was not reliably possible at the 
magnification available. As with nuclear expression in tumour cells, stromal 
expression of JAK1 was associated with improved CSS in ER positive disease and 
was associated with reduced tumour size. Conversely, but similarly to tumour 
cytoplasmic JAK2 expression, high stromal JAK2 expression was associated with 
worse CSS overall, in ER- disease and in the luminal B and HER2-enriched 
subtypes. It was interesting to note that these associations in these two HER2 
positive subtypes were the only ones independent of other prognostic factors. 
Stromal JAK1 and JAK2 expression were weakly correlated with stromal IL6R 
expression which suggests, while some of the JAK expression is due to IL6R 
activation, other ligands and receptors are likely to be important. Stromal 
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expression of both JAKs was associated with membranous ILR expression in 
tumour cells which may simply reflect the presence of IL6 in the tumour 
microenvironment. It is interesting to note that high stromal JAK2 expression is 
associated with lower numbers of CD4+ and CD8+ lymphocytes, suggesting that it 
is other stromal cell types in which the pathway is being activated, and this may 
be key to its association with poorer prognosis. For example, it may be that in 
these tumours there is an imbalance in the stromal cells in the 
microenvironment with fewer lymphocytes and higher numbers of MSCs, CAFs 
and other immune cell types. The JAK/STAT pathway has been reported to have 
a role in homing of MSCs(328) and their cytokine profile(329), in activation of 
inflammatory CAFS and their crosstalk with tumour cells(330-332), in dendritic 
cell differentiation and function(333) and in development and maturation of NK 
cells(334). There is evidence for the involvement of MSCs and CAFs in breast 
cancer progression, metastases and chemoresistance(335-343). 
The findings of the present study suggest both positive and negative roles for the 
JAKs in tumour progression. Higher expression of JAK1 is predominantly 
associated with better prognosis, with the exception of TNBC, while JAK2 
expression is associated with poorer prognosis. None of the associations with 
survival observed in this study were independent of other known prognostic 
factors and therefore, expression of JAK1 or JAK2 alone is unlikely to be of 
clinical use as a prognostic marker. However, their role in tumour progression 
suggests a potential role for JAK inhibitors in some breast tumours. They may 
have a role in TNBC since both nuclear JAK1 and cytoplasmic JAK2 were 
associated with poor prognosis in this subtype. JAK expression levels could 
potentially be used as predictive markers for treatment response. Given the 
complex interplay between different pathways they are likely to be most 
efficacious in combination with other treatments so further work is warranted in 
this subtype to fully understand the interplay between these pathways and to 
establish what treatment combinations may be most effective. In ER positive 
disease their potential is less clear and certainly, JAK1 inhibition seems likely to 
be of no benefit or even to be counter-productive so, on the basis of the findings 
of this study, any investigation into JAK inhibitors in ER positive disease should 
be with selective JAK2 inhibitors.  
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Ruxolitinib, a selective JAK1/2 inhibitor, is currently in clinical use for 
myeloproliferative diseases, which are associated with JAK mutations,(315) but 
the role of JAK inhibitors in solid tumours has not been fully established and 
trials are ongoing. Despite promising results with JAK inhibitors in pre-clinical 
studies of breast cancer(344, 345), some ruxolitinib breast cancer trials were 
terminated due to lack of clinical response(346-348). The opposing associations 
with CSS of JAK1 and JAK2 in this study may form part of the explanation for 
these disappointing results, though one study was in TNBC only(346) in which, 
based on our findings, we might expect a response. However, the study was in 
patients with metastatic disease so the disease process may be too advanced at 
this stage for JAK inhibition to have a significant clinical impact. Two other trials 
of ruxolitinib in breast cancer remain active at present(349, 350), as well as one 
investigating its effect on premalignant breast cells (ADH, ALH, LCIS or 
DCIS)(351). Two studies of the JAK2-specific inhibitor WP1066 in brain tumours 
are currently active, while two of pacritinib in colorectal cancer and in NSCLC 
have been terminated(315). 
In summary, the present study describes for the first time nuclear expression of 
JAK1 and 2 in breast cancer cells. It reports an association between high nuclear 
JAK1 and cytoplasmic JAK2 expression and poor CSS, warranting further 
investigation of JAK inhibitors in TNBC. Improved CSS is observed in ER+ disease 
with high nuclear and stromal JAK1 expression so JAK1 inhibitors should be 
avoided in these cancers. There is evidence for high expression of JAK2 in 
certain types of stromal cells, in part activated by IL6 signalling, leading to a 
pro-tumour microenvironment and worse cancer outcomes but further work to 
determine the stromal cells implicated is indicated. JAK2 inhibition in stromal 






9 STAT3 in primary operable breast cancer 
9.1 Introduction 
The previous two chapters have investigated the role of IL6 and JAKs 1 and 2 in 
primary operable breast cancer. Their downstream target in the IL6/JAK/STAT3 
pathway is STAT3. However, as previously discussed, they also activate other 
cell signalling pathways. Therefore, further investigation of the expression of 
STAT3 in primary operable breast cancer and its relationship to IL6 and JAK 
expression is required to more fully describe the role of this pathway in these 
cancers. 
STAT3 is a transcription factor with numerous downstream targets, resulting in 
key roles in various processes including haematopoiesis, immune development, 
stem cell maintenance(82, 83), and mammary epithelial cell growth, 
differentiation, apoptosis and post-lactational mammary involution(84, 85, 352). 
The pathway can be activated by IL6 receptors but also by tyrosine kinases such 
as EGFR, serine kinases, G protein coupled receptors, Rho GTPases, cadherin 
engagement and toll-like receptors(353). Canonically it is phosphorylated by 
JAKs at a conserved tyrosine residue (Tyr705) leading to STAT3 dimerisation and 
translocation to the nucleus where it binds to regulatory DNA sequences(82). 
However, it can also undergo phosphorylation at a serine residue (Ser727) via 




Figure 9-1. Activation of STAT3.  Diagram illustrating the final stages of the IL6/JAK/STAT3 
pathway. The activated STAT3 dimer translocates into the cell nucleus where it binds to DNA and 
regulates transcription of various genes. STAT3 can also be phosphorylated at Ser727 via the 



























Although STAT3 regulates cell death in breast involution, in breast cancer 
evidence suggests that it promotes cell survival(352). STAT3 has been observed 
to be constitutively active in cancer cells(354). Some oncogenic STAT3 target 
genes include proliferation genes (Bcl-xL, MCL1, survivin), angiogenesis-
promoting genes (Hif-1α, VEGF) and EMT-associated genes (vimentin, TWIST, 
MMP-9)(355). Though evidence from preclinical studies suggests a pro-
tumourigenic role for STAT3(91-100), results of clinical studies of STAT3 and 
pSTAT3 have been mixed(76, 101-107). As detailed in chapter 1, some have 
reported an association between STAT3 and poorer prognosis(103), some with 
improved prognosis(76, 104-106), and some observed no statistically significant 
associations(102, 104). STAT3 inhibitors have yielded promising results in vivo 
but challenges exist in bringing them to clinical use(356). Early-stage clinical 
trials in various tumour types have reported conflicting results (357). Therefore, 
further work is required to better understand the role of STAT3 in breast cancer.  
From the preclinical evidence, it could be hypothesised that, in the present 
cohort of breast cancer patients, high levels of tSTAT3 and pSTAT3 expression 
would be associated with poorer CSS. However, in view of the mixed results 
from clinical studies to date, the question arises as to whether the pro or anti 
tumour activity of STAT3 is influenced by other factors, such as the tumour 
subtype, the pathway which is activating it and influences from the tumour 
microenvironment, and the different sites of activation/phosphorylation. 
Specifically, there is minimal data in the literature regarding the serine 727 
phosphorylation site of STAT3 so it could be postulated that phosphorylation at 
this site may modify the response of activated STAT3 observed in preclinical 
studies. This study aims to describe the expression of total STAT3 (tSTAT3) and 
of both its phosphorylated forms, pSTAT3(Tyr705) and pSTAT3(Ser727), and to 
describe their associations with clinicopathological characteristics, CSS and 
other components of the IL6/JAK/STAT3 pathway. 
9.2 Materials and methods 
9.2.1 Patient cohort 
A previously constructed TMA from the 1800 cohort was utilised in this study. 
Patient characteristics are detailed in chapter 2.  
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9.2.2 TMA slide staining and scanning 
TMAs were stained in triplicate for pSTAT3(Tyr705), pSTAT3(Ser727) and total 
STAT3 (tSTAT3) using the immunohistochemistry technique and antibodies 
detailed in chapter 2. They were scanned into Slidepath software as previously 
described. 
9.2.3 Scoring for pSTAT3(Tyr705), pSTAT3(Ser727) tSTAT3 
expression 
Each TMA core was scored by the author using the weighted histoscore method 
described in chapter 2. Cores with <20% of the core missing by visual assessment 
were scored. For all three antibodies, nuclear and cytoplasmic expression in 
tumour cells were scored separately. A separate score was also given for 
expression in stromal cells (differentiation between nuclear and cytoplasmic 
expression in these smaller cells was not reliably possible at 20x magnification, 
so cellular compartments were not assessed). 
9.2.4 Molecular subtyping 
ER, PR, HER2 and Ki67 profiling was already available. This data was employed 
to divide the cohort into the four main molecular subtypes of breast cancer, as 
detailed in chapter 1, for subgroup analysis. 
9.2.5 Statistical analysis 
Initial analysis using ROC curves, division into tertiles, and the median 
expression was carried out to determine the optimum threshold for division into 
high and low expression groups for further analysis. Analysis of associations with 
clinicopathological characteristics and with cancer specific survival was carried 
out as described in chapter 2. This analysis was carried out initially in the full 
cohort, then in the ER positive and ER negative cohorts separately, and 





9.3.1 Formation of the cohort for tSTAT3 
609 patients had at least one core which was assessable for tSTAT3 in tumour 
nuclei and cytoplasm. 562 had at least 1 core which was assessable for stromal 




Figure 9-2. Formation of the tSTAT3 cohort.  Flow diagram to illustrate the number of patients within the 1800 cohort with at least 1 core which was assessable for 
tSTAT3 expression in the tumour cell nucleus and cytoplasm, and separately in the stroma. The numbers available for subgroup analysis by ER status and by 
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9.3.2 Total STAT3 expression 
tSTAT3 expression was observed in the nucleus and cytoplasm of tumour cells 
and in stromal cells. Examples of tSTAT3 staining are shown below. 
 
Figure 9-3. Examples of tSTAT3 staining.  TMA cores stained using IHC for tSTAT3: a) breast 
core with moderate and strong nuclear and cytoplasmic staining at 10x magnification with an inset 
at 40x magnification, b) breast core with weak cytoplasmic staining, c) true positive core (control, 
liver) at 10x magnification, d) true negative core at 10x magnification. 
 
Median WHS for total STAT3 expression in tumour was 106 (0-260) which was 
similar to that for cytoplasmic expression which was 105 (0-209.33). Median 
stromal tSTAT3 WHS was 82.50 (0-205). tSTAT3 expression in the 3 locations 









Figure 9-4. Expression of tSTAT3. Histograms to illustrate tSTAT3 expression in a) tumour cell nuclei, b) tumour cell cytoplasm and c) stromal cells. 
 
Figure 9-5. Boxplots of tSTAT3 expression. Boxplots to illustrate the comparative expression of tSTAT3 in tumour nuclei, cytoplasm and stromal cells.
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Nuclear tSTAT3 expression was higher in ER positive disease and, within the 
molecular subtypes, highest in luminal A cancers and lowest in HER2-enriched 





Figure 9-6. Boxplots of nuclear tSTAT3 by receptor status. Boxplots to illustrate the differences 
in nuclear tSTAT3 expression by a) ER status (p=0.033) and b) molecular subtype (p<0.001). 
 
There was no difference between the subtypes in cytoplasmic tSTAT3 expression 





Figure 9-7. Boxplots of cytoplasmic tSTAT3 by receptor status. Boxplots to illustrate the 





Stromal expression was higher in ER positive disease with the lowest expression 





Figure 9-8. Boxplots of stromal tSTAT3 by receptor status. Boxplots to illustrate the differences 
in stromal tSTAT3 expression by a) ER status (p<0.001) and b) molecular subtype (p=0.001). 
 
There was moderate positive correlation between each of the tSTAT3 expression 









Figure 9-9. Correlation between tSTAT3 expression sites. Scatter plots to illustrate the correlation between tSTAT3 expression in different sites: a) nuclear and 
cytoplasmic expression (Pearson correlation 0.507, p<0.001), b) nuclear and stromal expression (Pearson correlation 0.386, p<0.001), c) cytoplasmic and stromal 
expression (Pearson correlation 0.319, p<0.001). 
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9.3.3 The relationship between total STAT3 and CSS 
ROC curves were created to determine thresholds for division of patients into 
high and low expression groups for further analysis (Figure 9-10). From these, a 
threshold of 111.50 was derived for nuclear tSTAT3 expression and a threshold of 
65.50 was derived for stromal tSTAT3 expression. No threshold for cytoplasmic 
tSTAT3 expression could be derived from the ROC curve so, after some 
exploratory survival analysis using tertiles and the median, a threshold of 121.33 









Figure 9-10. ROC curves for tSTAT3 expression and CSS. ROC curves to illustrate the relationship with CSS of tSTAT3 expression in a) tumour cell nuclei (AUC 
0.470), b) tumour cell cytoplasm (AUC 0.542) and c) stromal cells (AUCC 0.520).
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9.3.3.1 Nuclear tSTAT3 expression and CSS 
249 (40.9%) patients had high nuclear tSTAT3 expression (mean WHS>111.50). In 
the full cohort, low nuclear tSTAT3 expression was associated with worse CSS 
(high v low: HR 0.66, 95% CI 0.46-0.95, p=0.024) but when analysed by ER status 
there was no statistically significant association in either ER positive (HR 0.63, 
95% CI 0.39-1.04, p=0.071) or ER negative disease (HR 0.75, 95% CI 0.44-1.29, 
p=0.299) (Figure 9-11). This was also the case in each of the individual 
molecular subtypes (Figure 9-12). The association in the full cohort was not 









Figure 9-11. The relationship between nuclear tSTAT3 expression and CSS. Kaplan meier graphs to illustrate the relationship between nuclear tSTAT3 expression 











Figure 9-12. The relationship between nuclear tSTAT3 expression and CSS by molecular 
subtype. Kaplan meier graphs to illustrate the relationship between nuclear tSTAT3 expression in 
tumour cells and CSS in a) luminal A (n=253, p=0.070), b) luminal B (n=100, p=0.497), c) HER2-
enriched (n=68, p=0.600) and d) triple negative (n=138, p=0.662) breast cancer. 
9.3.3.2 Cytoplasmic tSTAT3 expression and CSS 
203 (33.3%) patients had high cytoplasmic tSTAT3 expression (mean WHS 
>121.33). In the full cohort, high cytoplasmic expression of tSTAT3 was 
associated with worse CSS (high v low: HR 1.41, 95% CI 1.00-1.99, p=0.052) and 
this was particularly the case in ER positive (HR 1.76, 95% CI 1.10-2.82, p=0.020) 
but not ER negative disease (HR 1.12, 95% CI 0.67-1.87, p=0.674) (Figure 9-13). 
There was no significant relationship between cytoplasmic tSTAT3 expression 
and CSS in any of the molecular subtypes (Figure 9-14). The associations in the 
full cohort (p=0.105) and in ER positive disease (p=0.144) were not independent 









Figure 9-13. The relationship between cytoplasmic tSTAT3 expression and CSS. Kaplan meier graphs to illustrate the relationship between cytoplasmic tSTAT3 











Figure 9-14. The relationship between cytoplasmic tSTAT3 expression and CSS by 
molecular subtype.  Kaplan meier graphs to illustrate the relationship between cytoplasmic 
tSTAT3 expression in tumour cells and CSS in a) luminal A (n=253, p=0.185), b) luminal B (n=100, 
p=0.247), c) HER2-enriched (n=68, p=0.595) and d) triple negative (n=138, p=0.764) breast 
cancer. 
9.3.3.3 Stromal tSTAT3 expression and CSS 
344 (61.2%) patients had high stromal tSTAT3 expression (mean WHS>65.50). In 
the full cohort there was a trend towards worse CSS in those with high stromal 
tSTAT3 expression (high v low: HR 1.46, 95% CI 1.00-2.15, p=0.053). When 
analysed by ER status, in ER negative disease high stromal tSTAT3 expression was 
significantly associated with worse CSS (HR 1.96, 95% CI 1.16-3.31, p=0.012) but 
not in ER positive disease (HR 1.32, 95% CI 0.75-2.34, p=0.340) (Figure 9-15). 
When analysed within the molecular subtypes, high stromal tSTAT3 expression 
was associated with worse CSS in triple negative disease (HR 2.02, 95% CI 1.05-
3.89, p=0.036) but not in the other 3 subtypes (Figure 9-16). The associations in 
ER negative (p=0.242) and triple negative disease (p=0.689) were not 










Figure 9-15. The relationship between stromal tSTAT3 expression and CSS. Kaplan meier graphs to illustrate the relationship between stromal tSTAT3 expression 











Figure 9-16. The relationship between stromal tSTAT3 expression and CSS by molecular 
subtype. Kaplan meier graphs to illustrate the relationship between stromal tSTAT3 expression 
and CSS in a) luminal A (n=225, p=0.132), b) luminal B (n=90, p=0.829), c) HER2-enriched (n=67, 
p=0.373) and d) triple negative (n=133, p=0.032) breast cancer. 
9.3.4 Associations between tSTAT3 expression and 
clinicopathological characteristics 
High nuclear tSTAT3 expression was associated with lower grade (p<0.001), ER 
positivity (p=0.014), HER2 negativity (p=0.001) and low necrosis (p=0.004) (Table 
9-1). There were no significant associations observed between cytoplasmic 
tSTAT3 and the clinicopathological characteristics studied (Table 9-1).
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 Nuclear tSTAT3 expression p Cytoplasmic tSTAT3 expression p 




















































































































































































































































Table 9-1. The association between nuclear and cytoplasmic tSTAT3 expression and clinicopathological characteristics. Table detailing the associations 




High stromal tSTAT3 expression was associated with HER2 positivity (p=0.024), 






















































































































































Table 9-2. The association between stromal tSTAT3 expression and clinicopathological 
characteristics in ER negative disease. Table detailing the associations between stromal 
tSTAT3 expression and clinicopathological characteristics in patients with ER negative breast 




9.3.5 Formation of the cohort for pSTAT3(Tyr705) 
718 patients had at least one core which was assessable for pSTAT3(Tyr 705) 
expression in tumour cell nuclei and cytoplasm, while 784 had at least one core 




Figure 9-17. Formation of the pSTAT3(Tyr705) cohort. Flow diagram to illustrate the number of patients within the 1800 cohort with at least 1 core which was 
assessable for pSTAT3(Tyr705) expression in the tumour cell nucleus and cytoplasm, and separately in the stroma. The numbers available for subgroup analysis by 
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9.3.6 pSTAT3(Tyr 705) expression 
pSTAT3(Tyr705) expression was observed in the nucleus and cytoplasm of tumour 
cells and in stromal cells. Examples of tSTAT3 staining are shown below. 
 
Figure 9-18. Examples of pSTAT3(Tyr 705) staining. TMA cores stained using IHC for 
pSTAT3(Tyr705): a) breast core with predominantly moderate cytoplasmic staining at 10x 
magnification with an inset at 40x magnification, b) breast core with predominantly weak 
cytoplasmic staining, c) true positive core (control, liver) at 10x magnification, d) true negative core 
at 10x magnification. 
Median expression of pSTAT3(Tyr705) was mean WHS 23.33 (0-300) in tumour 
cell nuclei, 56.67 (0-300) in tumour cell cytoplasm and 6.67 (0-236.67) in 
stromal cells. pSTAT3(Tyr705) expression in the 3 locations is illustrated in the 










Figure 9-19. Expression of pSTAT3(Tyr705).  Histograms to illustrate the expression of pSTAT3(Tyr705) in a) tumour nuclei, b) tumour cytoplasm and c) stroma. 
 
Figure 9-20. Boxplots of pSTAT3(Tyr705) expression. Boxplots to compare the expression of pSTAT3(Tyr705) in tumour nuclei, cytoplasm and in stroma.
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There was no significant difference in nuclear pSTAT3(Tyr705) expression 





Figure 9-21. Boxplots of nuclear pSTAT3(Tyr705) by receptor status. Boxplots to illustrate the 
differences in nuclear pSTAT3(Tyr705) expression by a) ER status (p=0.303) and b) molecular 
subtype (p=0.159). 
 
Similarly, there was no significant difference in cytoplasmic pSTAT3(Tyr705) 





Figure 9-22. Boxplots of cytoplasmic pSTAT3(Tyr705) by receptor status. Boxplots to illustrate 
the differences in cytoplasmic pSTAT3(Tyr705) expression by a) ER status (p=0.987) and b) 










Figure 9-23. Boxplots of stromal pSTAT3(Tyr705) by receptor status. Boxplots to illustrate the 
differences in stromal pSTAT3(Tyr705) expression by a) ER status (p<0.001) and b) molecular 
subtype (p<0.001). 
There was a moderate positive correlation between nuclear and cytoplasmic 
pSTAT3(Tyr705) expression and a weak correlation between each of the tumour 









Figure 9-24. Correlation between pSTAT3(Tyr705) expression sites. Scatter plots to illustrate the correlation between pSTAT3(Tyr705) expression in different sites: 
a) nuclear and cytoplasmic expression (Pearson correlation 0.625, p<0.001), b) nuclear and stromal expression (Pearson correlation 0.236, p<0.001), c) cytoplasmic 
and stromal expression (Pearson correlation 0.187, p<0.001). 
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9.3.7 The relationship between pSTAT3(Tyr 705) and CSS 
ROC curves were constructed to determine thresholds for division into high and 
low expression groups for further analysis (Figure 9-25). From these, thresholds 
of a mean WHS of 8.50 and 42.50 were derived for nuclear and cytoplasmic 
pSTAT3(Tyr705) expression respectively. As no threshold could be derived from 










Figure 9-25. ROC curves for pSTAT3(Tyr705) expression and CSS. ROC curves to illustrate the relationship between pSTAT3(Tyr705) and CSS in a) tumour cell 
nuclei (AUC 0.470), b) tumour cell cytoplasm (AUC 0.510) and c) stromal cells (AUC 0.498).
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9.3.7.1 Nuclear pSTAT3(Tyr705) expression and CSS 
493 (68.7%) of tumours had high (mean WHS >8.50) nuclear pSTAT3(Tyr705) 
expression. There was no significant association between nuclear 
pSTAT3(Tyr705) expression and CSS in the whole cohort or when analysed by ER 
status (Figure 9-26). However, when analysed by molecular subtype, low 
nuclear pSTAT3(Tyr705) expression was associated with worse CSS in luminal A 
cancers (high v low: HR 0.53, 95% CI 0.28-1.00, p=0.048) but there was no 
significant association observed in the other three subtypes (Figure 9-27). The 
association in luminal A disease was not independent of other known 










Figure 9-26. The relationship between nuclear pSTAT3(Tyr 705) expression and CSS. Kaplan meier graphs to illustrate the relationship between nuclear 
pSTAT3(Tyr705) expression in tumour cells and CSS in a) the full cohort (n=718, p=0.063), b) ER positive disease (n=488, p=0.080) and c) ER negative disease 











Figure 9-27. The relationship between nuclear pSTAT3(Tyr705) expression and CSS by 
molecular subtype. Kaplan meier graphs to illustrate the relationship between nuclear 
pSTAT3(Tyr705) expression and CSS in a) luminal A (n=316, p=0.045), b) Luminal B (n=108, 
p=0.333), c) HER2-enriched (n=65, p=0.788) and d) triple negative (n=152, p=0.534) breast 
cancer. 
9.3.7.2 Cytoplasmic pSTAT3(Tyr705) expression and CSS 
440 (61.3%) patients had high (mean WHS >42.50) cytoplasmic pSTAT3(Tyr705) 
expression. No significant association was observed between cytoplasmic 
pSTAT3(Tyr705) expression and CSS when analysed in the full cohort, by ER 









Figure 9-28. The relationship between cytoplasmic pSTAT3(Tyr 705) expression and CSS. Kaplan meier graphs to illustrate the relationship between cytoplasmic 












Figure 9-29. The relationship between cytoplasmic pSTAT3(Tyr705) expression and CSS by 
molecular subtype. Kaplan meier graphs to illustrate the relationship between cytoplasmic 
pSTAT3(Tyr705) expression and CSS in a) luminal A (n=316, p=0.810), b) Luminal B (n=108, 
p=0.355), c) HER2-enriched (n=65, p=0.276) and d) triple negative (n=152, p=0.065) breast 
cancer. 
9.3.7.3 Stromal pSTAT3(Tyr705) expression and CSS 
No significant association was observed between stromal pSTAT3(Tyr705) 
expression and CSS when analysed in the full cohort, by ER status or by 









Figure 9-30. The relationship between stromal pSTAT3(Tyr 705) expression and CSS. Kaplan meier graphs to illustrate the relationship between stromal 












Figure 9-31. The relationship between stromal pSTAT3(Tyr705) expression and CSS by 
molecular subtype. Kaplan meier graphs to illustrate the relationship between stromal 
pSTAT3(Tyr705) expression and CSS in a) luminal A (n=345, p=0.126), b) Luminal B (n=117, 
p=0.568), c) HER2-enriched (n=68, p=0.269) and d) triple negative (n=163, p=0.463) breast 
cancer. 
9.3.8 Associations between pSTAT3(Tyr705) expression and 
clinicopathological characteristics 
High nuclear pSTAT3(Tyr705) expression was associated with younger age 
(p=0.006), more lobular cancers (p=0.008), low necrosis (p=0.017), lower KM 
score (p=0.042) and high budding (p<0.001) (Table 9-3). In luminal A cancers it 

































































































































































Table 9-3. The association between nuclear pSTAT3(Tyr705) expression and 
clinicopathological characteristics. Table detailing the associations between nuclear 
pSTAT3(Tyr705) expression and clinicopathological characteristics. Statistically significant p values 
are highlighted in bold. 
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9.3.9 Formation of the cohort for pSTAT3(Ser727) 
727 patients had at least one core which was assessable for pSTAT3(Ser727) 
expression in tumour cell nuclei and cytoplasm while 786 had at least one core 





Figure 9-32. Formation of the pSTAT3(Ser727) cohort. Flow diagram to illustrate the number of patients within the 1800 cohort with at least 1 core which was 
assessable for pSTAT3(Ser727) expression in the tumour cell nucleus and cytoplasm, and separately in the stroma. The numbers available for subgroup analysis by 
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9.3.10 pSTAT3(Ser727) expression 
pSTAT3(Ser727) expression was observed in the nucleus and cytoplasm of tumour 
cells and in stromal cells. Examples of tSTAT3 staining are shown below. 
 
Figure 9-33. Examples of pSTAT3(Ser727) staining. TMA cores stained using IHC for 
pSTAT3(Ser727): a) breast core with predominantly moderate cytoplasmic staining at 10x 
magnification with an inset at 40x magnification, b) breast core with predominantly weak 
cytoplasmic staining, c) true positive core (control, tonsil) at 10x magnification, d) true negative 
core at 10x magnification. 
Median expression of pSTAT3(Ser727) was mean WHS 145 (0-300) in tumour cell 
nuclei, 120 (0-300) in cytoplasm and 3.33 (0-110) in stroma. pSTAT3(Ser727) 











Figure 9-34. Expression of pSTAT3(Ser727). Histograms to illustrate the expression of pSTAT3(ser727) in a) tumour cell nuclei, b) tumour cytoplasm and c) stroma. 
 
Figure 9-35. Boxplots of pSTAT3(Ser727) expression. Boxplots to compare the expression of pSTAT3(Ser727) in tumour nuclei, cytoplasm and in stroma.
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Nuclear pSTAT3(Ser727) expression was higher in ER+ disease and, within the 
molecular subtypes, was highest in luminal A cancers and lowest in the HER2-





Figure 9-36. Boxplots of nuclear pSTAT3(Ser727) expression by receptor status. Boxplots to 
illustrate the differences in nuclear pSTAT3(Ser727) expression by a) ER status (p<0.001) and b) 
molecular subtype (p<0.001). 
Similarly, cytoplasmic pSTAT3(Ser727) expression was higher in ER+ disease and, 
within the molecular subtypes, was highest in luminal A cancers and lowest in 





Figure 9-37. Boxplots of cytoplasmic pSTAT3(Ser727) by receptor status. Boxplots to illustrate 
the differences in cytoplasmic pSTAT3(Ser727) expression by a) ER status (p<0.001) and b) 
molecular subtype (p<0.001).  
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Figure 9-38. Boxplots of stromal pSTAT3(ser727) by receptor status. Boxplots to illustrate the 
differences in stromal pSTAT3(Ser727) expression by a) ER status (p<0.001) and b) molecular 
subtype (p<0.001). 
 
There was a strong positive correlation between nuclear and cytoplasmic 
pSTAT3(Ser727) expression and a weak positive correlation between each of the 









Figure 9-39. Correlation between pSTAT3(Ser727) expression sites. Scatter plots to illustrate the correlation between pSTAT3(Ser727) expression in different 
sites: a) nuclear and cytoplasmic expression (Pearson correlation 0.810, p<0.001), b) nuclear and stromal expression (Pearson correlation 0.142, p<0.001), c) 
cytoplasmic and stromal expression (Pearson correlation 0.239, p<0.001). 
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9.3.11 The relationship between pSTAT3(Ser727) and CSS 
ROC curves were constructed to determine thresholds for division into high and 
low expression groups for further analysis (Figure 9-40). From these, thresholds 
of mean WHS 181.25 for nuclear, 128.75 for cytoplasmic and 0.50 for stromal 









Figure 9-40. ROC curves for pSTAT3(Ser727) expression and CSS. . ROC curves to illustrate the relationship between pSTAT3(Ser727) and CSS in a) tumour cell 
nuclei (AUC 0.432), b) tumour cell cytoplasm (AUC 0.438) and c) stromal cells (AUC 0.481).
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9.3.11.1 Nuclear pSTAT3(Ser727) expression and CSS 
242 (33.3%) patients had high (mean WHS>181.25) nuclear pSTAT3(Ser727) 
expression. High nuclear pSTAT3(Ser727) expression was associated with 
improved CSS in the full cohort (high v low: HR 0.55, 95% CI 0.38-0.81, p=0.002) 
and in ER positive (HR 0.56, 95% CI 0.35-0.90, p=0.016) but not ER negative 
disease (Figure 9-41). When analysed within the molecular subtypes, the same 
was true in luminal A cancers (HR 0.48, 95% CI 0.24-0.95, p=0.036) but not in the 









Figure 9-41. The relationship between nuclear pSTAT3(Ser727) expression and CSS. Kaplan meier graphs to illustrate the relationship between nuclear 
pSTAT3(Ser727) expression in tumour cells and CSS in a) the full cohort (n=727, p=0.002), b) ER positive disease (n=499, p=0.014) and c) ER negative disease 











Figure 9-42. The relationship between nuclear pSTAT3(Ser727) expression and CSS by 
molecular subtype. Kaplan meier graphs to illustrate the relationship between nuclear 
pSTAT3(Ser727) expression and CSS in a) luminal A (n=323, p=0.032), b) Luminal B (n=114, 
p=0.502), c) HER2-enriched (n=65, p=0.178) and d) triple negative (n=150, p=0.750) breast 
cancer. 
On multivariate analysis, controlling for other known prognostic factors in each 
subtype, it was only in luminal A disease that nuclear pSTAT3(Ser727) expression 























































Table 9-4. Multivariate analysis for nuclear pSTAT3(Ser727) in luminal A disease.  Table 
detailing the relationship with CSS of nuclear pSTAT3(Ser727) in luminal A disease when 
controlling for other known prognostic factors. Factors with p<0.05 on univariate analysis were 
entered into the equation. 
9.3.11.2 Cytoplasmic pSTAT3(Ser727) expression and CSS 
337 (46.4%) patients had high (mean WHS>128.75) cytoplasmic pSTAT3(Ser727) 
expression. Low cytoplasmic pSTAT3(Ser727) expression was associated with 
worse CSS in the full cohort (high v low: HR 0.58, 95% CI 0.41-0.80, p=0.001), ER 
positive (HR 0.47, 95% CI 0.31-0.74, p=0.001) and specifically luminal A (HR 0.48, 









Figure 9-43. The relationship between cytoplasmic pSTAT3(Ser727) expression and CSS. Kaplan meier graphs to illustrate the relationship between cytoplasmic 
pSTAT3(Ser727) expression in tumour cells and CSS in a) the full cohort (n=727, p=0.001), b) ER positive disease (n=499, p=0.001) and c) ER negative disease 











Figure 9-44. The relationship between cytoplasmic pSTAT3(Ser727) expression and CSS by 
molecular subtype. Kaplan meier graphs to illustrate the relationship between cytoplasmic 
pSTAT3(Ser727) expression and CSS in a) luminal A (n=323, p=0.023), b) Luminal B (n=114, 
p=0.443), c) HER2-enriched (n=65, p=0.246) and d) triple negative (n=150, p=0.705) breast 
cancer. 
On multivariate analysis, controlling for other known prognostic factors in each 
subtype, it was only in luminal A disease that cytoplasmic pSTAT3(Ser727) 
expression was independently associated with CSS (HR 0.37, 95% CI 0.18-0.76, 
























































Table 9-5. Multivariate analysis for cytoplasmic pSTAT3(Ser727) in luminal A disease. Table 
detailing the relationship with CSS of cytoplasmic pSTAT3(Ser727) in luminal A disease when 
controlling for other known prognostic factors. Factors with p<0.05 on univariate analysis were 
entered into the equation. 
 
9.3.11.3 Stromal pSTAT3(Ser727) expression and CSS 
424 (53.9%) patients had high (mean WHS>0.50) stromal pSTAT3(Ser727) 
expression. There was no significant association between stromal 
pSTAT3(Ser727) expression in the full cohort or in ER positive disease but in ER 
negative disease, low expression was associated with worse CSS (high v low: HR 
0.61, 95% CI 0.38-0.97, p=0.037) (Figure 9-45). There was no significant 
association observed within any of the molecular subtypes though there was a 
trend towards worse CSS in patients with low pSTAT3(Ser727) expression in the 
HER2-enriched cohort of 68 patients (HR 0.44, 95% CI 0.19-1.03, p=0.059) 
(Figure 9-46).  The association in ER negative disease was not independent of 









Figure 9-45. The relationship between stromal pSTAT3(Ser727) expression and CSS. Kaplan meier graphs to illustrate the relationship between stromal 
pSTAT3(Ser727) expression in tumour cells and CSS in a) the full cohort (n=786, p=0.141), b) ER positive disease (n=538, p=0.265) and c) ER negative disease 











Figure 9-46. The relationship between stromal pSTAT3(Ser727) expression and CSS by 
molecular subtype. Kaplan meier graphs to illustrate the relationship between stromal 
pSTAT3(Ser727) expression and CSS in a) luminal A (n=353, p=0.541), b) Luminal B (n=120, 
p=0.450), c) HER2-enriched (n=68, p=0.051) and d) triple negative (n=160, p=0.134) breast 
cancer. 
9.3.12 Associations between pSTAT3(Ser727) expression and 
clinicopathological characteristics 
High nuclear pSTAT3(Ser727) expression was associated with smaller cancers 
(p<0.001), lower tumour grade (p<0.001), ER positivity (p<0.001), HER2 
negativity (p<0.001), low necrosis (p<0.001), low KM score (p<0.001), low CD8+ 
lymphocytes (p=0.004) and high budding (p=0.032) (Table 9-6).  
High cytoplasmic pSTAT3(Ser727) expression was associated with smaller 
tumours (p=0.011), lower grade (p<0.001), ER positivity (p=0.001), HER2 
negativity (p=0.001) and low necrosis (p<0.001) (Table 9-6).
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 Nuclear pSTAT3(Ser727) expression p Cytoplasmic pSTAT3(Ser727) expression p 




















































































































































































































































Table 9-6. The association between nuclear and cytoplasmic pSTAT3(Ser727) expression and clinicopathological characteristics. Table detailing the 
associations between nuclear and cytoplasmic pSTAT3(Ser727) expression and clinicopathological characteristics. Significant p values are highlighted in bold. 
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High stromal pSTAT3(Ser727) expression was associated with high KM score 
(p=0.037) and high CD4+ lymphocytes (p<0.001) (Table 9-7). 


















































































































































Table 9-7. The association between stromal pSTAT3(Ser727) expression and 
clinicoplathological characteristics in ER negative disease. Table detailing the associations 
between stromal pSTAT3(Ser727) expression and clinicopathological characteristics in ER 




9.3.13 Associations between STAT3 and CSS in different 
disease stages 
To investigate whether there was any evidence for a different role for STAT3 at 
different stages of disease, the associations between the different forms and 
tumour cell expression sites of STAT3 and CSS in the different T and N stages 
were analysed. 
9.3.13.1 Associations between STAT3 and CSS by tumour stage 
In T1 breast cancers, high nuclear and cytoplasmic pSTAT3(Ser727) expression 
were associated with improved CSS (nuclear: HR 0.51, 95% CI 0.28-0.90, 
p=0.020; cytoplasmic: HR 0.60, 95% CI 0.35-1.01, p=0.052). High nuclear tSTAT3 
expression was also associated with improved CSS (HR 0.47, 95% CI 0.24-0.93, 
p=0.030) (Figure 9-47). There was no significant relationship between nuclear 










Figure 9-47. Association between STAT3 and CSS in T1 breast cancer. Kaplan meier graphs illustrating the relationship between CSS and a) nuclear 






In T2 breast cancers, high nuclear pSTAT3(Tyr705) expression was associated 
with improved CSS (HR 0.64, 95% CI 0.40-1.01, p=0.053) (Figure 9-48) and was 
the only STAT3 form and expression site significantly associated with CSS. 
 
Figure 9-48. Association between nuclear pSTAT3(Tyr705) expression and CSS in T2 breast 
cancer. Kaplan meier graph to illustrate the relationship between pSTAT3(Tyr705) expression and 
CSS in T2 breast cancer (p=0.050).  
In T3 breast cancers, high cytoplasmic tSTAT3 expression was associated with 
poorer CSS (HR 3.12, 95% CI 1.07-9.06, p=0.037) (Figure 9-49) and was the only 
STAT3 form and expression site significantly associated with CSS in this cohort. 
 
Figure 9-49. Association between cytoplasmic tSTAT3 and CSS in T3 breast cancer. Kaplan 
meier graph to illustrate the relationship between cytoplasmic tSTAT3 expression and CSS in T3 
breast cancer (p=0.028). 
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9.3.13.2 Associations between STAT3 and CSS by nodal stage 
In node negative disease, none of the STAT3 forms and expression sites was 
significantly associated with CSS (data not shown). 
In node positive disease both high nuclear and cytoplasmic pSTAT3(Ser727) 
expression were associated with improved CSS (nuclear: HR 0.52, 95% CI 0.32-
0.85, p=0.008; cytoplasmic: HR 0.59, 95% CI 0.39-0.88, p=0.011). High nuclear 
pSTAT3(Tyr705) (HR 0.59, 95% CI 0.40-0.87, p=0.007) and tSTAT3 expression (HR 
0.64, 95% CI 0.41-1.00, p=0.048) were also associated with improved CSS in this 









Figure 9-50. Associations between STAT3 and CSS in node positive disease. Kaplan meier 
graphs illustrating the relationships between CSS and a) nuclear pSTAT3(Ser727) expression 
(p=0.007), b) cytoplasmic pSTAT3(Ser727) expression (p=0.010), c) nuclear pSTAT3(Tyr705) 




9.3.15 The relationship between pSTAT3(Tyr705), pSTAT3(Ser727) 
and tSTAT3 
The relationship between pSTAT3(Tyr705), pSTAT3(Ser727) and tSTAT3 
expression was evaluated using association analysis. 
High nuclear pSTAT3(Tyr705) expression was associated with high nuclear 
(p<0.001), cytoplasmic (p<0.001) and stromal (p=0.007) pSTAT3(Ser727) 
expression and with high nuclear tSTAT3 expression (p<0.001) (Table 9-8). 
High cytoplasmic pSTAT3(Tyr705) expression was associated with high nuclear 
(p=0.010), cytoplasmic (p=0.020) and stromal (p=0.027) tSTAT3 expression and 
with high cytoplasmic pSTAT3(Ser727) expression (p<0.001) (Table 9-8). 
High stromal pSTAT3(Tyr705) expression was associated with high stromal 
pSTAT3(Ser727) expression (p<0.001) (Table 9-8).
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Table 9-8. The association between pSTAT3(Tyr705) expression and the other STAT3 forms. Table detailing the associations between pSTAT3(Tyr705), 
pSTAT3(Ser727) and tSTAT3 in their different expression sites. Statistically significant p values are highlighted in bold.
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Correlation analysis was also carried out. There was a moderate positive 
correlation between nuclear pSTAT3(Tyr705) expression and both nuclear and 
cytoplasmic pSTAT3(Ser727) expression (Figure 9-51). Other combinations of 






Figure 9-51. Correlation between nuclear pSTAT3(Tyr705) and pSTAT3(Ser727) 
expression.Scatter plots to illustrate the correlation between nuclear pSTAT3(Tyr705) expression 
and a) nuclear pSTAT3(Ser727) expression (Pearson correlation 0.377, p<0.001) and b) 
cytoplasmic pSTAT3(Ser727) expression (Pearson correlation 0.357, p<0.001). 
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High nuclear pSTAT3(Ser727) expression was associated with high nuclear tSTAT3 
expression (p<0.001) (Table 9-9). 
High cytoplasmic pSTAT3(Ser727) expression was associated with high nuclear 
(p<0.001) and cytoplasmic (p=0.002) tSTAT3 expression (Table 9-9). 
High stromal pSTAT3(Ser727) expression was associated with high cytoplasmic 
tSTAT3 expression (p<0.001) (Table 9-9). 
The association between pSTAT3(Ser727) and pSTAT3(Tyr705) expression has 
already been detailed above.
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Table 9-9. The association between pSTAT3 (Ser727) and tSTAT3 expression. Table detailing the associations between pSTAT3(Ser727) and tSTAT3 expression 






9.3.16 The relationship between pSTAT3(Tyr705), pSTAT3(Ser727) 
and tSTAT3 and other components of the IL6/JAK/STAT3 
pathway 
To evaluate the relationship between pSTAT3(Tyr705), pSTAT3(Ser727) and 
tSTAT3 expression and the other components of the IL6/JAK/STAT3 pathway 
studied so far in this thesis, association analysis was carried out. 
9.3.16.1 Associations between tSTAT3 expression, IL6/IL6R and JAKs 1 
and 2. 
High nuclear tSTAT3 expression was associated with high nuclear JAK2 
expression (p=0.002) (Table 9-10). 
High cytoplasmic tSTAT3 expression was associated with the highest and lowest 
tertiles of stromal IL6 expression (p<0.001), high cytoplasmic (p<0.001) and 
stromal IL6R (p=0.020), and high cytoplasmic JAK2 expression (p<0.001) (Table 
9-10). 
High stromal tSTAT3 expression was associated with high cytoplasmic (p=0.013) 
and stromal IL6R (p<0.001), high stromal JAK1 (p=0.039) and high cytoplasmic 




 Nuclear expression p Cytoplasmic expression p Stromal expression p 
Low High Low High Low High 

























































































































































































































































Table 9-10. The association between tSTAT3 and IL6/IL6R and JAK expression. Table detailing the associations between tSTAT3 expression in different sites and 
Il6, IL6R, JAK1 and JAK2 expression. Significant p values are highlighted in bold. 
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9.3.16.2 Associations between pSTAT3(Tyr705) expression, IL6/IL6R and 
JAKs 1 and 2 
High nuclear pSTAT3(Tyr705) expression was associated with low tumour 
(p=0.005) and stromal IL6 (p=0.003), high nuclear JAK1 (p=0.028), low 
cytoplasmic (p=0.001) and stromal JAK2 (p=0.003) (Table 9-11). 
High cytoplasmic pSTAT3(Tyr705) expression was associated with low tumour IL6 
(p=0.035) and low cytoplasmic JAK2 (p=0.011) (Table 9-11). 
High stromal pSTAT3(Tyr705) expression was associated with higher stromal IL6 
(p=0.020), high membranous IL6R (p=0.006), low stromal JAK1 (p=0.034) and low 
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Table 9-11. The association between pSTAT3(Tyr705) and IL6/IL6R and JAK expression. Table detailing the associations between pSTAT3(Tyr705) expression in 




9.3.16.3 Associations between pSTAT3(Ser727) expression, IL6/IL6R and 
JAKs1 and 2. 
High nuclear pSTAT3(Ser727) expression was associated with low cytoplasmic 
(p=0.037) and membranous IL6R (p=0.001) (Table 9-12). 
High cytoplasmic pSTAT3(Ser727) expression was associated with high 
cytoplasmic JAK1 (p=0.033) and low stromal JAK2 expression (p=0.026) (Table 
9-12). 
High stromal pSTAT3(Ser727) expression was associated with low stromal IL6 
(p=0.024), low nuclear (p=0.007) and high cytoplasmic JAK1 (p=0.044) and low 
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Table 9-12. The association between pSTAT3(Ser727) and IL6/IL6R and JAK expression. Table detailing the associations between pSTAT3(Ser727) expression in 
different sites and Il6, IL6R, JAK1 and JAK2 expression. Significant p values are highlighted in bold. 
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Correlation analysis was also carried out. There was moderate positive 
correlation between cytoplasmic tSTAT3 and IL6R expression and between 
stromal tSTAT3 expression and both stromal IL6R and JAK2 expression (Figure 
9-52). All other combinations of phosphorylated or total STAT3 and IL6, IL6R, 








Figure 9-52. Correlation between tSTAT3 and ILR and JAK expression. Scatter plots to 
illustrate the correlation between a) cytoplasmic tSTAT3 and IL6R expression (Pearson correlation 
0.305, p<0.001), b) stromal tSTAT3 and IL6R expression (Pearson correlation 0.360, p<0.001) and 
c) stromal tSTAT3 and JAK2 expression (Pearson correlation 0.361, p<0.001). 
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9.3.17 Combining forms of pSTAT3 
As both nuclear pSTAT3(Tyr705) and pSTAT3(Ser727) were associated with 
improved CSS, and there was a positive association observed between the two 
phosphorylated forms, a score was created combining the two to investigate 
whether there was additional prognostic power when both were elevated. 
Patients were divided into three groups where expression of pSTAT3(Tyr705) and 
pSTAT3(Ser727) were both low, only one was high, or both were high. The 
relationship with CSS was then examined. 
In the full cohort, no significant association with CSS was observed when 
expression of only one phosphorylation site was high but high expression of both 
pSTAT3(Tyr705) and pSTAT3(Ser727) was associated with improved CSS (score 1 v 
0: HR 0.79, 95% CI 0.55-1.14, p=0.214; score 2 v 0: HR 0.47, 95% CI 0.29-0.76, 
p=0.002). The same was the case in ER positive (score 1 v 0: HR 0.74, 95% CI 
0.45-1.22, p=0.239; score 2 v 0: HR 0.43, 95% CI 0.23-0.81, p=0.010) and luminal 
A disease (score 1 v 0: HR 0.54, 95% CI 0.26-1.12, p=0.099; score 2 v 0: HR 0.35, 
95% CI 0.15-0.85, p=0.020) (Figure 9-53). As might be expected from the results 
for the individual phosphorylation sites detailed above, there was no significant 










Figure 9-53. The association between a combined pSTAT3 score and CSS.Kaplan meier graphs illustrating the relationship between a combined score of 





The work in this chapter has evaluated expression levels of phosphorylated and 
total STAT3 in primary operable breast cancer, and their associations with 
survival, clinicopathological characteristics and other components of the 
IL6/JAK/STAT3 pathway. One principle and novel finding of the study was the 
association between high nuclear and cytoplasmic expression of pSTAT3(Ser727) 
and improved CSS in luminal A cancers, independent of other known prognostic 
features. 
In this study, high nuclear and cytoplasmic pSTAT3(Ser727) expression was 
associated with improved CSS in the full cohort, in ER positive disease and in 
luminal A cancers but it was only in the luminal A molecular subtype that this 
was independent of other known prognostic factors. High expression in these 
sites was also associated with good prognostic features of the tumour including 
smaller size, lower grade, ER positivity, HER2 negativity and low tumour 
necrosis. Interestingly though, nuclear expression was also associated with low 
KM grade, low CD8+ TILs and high tumour budding. These findings suggest a 
potential regulatory role for serine STAT3 phosphorylation in primary operable 
breast cancer. 
There is very little in the published literature regarding the relationship between 
the serine phosphorylation of STAT3 and breast cancer outcomes. Of those 
clinical studies of pSTAT3 in breast cancer, most either investigate 
pSTAT3(Tyr705)(102, 104-107) or they do not specify the phosphorylation site 
studied(358). One study which did investigate pSTAT3(Ser727) expression in 
breast cancer tissues reported higher expression in cancer tissues compared to 
adjacent normal tissue. In contrast to the present study, they reported higher 
expression in ER negative compared to ER positive tumours and they also 
observed a positive rather than negative correlation between pSTAT3(Ser727) 
expression levels and tumour stage and size and a negative correlation with ER 
status(101). There are a number of possible explanations for these directly 
opposing results. Firstly, the Yeh et al study was considerably smaller than this 
one, analysing tissue from 68 patients(101). Because of the size of their cohort, 
there were only 6 and 5 patients respectively with stage 1 and stage 3 disease. 
Their cohort was also dominated by ER negative disease (60.3%) while the cohort 
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in the present study is more heavily dominated by ER positive disease and it was 
in ER+ cancers that significant associations with outcome were observed. Finally, 
the methods for quantifying pSTAT3(Ser727) expression and analysis were quite 
different as the authors normalised pSTAT3(Ser727) expression against tSTAT3 
expression and then analysed the data in groupings related to the difference in 
expression between cancer tissues and normal breast tissue(101).  
Despite the paucity of clinical studies regarding pSTAT3(Ser727) in breast 
cancer, such that the finding in this study is entirely novel to the literature, the 
findings are in keeping with the results of some preclinical studies. Early studies 
reported decreased transcription with serine phosphorylation of STAT3(359-361), 
supporting the hypothesis of its regulatory role. There is evidence that serine 
phosphorylation of STAT3 leads to dissociation of pSTAT3(Tyr705) and 
consequently inactivation of STAT3(362). However, in the present study a 
positive rather than negative association was observed between both nuclear 
and cytoplasmic pSTAT3(Ser727) expression and pSTAT3(Tyr705) expression. In 
opposition to this regulatory role, one breast cancer study concluded that serine 
phosphorylation is required for the full transcription activity of cyclin D1 
expression which leads to increased breast cancer growth(363). There is also 
evidence of a role for serine phosphorylation of STAT3 in the mitochondria in 
tumour progression and metastasis(364). Similarly, preclinical studies in other 
cancers provide evidence for a pro-tumour role for pSTAT3(Ser727), including in 
haematological malignancies(365, 366), gastric cancer(367, 368) and prostate 
cancer(369). A study in lung cancer suggested that both phosphorylation sites 
were important in the process of EMT-MET switch(370) which is interesting to 
note as nuclear expression of both phosphorylated STAT3 types was associated 
with higher budding in our study.    
In the present study, high nuclear pSTAT3(Ser727) expression was associated 
with low cytoplasmic and membranous IL6R expression and cytoplasmic 
expression was associated with low JAK2 expression. This suggests that it is not 
the IL6/JAK2/STAT3 pathway that leads to serine phosphorylation of STAT3. This 
is in keeping with the published literature which describes serine 
phosphorylation of STAT3 via the ERK/MAPK pathway(359), IL6/PKC 
pathway(360) and by JNK(361). Specifically in breast cancer, one pre-clinical 
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study reported induction of STAT3 serine phosphorylation by progestins via the 
c-Src/p42/p44 MAPK pathways(363).  
 
Figure 9-54. Serine phosphorylation of STAT3. Diagram illustrating the proposed mechanisms 
by which STAT3 is phosphorylated at Ser727 via the ERK/MAPK pathway. 
Like pSTAT3(Ser727) expression, high nuclear pSTAT3(Tyr705) expression was 
associated with improved CSS in luminal A disease, though this was not 
independent of other known prognostic factors and there was no association 
with CSS in the full cohort or any of the other subtypes. There was also no 
































examined the relationship between pSTAT3(Tyr705) expression and breast 
cancer outcomes and, in the main, findings are consistent with the results of this 
study, reporting either improved outcomes with high expression(104-107) or no 
significant association(102). The clinical findings are unexpected in the context 
of some preclinical studies which support a role for tyrosine phosphorylated 
STAT3 in breast cancer cell migration and metastasis(95), promotion of cell 
survival via Survivin(371) and promotion of angiogenesis via VEGF(372). However, 
other studies have reported anti-tumour activity including upregulation of tissue 
inhibitors of metalloproteinase leading to decreased invasiveness of breast 
cancer(373), and promotion of apoptosis in mammary epithelial cells(374). 
Nuclear pSTAT3(Tyr705) expression was associated with high nuclear JAK1 
expression, suggesting a relationship between the two, but cell line studies 
would be required to investigate this further.  
While high nuclear tSTAT3 was also associated with improved CSS in this study, 
high cytoplasmic expression was associated with worse CSS in the full and ER 
positive cohorts. As in this study the activated, phosphorylated forms of STAT3 
seem to be protective, this may simply reflect a higher proportion of inactive 
STAT3 in these patients. The finding is in keeping with another study which 
reported worse breast cancer outcomes with higher expression of tSTAT3(103), 
though a larger study of node negative cancers reported no significant 
association(104). However, this latter study is also supported by the present 
study as no significant associations were observed in the subgroup analysis in the 
lymph node negative cohort. The present study does provide evidence of a 
varying role for STAT3 in different disease stages as serine phosphorylation was 
associated with improved survival in T1 disease only, while nuclear 
pSTAT3(Tyr705) was in T2 disease and in T3 disease, tSTAT3 was actually 
associated with worse CSS. Somewhat counterintuitively given the associations 
with better outcomes in lower tumour stage cancers, it was in lymph node 
positive disease that significant associations were observed between nuclear and 
cytoplasmic pSTAT3(Ser727), nuclear pSTAT3(Tyr705) and nuclear tSTAT3 
expression and improved CSS. This is supported by a study which reported an 
association between nuclear pSTAT3(Tyr705) expression and improved survival in 
node positive disease(76). One possible explanation may be that STAT3 plays a 
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different role in growth of the primary tumour compared to metastasised cells 
and there has been some published evidence in mice to support this theory(375). 
In this study, stromal STAT3 expression was different in several ways to tumour 
expression. While tumour pSTAT3(Ser727) expression was higher in ER+ cancers, 
stromal pSTAT3(Tyr705) and pSTAT3(Ser727) expression was higher in ER 
negative disease. This could simply reflect higher inflammatory infiltrates in 
these cancers, however stromal tSTAT3 expression was higher in ER positive 
disease. In ER negative disease, high stromal expression of pSTAT3(Ser727) was 
associated with improved CSS whereas high tSTAT3 expression was associated 
with worse CSS, particularly in TNBC. The latter is in keeping with evidence in 
the literature of the pro-tumourigenic role of JAK/STAT3 in the tumour 
microenvironment. Pre-clinical studies in breast cancer report that JAK1/STAT3, 
stimulated by LIF, trigger a switch of fibroblasts to pro-invasive CAFs(332, 376, 
377). Other studies provide evidence that activation of STAT3 in various immune 
cells leads to inhibition of proinflammatory cytokine production by 
macrophages, reduced DC maturation, suppression of CD8+ lymphocytes, 
reduced antitumour cytotoxic activity of macrophages, neutrophils and NK cells, 
and may increase Treg lymphocyte proliferation(295). 
Stromal pSTAT3(Tyr705) expression was associated with high stromal IL6 which 
may represent either or both of increased IL6 production secondary to STAT3 
activation or activation of the STAT3 pathway by IL6. Conversely, 
pSTAT3(Ser727) expression was associated with low stromal IL6, similarly either 
supporting a regulatory role for serine phosphorylation and therefore less IL6 
production, or reflecting stimulation by other ligands. High stromal 
pSTAT3(Tyr705) was associated with low stromal JAK1 and both phosphorylation 
sites were associated with low stromal JAK2. Further mechanistic experiments 
are required to explain this relationship. 
In summary, despite preclinical evidence of a pro-tumourigenic role for 
activated STAT3 in the proliferation, survival, metastasis and invasion and 
angiogenesis of breast cancer cells(354), this present study, along with other 
clinical studies, has observed an association between activated STAT3 and 
improved CSS, suggesting a regulatory anti-tumour role for STAT3. To the 
knowledge of the author, this is one of the first and the biggest clinical study to 
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date to investigate the role of pSTAT3(Ser727) in primary operable breast 
cancer. Nuclear and cytoplasmic pSTAT3(Ser727) expression was associated with 
improved CSS independently of other prognostic factors in luminal A disease and 
particularly in T1 and node positive disease meaning that it may have a 
prognostic role in these patients, for instance in decisions regarding adjuvant 
chemotherapy in luminal A, node positive disease. It may also serve as a 
predictive factor as there is evidence that STAT3 is involved in 
chemoresistance(378, 379), as well as resistance to other systemic 
therapies(380, 381) and radiotherapy(382), but further research would be 
required to establish this. Results of preclinical studies raised hopes that STAT3 
inhibitors may have a role in breast cancer treatment. However, the findings of 
this study would caution against their use, particularly in luminal A cancers, and 
may provide some evidence towards the reasons for the disappointing results 
seen in trials of STAT inhibitors to date(357). Early phase trials in many cancers, 
including breast, are ongoing(383). There may be some patient populations in 
which STAT3 inhibitors could have a role but trials should be targeted at very 
specific groups, for example those with T3 disease and particularly those with 
TNBC if the STAT inhibitors can be targeted towards cells in the tumour stroma 
as well as the tumour cells. tSTAT3 expression could potentially be useful as a 
predictive marker for response. Similarly, in view of the findings of this study, it 
would be interesting to include pSTAT3(Ser727) expression in any studies of 
MAPK inhibitors in breast cancer as cancers under regulatory control by serine 
phosphorylation of STAT3 could, in theory, be promoted by use of MAPK 
inhibitors if this is the activating pathway. Again, much more research would be 
required to establish this and it is clear from this study and the preceding two 
chapters that it is impossible to wholly isolate one pathway for study and 
targeting given the complex interplay between different pathways in tumour 
cells and those of the tumour microenvironment. 
In conclusion, this is the first clinical study to report an association between 
pSTAT3(ser727) and improved CSS so further work into its role  as a prognostic 
marker in certain subtypes of breast cancer is warranted. The results of this 
study would support the investigation of pSTAT3(Ser727), pSTAT3(Tyr705) and 
tSTAT3 expression as part of any STAT or MAPK inhibitor studies as there may be 
a role for one or all of them as predictors of response.  
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10 Discussion  
10.1 General discussion and conclusions 
The work of this thesis has focussed on the role in primary operable breast 
cancer of the systemic inflammatory response, local inflammation, specific 
phenotypic features of the tumour and the IL6/JAK/STAT3 pathway which is one 
link between signals in the tumour microenvironment and tumour cells. This 
exploratory work was carried out with a view to identifying potential prognostic 
biomarkers to aid in the complex treatment decision-making process in this 
heterogenous disease, and to identify potential targets for therapy meriting 
further investigation, either in cancers which have developed resistance to 
current treatments, or in TNBC for which no targeted treatments are currently 
available.  
Firstly, a number of circulating markers of the systemic inflammatory response 
were investigated by means of a literature review, meta-analysis and pilot study 
of 448 West of Scotland patients. The preoperative NLR, albumin and, to a lesser 
degree, LMR were identified as having a prognostic role in primary operable 
breast cancer. However, there was insufficient evidence to reach a conclusion 
regarding suitable thresholds for use in clinical practice, or to ascertain in which 
molecular subtypes they may best be used. Evidence suggests that systemic 
inflammation in early-stage breast cancer is an uncommon finding and becomes 
a more prominent feature in locally advanced and metastatic disease. This 
further calls into question the likely clinical utility of these markers in primary 
operable breast cancer. However, they do have the advantage of requiring only 
a routine blood test and, since the writing of the systematic review, further 
evidence has been published in support of a prognostic role for NLR in 
particular(384-390), so it may be that this does find a place in clinical practice 
due to its simplicity and low cost, for instance in low-resource countries.  
In view of the doubts regarding the clinical utility of these markers, the work in 
this thesis then focussed on the role of the local inflammatory response in 
primary operable breast cancer. Because its prognostic value in colorectal 
cancer has been widely reported(183, 184), the Klintrup-Makinen grade was 
investigated in primary operable breast cancer. In colorectal cancer, higher KM 
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score is associated with improved prognosis(183, 184), suggesting an anti-tumour 
role for the inflammatory infiltrate. However, the relationship was more 
complex in this cohort of breast cancer patients. An association with CSS was 
observed but this was not independent of other known prognostic factors and it 
was both the highest and the lowest scores which were associated with the best 
CSS. There is very little in the published literature regarding the KM score in 
breast cancer with which to compare, so this finding requires validation in other 
cohorts. The findings unfortunately do not support the use of the KM grade as a 
prognostic tool in breast cancer in contrast to that observed with other solid 
tumours such as colorectal cancer. The composition of the inflammatory 
infiltrate may be more important. Multiplex IHC would be required to ascertain 
this composition and also inform us on the spatial relationships between 
different immune cells. In the current study high CD8+ TILs were associated with 
improved CSS. TILs are of interest as prognostic and predictive biomarkers in 
breast cancer and a better understanding of their interactions with the tumour 
will hopefully lead to improved selection of patients who will benefit from 
immune checkpoint inhibitors.  However, a dedicated International TILs 
Workshop has recently had a focus on TILs research, so it was decided that this 
would not be the focus of the current thesis. Instead, the appeal of prognostic 
markers which only require a single H&E-stained slide led to the investigation of 
features other than the KM grade which fulfil this specification and have been 
reported to have a prognostic role in other cancers, namely tumour necrosis, TSP 
and tumour budding.  
In a cohort of over 1000 patients, the work of this thesis has provided evidence 
of a prognostic role for necrosis in ER positive disease and each of necrosis, TSP 
and tumour budding in ER negative disease. Additionally, a novel score which 
combined all 3 features has prognostic value in both ER positive and ER negative 
disease, and in each of the receptor subtypes except for ER+/HER2+ cancers, 
though this may be because of a lack of statistical power in this smaller group.  
In ER+/HER2- disease the score identifies a poor prognostic group, with all 3 
features high, who have significantly worse CSS compared to those with the 
lower 3 scores. The score may therefore have a role in clinical practice to aid 
decision making regarding adjuvant chemotherapy and duration of endocrine 
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therapy. Currently, in the UK, several tools are available to aid these decisions. 
Predict is an online tool which uses data regarding prognostic factors including 
tumour size, grade, nodal involvement, ER, HER2, Ki-67 and menopausal status 
to estimate the benefit from adjuvant treatments in terms of survival gain(39). 
NICE recommends the use of the gene assays EndoPredict, Oncotype DX Breast 
Recurrence Score or Prosigna in patients with ER positive, HER2 negative, lymph 
node negative breast cancer who have an intermediate risk of distant recurrence 
using Predict or the NPI, if the result would influence the decision regarding 
adjuvant chemotherapy(52). These tests are not currently recommended for use 
in lymph node positive disease. However, Optima is a trial currently recruiting in 
the UK which uses the Prosigna gene score to predict benefit from chemotherapy 
for ER+/HER2-, lymph node positive patients to see if a proportion of patients 
with lymph node metastases could avoid chemotherapy(391, 392). These gene 
assays are expensive and, in the case of Oncotype DX which is used in the West 
of Scotland, requires a sample to be sent away to a single lab in the USA for 
testing. The necrosis/TSP/budding score has the advantage of being inexpensive, 
requiring a single H&E slide, and it can be performed locally. If this score was 
validated in other cohorts it would then be useful to compare its prognostic 
power to that of the gene assays as, if equivocal, the use of this score could 
prove both cost and time efficient. If it did perform similarly, it could be 
postulated that necrosis, TSP and budding represent phenotypic features 
influenced by the genes tested in these scores. Alternatively, in view of the fact 
that the necrosis/TSP/budding score was prognostic independent of the factors 
used in the Predict tool, it would be interesting to evaluate whether using it in 
addition to the Predict score could improve prognostic performance and reduce 
the number of patients requiring Oncotype DX or equivalent.  
In ER negative disease, and in particular TNBC, the necrosis/TSP/budding score 
stratifies patient outcomes. On multivariate analysis, the highest score had a HR 
of 8.11 in this cohort, compared to those with the lowest score. This compares 
to a HR of 3.15 for lymph node positivity, the only other factor which was 
independently prognostic in the ER negative cohort. It therefore may be useful 
to identify a particularly high-risk group of patients who should be treated 
aggressively. On the other hand, the cohort with a score of 0 appear to have 
favourable outcomes and therefore, if validated, this score may be of clinical 
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utility to identify a cohort of patients who could be treated less aggressively. It 
should be noted that the scoring in this thesis was carried out on full section 
slides from resection specimens and therefore its applicability in the setting of 
neoadjuvant therapy and the possibility of adapting scoring to biopsy specimens 
is unknown at present.  
Given the prognostic power of this score in triple negative breast cancer, a 
better understanding of the features it comprises may help to develop targeted 
treatments for this poor prognostic group of patients. Of the 3 components of 
the score, tumour budding had the highest prognostic power (HR 3.05 on 
univariate analysis, HR 2.15 on multivariate analysis) and is interesting because 
the molecular mechanisms driving this phenotype are poorly understood at 
present. With the aim of gaining a better understanding of the molecular 
mechanisms driving tumour budding, a small pilot study was carried out for 
which transcriptomic analysis was performed to compare the transcriptome of 
patients with high budding to those with low budding. Despite the small sample 
size (due to financial limitations), 9 genes were identified which justify further 
investigation. Of particular interest is the ODAM gene which was under-
expressed in high budding tumours, which may lead to reduced cell adhesion and 
increased migration and invasiveness. The other gene of particular interest is 
JUNB which was over-expressed in high budding tumours and may be significant 
in EMT. It may be that targeting of these genes could lead to reduced tumour 
budding and improved prognosis. However, much more work is required to 
establish this hypothesis and funding is currently being sought in the lab for 
further research in this area. 
Regarding the practicalities of the necrosis/TSP/budding score, the presence or 
absence of necrosis is frequently commented upon in routine pathology reports, 
therefore, the routine standardised reporting of this feature should not prove 
too challenging a step. TSP is a quick and straightforward feature to report. 
Tumour budding is more time-consuming to quantify. However, there is 
precedent for its use as it has been recommended for routine reporting in 
colorectal cancer(75, 77). Another method of assessing tumour budding is pan-
cytokeratin staining but further comparison studies of the two methods are 
required(75). The findings of this thesis require to be validated in other cohorts 
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with scoring carried out by a qualified pathologist (scoring for the work in this 
thesis was carried out by two research fellows) but if the findings are confirmed, 
work to develop automated scoring would be warranted. The advances in digital 
image analysis provide potential for its use in tumour budding scoring, both in 
breast and colorectal cancer and discussions are in progress between groups with 
an interest in this technology and the host lab regarding researching and 
developing this. 
In pursuit of a link between components of the tumour microenvironment, such 
as the inflammatory infiltrate discussed in chapter 4, and phenotypic features of 
the tumour associated with poorer prognosis, such as those outlined above, the 
final three chapters of this thesis investigated the IL6/JAK/STAT3 cell signalling 
pathway. In this cohort, the findings of this work did not demonstrate clear 
associations and correlations between expression of all the different components 
of the pathway. This supports other evidence that numerous signalling pathways 
within cells interact, with substantial crosstalk. For instance, IL6 can activate 
other pathways, other ligand and receptor complexes can activate JAKs and 
other pathways can lead to STAT3 phosphorylation. It is likely to be the balance 
between activation of these different pathways which is of key importance in 
cancer progression. However, there were several key findings of note.  
Firstly, some significant associations were observed between components of the 
pathway and some of the phenotypic features investigated in earlier chapters. 
High membranous IL6R was associated with low tumour budding raising the 
possibility that one of the pathways involving IL6R may exert a regulatory effect 
on the development of this phenotype. On the other hand, high nuclear 
expression of pSTAT3(Ser727) was associated with high budding. STAT3 is 
phosphorylated at the serine 727 site by pathways other than JAK mediated ones 
so it may be that one of these pathways is important in the development of 
budding, justifying further investigation. It was interesting that budding and 
nuclear pSTAT3(Ser727) were positively associated in the full cohort considering 
that, in this thesis, budding was a poor prognostic factor while nuclear 
pSTAT3(Ser727) was a good prognosis factor. However, the former was in ER 
negative disease and the latter in ER positive disease, and there was no 
statistically significant association observed when analysed within each of the 
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two ER subgroups. High stromal JAK1 was also associated with high tumour 
budding, suggesting a possible influence of stromal cells in the promotion of this 
phenotype.  
In ER positive, or specifically in luminal A disease, a combined score of high 
tumour IL6 and high membranous IL6R was associated with worse CSS while high 
nuclear and stromal JAK1, and high nuclear expression of both phosphorylated 
forms of STAT3 were associated with improved CSS. This suggests a regulatory 
role on tumour progression of activation of the JAK/STAT3 pathway and implies 
that IL6 exerts its protumour effects via other pathways. Therefore, these 
results suggest that there may be a role for IL6 inhibitors in ER positive breast 
cancers with high IL6 expression, but trials of JAK and STAT3 inhibitors are likely 
to produce disappointing results in this subset of breast cancer patients. The 
association with the novel score of tumour IL6 and membranous IL6 and worse 
CSS, and that of high pSTAT3(Ser727) expression and improved CSS, are new 
findings not previously described in the literature and raise the possibility that, 
once validated, they could be used as prognostic tools to aid treatment decisions 
in some luminal A cancers. 
In ER negative, or specifically triple negative breast cancer, high nuclear JAK1 
and cytoplasmic JAK2 expression were associated with worse CSS, suggesting 
that JAK inhibitors may have a role in TNBC. The other significant associations in 
ER negative breast cancer all involved stromal expression, providing further 
evidence for the role of the tumour microenvironment in the progression of 
these tumours. High stromal JAK2 and tSTAT3 expression were associated with 
worse CSS while high pSTAT3(Ser727) expression was associated with improved 
CSS. 
Throughout this thesis, results have varied between the different molecular (or 
surrogate receptor) subtypes. This further supports the understanding of breast 
cancer as a heterogenous disease with subtypes which behave differently and 
respond to different treatments. Going forward it would seem sensible to focus 




The majority of the work in this thesis has the strength that it is carried out in a 
large cohort of patients. This is particularly the case for the work involving 
Klintrup-Makinen grade, necrosis, TSP and tumour budding for which it was 
possible to combine two cohorts resulting in over 1000 patients for analysis. 
However, despite this, small numbers remain in the least common subtypes 
(luminal B and HER-2 enriched or equivalent surrogate receptor subtypes) so lack 
of statistical power may affect results in these subtypes. The work is further 
strengthened by the long length of patient follow up, which is important in 
breast cancer studies due to late disease recurrence. However, it comes with 
the trade-off that a historical cohort were managed for their cancer in a 
different era under different guidelines and with some variation in available 
treatments compared to modern day practices, which may raise questions as to 
the applicability of the results in present day practice. Validation in more recent 
cohorts is required.  
In conclusion, a combined score of tumour necrosis, TSP and tumour budding has 
a prognostic role in both ER positive and ER negative primary operable breast 
cancer. It is a straightforward and low-cost method to stratify risk and could 
have a role in decisions regarding adjuvant treatment. Further work is required 
to better understand tumour budding and to identify therapeutic targets for 
patients with ER negative cancer and high tumour budding. A combination of 
high tumour IL6 and high membranous IL6R is associated with worse prognosis in 
ER positive cancers so IL6 inhibitors may have a role in selected patients. This 
pro-tumourigenic effect does not appear to be via the JAK/STAT3 pathway. The 
JAK/STAT3 pathway, and particularly serine phosphorylation of STAT3 via other 
pathways, may have a regulatory effect on progression of ER positive primary 
operable breast cancer and therefore JAK and STAT3 inhibitors are unlikely to be 
of benefit in this group. However, in ER negative disease high expression of JAKs 
was associated with worse CSS and therefore JAK inhibitors may have a role in 
selected patients with ER negative breast cancer. There is evidence for an 
influence of stromal cells on progression of ER negative breast cancers. More 
work is required, both in pre-clinical and clinical studies, to develop 
understanding of the complex interactions and crosstalk between different cell 
signalling pathways in tumour cells, and how they are influenced by factors in 
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the tumour microenvironment. Further studies investigating the mechanisms 
would help elucidate specific drivers to tumour progression.  
10.2 Further work 
The associations with CSS of the necrosis/TSP/budding score require validation 
in other cohorts, particularly more modern ones. The data in this study suggests 
that differences in prognosis of the four groups are evident by five years of 
follow up, if not earlier in ER negative disease, so it should be possible to power 
a study with shorter follow up than the cohorts in this thesis. Following this, the 
prognostic performance of the score should be compared to existing prognostic 
tools to determine in what role it may have most clinical utility. In parallel to 
this work, it would be useful to investigate the potential to develop automated 
scoring of the component features of the score and collaborations are being 
sought with an aim to facilitate this work. 
To identify potential therapeutic targets for patients with ER negative breast 
cancer and high tumour budding, a group with a particularly poor prognosis, 
further work to identify genes associated with tumour budding is required. The 
pilot study in this thesis identified 9 genes of potential interest. Funding is being 
sought to carry out a larger study having verified TempOSeq as an appropriate 
technique for this work. Gene expression will need to be validated at the protein 
level in the cohort also. 
To better understand the findings of this thesis regarding components of the 
IL6/JAK/STAT3 pathway, other members in the lab are carrying out IHC work in 
the same cohort for other cell signalling pathways which should then allow the 
data to be combined and interactions between the pathways analysed. This will 
be of particular interest regarding serine phosphorylation of STAT3. Mechanistic 
cell line studies will also be required to gain a better understanding of the 










Tumour necrosis, budding and TSP in primary operable ductal 
cancer 
Below is survival and association analysis for necrosis, budding and TSP in ductal 
cancer, including the combined scores. There was very little difference between 
these results and those in the full cohort so the analysis is not included in the 
main thesis. 
Associations between necrosis and CSS in ductal breast cancer 
In the full cohort, necrosis was associated with worse CSS (10yr CSS 87% v71%, 
p<0.001; HR 2.28, 95% CI 1.74-2.99, p<0.001). In ER positive disease, this was 
maintained (10yr CSS 87% v 73%, p<0.001; HR 2.01, 95% CI 1.43-2.83, p<0.001). 
In ER negative disease, necrosis was associated with worse CSS (10yr CSS 86% v 







The relationship between tumour necrosis and CSS in primary operable ductal breast 
cancer.  Kaplan Meier survival graphs for CSS in patients with high compared to low necrosis in 
ductal breast cancer. a) Full cohort n=1080, p<0.001; b) ER positive n=737, p<0.001; c) ER 
negative n=340, p=0.001 
In ER+/HER2- cancers, high necrosis was associated with worse CSS (10yr CSS 87% 
v 73%, p=0.001; HR 1.89, 95% CI 1.28-2.79, p=0.001) and this was also the case in 
ER+/HER2+ cancers (10yr CSS 77% v 61%, p=0.040; HR 2.28, 95% CI 1.00-5.20, 
p=0.051). In ER-/HER2+ cancers, necrosis was not significantly associated with 
CSS (10yr CSS 72% v 67%; HR 1.25, 95% CI 0.43-3.63, p=0.676). In ER-/HER2- 
disease, necrosis was associated with worse CSS (10yr CSS 85% v 70%, p=0.006; 












The relationship between tumour necrosis and CSS in primary operable ductal breast 
cancer, by molecular subtype. Kaplan Meier survival graphs for CSS in patients with high 
compared to low necrosis in ductal breast cancer. a) ER+/HER2- n=563, p=0.001; b) ER+/HER2+ 
n=81, p=0.045; c) ER-/HER2+ n=87, p=0.675; d) ER-/HER2- n=221, p=0.006     
Associations between necrosis and clinicopathological characteristics in 
ductal breast cancer 
High tumour necrosis was associated with younger age (p=0.001), larger tumour 
size (p<0.001), higher tumour grade (p<0.001), nodal (p=0.024) and HER2 
positivity (p<0.001), ER and PR negativity (p<0.001), a higher Klintrup Makinen 
(KM) score (p<0.001) and low TSP (p=0.032). In the patients for whom these 
markers were available, necrosis was associated with high CD4+ lymphocytes 
(n=592, p<0.001) and high CD68+ cells (n=369, p<0.001). 
 
Associations between budding and CSS in ductal breast cancer 
In the full ductal cohort, high tumour budding was associated with worse CSS 
(10yr CSS 83% v 71%, p<0.001; HR 1.73, 95% CI 1.31-2.29, p<0.001). In ER positive 
disease, tumour budding was not associated with CSS (10yr CSS 84% v 79%, 
p=0.148; HR 1.34, 95% CI 0.93-1.93, p=0.117). However, in ER negative disease, 
high budding was associated with worse CSS (10yr CSS 80% v 47%, p<0.001; HR 









The relationship between tumour budding and CSS in primary operable ductal breast 
cancer. Kaplan Meier survival graphs for CSS in patients with high compared to low tumour 
budding in ductal breast cancer. a) Full cohort n=1080, p<0.001; b) ER positive n=737, p=0.116; c) 
ER negative n=340, p<0.001 
High budding was not significantly associated with CSS in either ER+/HER2- (10yr 
CSS 83% v 80%, p=0.560; HR 1.17, 95% CI 0.77-1.78, p=0.454) or ER+/HER2+ 
disease (10yr CSS 73% v 62%, p=0.278; HR 1.55, 95% CI 0.66-3.66, p=0.318). High 
budding was associated with worse CSS in both ER-/HER2+ (10yr CSS 76% v 36%, 
p=0.003; HR 3.38, 95% CI 1.56-7.32, p=0.002) and ER-/HER2- cancers (10yr CSS 












The relationship between tumour budding and CSS in primary operable ductal breast 
cancer, by molecular subtype.  Kaplan Meier survival graphs for CSS in patients with high 
compared to low tumour budding in ductal breast cancer. a) ER+/HER2- n=563, p=0.453; b) 
ER+/HER2+ n=81, p=0.314; c) ER-/HER2+ n=87, p=0.001; d) ER-/HER2- n=221, p=0.002  
Associations between budding and clinicopathological characteristics in 
ductal breast cancer 
High tumour budding was associated with lower tumour grade (p<0.001), nodal 
(p=0.001) and ER positivity (p=0.006), high TSP (p<0.001) and lower KM score 
(p=0.002). In the patients for whom these markers were available, high budding 
was associated with low CD4+ lymphocytes (n=596, p=0.017) and lower CD8+ 
lymphocytes (n=371, p=0.027).  
Associations between TSP and CSS in ductal breast cancer 
In the full ductal cohort, high TSP was associated with worse CSS (95% CI 81% v 
76%, p=0.041; HR 1.40, 95% CI 1.07-1.84, p=0.016). In ER positive disease, there 
was no significant association between TSP and CSS (10yr CSS 83% v 81%, 
p=0.461; HR 1.23, 95% CI 0.85-1.73, p=0.278). Conversely, in ER negative 
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disease, high TSP was associated with worse CSS (10yr CSS 78% v 64%, p=0.0101; 







The relationship between TSP and CSS in primary operable ductal breast cancer. Kaplan 
Meier survival graphs for CSS in patients with high compared to low TSP in ductal breast cancer. 
a) Full cohort n=1080, p0.015; b) ER positive n=737, p=0.277; c) ER negative n=340, p=0.004. 
TSP was not significantly associated with CSS in either ER+/HER2- (10yr CSS 84% 
v 79%, p=0.147; HR 1.47, 95% CI 0.99-2.19, p=0.055) or ER+/HER2+ cancers (10yr 
CSS 68% v 77%, p=0.586; HR 0.70, 95% CI 0.24-2.07, p=0.520). High TSP was 
associated with worse CSS in both ER-/HER2+ (10yr CSS 75% v 56%, p=0.043; HR 
2.24, 95% CI 1.05-4.79, p=0.037) and ER-/HER2- cancers (10yr CSS 77% v 64%, 












The relationship between TSP and CSS in primary operable ductal breast cancer, by 
molecular subtype. Kaplan Meier survival graphs for CSS in patients with high compared to low 
TSP in ductal breast cancer. a) ER+/HER2- n=563, p=0.054; b) ER+/HER2+ n=81, p=0.518; c) ER-
/HER2+ n=87, p=0.32; d) ER-/HER2- n=221, p=0.034. 
Associations between TSP and clinicopathological characteristics in ductal 
breast cancer 
High TSP was associated with high budding (p<0.001) but lower tumour grade 
(p<0.001), low or absent necrosis (p=0.032) and a lower Klintrup-Makinen (KM) 
score (p<0.001). In the patients for whom these markers were available, high 
TSP was associated with low CD4+ lymphocytes (n=596, p=0.035), low CD8+ 
(n=371, p=0.043) lymphocytes and lower CD68+ cells (n=369, p=0.003). 
Associations between the necrosis-budding score and CSS in ductal breast 
cancer 
In the full ductal cohort, a higher combined necrosis-budding score was 
associated with worse CSS (10yr CSS 87% v 80% v 49%, p<0.001; score 1 v 0: HR 
1.63, 95% CI 1.19-2.23, p=0.002; score 2 v 0: HR 4.63, 95% CI 3.19-6.73, 
p<0.001). In ER positive disease, a score of 2 was associated with worse CSS than 
a score of 0 (10yr CSS 86% v 82% v 60%, p<0.001; score 1 v 0: HR 1.35, 95% CI 
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0.93-1.97, p=0.112; score 2 v 0: HR 3.03, 95% CI 1.87-4.91, p<0.001). In ER 
negative disease a higher combined necrosis-budding score was associated with 
worse CSS (10yr CSS 89% v 77% v 31%, p<0.001; score 1 v 0: HR 2.51, 95% CI 1.20-







The relationship between the necrosis-budding score and CSS in primary operable ductal 
breast cancer. Kaplan Meier survival graphs for CSS in patients with a necrosis-budding score of 
2 compared to 1 compared to 0, in ductal breast cancer. a) Full cohort n=1080, p<0.001; b) ER 
positive n=737, p<0.001; c) ER negative n=340, p<0.001 
In ER+/HER2- disease, a score of 2 was associated with worse CSS than a score of 
0 (10yr CSS 85% v 84% v 60%, p=0.001; score 1 v 0: HR 1.13, 95% CI 0.73-1.74, 
p=0.583; score 2 v 0: HR 2.73, 95% CI 1.58-4.71, p<0.001). In ER+/HER2+ disease, 
combined necrosis-budding score was not significantly associated with CSS (10yr 
CSS 79% v 64% v 59%, p=0.071; score 1 v 0: HR 2.58, 95% CI 1.00-6.69, p=0.051; 
score 2 v 0: HR 2.55, 95% CI 0.81-8.06, p=0.110). In ER-/HER2+ cancers, a 
combined score of 2 was associated with worse CSS but this was of borderline 
statistical significance (10yr CSS 72% v 77% v 26%, p=0.002; score 1 v 0: HR 0.81, 
95% CI 0.23-2.81, p=0.735; score 2 v 0: HR 3.60, 95% CI 0.99-13.10, p=0.052). In 
ER-/HER2- cancers, an increasing combined necrosis-budding score was 
associated with worse CSS (10yr CSS 89% v 76% v 35%, p<0.001; score 1 v 0: HR 










The relationship between the necrosis-budding score and CSS in primary operable ductal 
breast cancer, by molecular subtype. Kaplan Meier survival graphs for CSS in patients with a 
necrosis-budding score of 2 compared to 1 compared to 0, in ductal breast cancer.  a) ER+/HER2- 
n=563, p-0.001; b) ER+/HER2+ n=81, p=0.098; c) ER-/HER2+ n=87, p<0.001; d) ER-/HER2- 
n=221, p<0.001 
Associations between the necrosis-budding score and clinicopathological 
characteristics in ductal breast cancer 
A high necrosis-budding score was significantly associated with younger age 
(p=0.023), larger tumour size (p<0.001), higher tumour grade (p<0.001), nodal 
positivity (p<0.001), ER and PR negativity (p<0.001, p<0.001), HER2 positivity 
(p=0.004) and higher KM grade (p<0.001). 
Associations between the necrosis-TSP score and CSS in ductal breast 
cancer 
In the full ductal cohort, a higher necrosis-TSP score was associated with worse 
CSS (10yr CSS 87% v 79% v 61%, p<0.001; score 1 v 0: HR 1.70, 95% CI 1.23-2.34, 
p=0.001; score 2 v 0: HR 3.61, 95% CI 2.46-5.30, p<0.001). In ER positive disease, 
a higher necrosis-TSP score was associated with worse CSS (10yr CSS 87% v 80% v 
67%, p=0.001; score 1 v 0: HR 1.55, 95% CI 1.07-2.27, p=0.022; score 2 v 0: HR 
2.89, 95% CI 1.70-4.90, p<0.001). In ER negative disease, a score of 2 was 
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associated with worse CSS than a score of 0 (10yr CSS 86% v 76% v 57%, p<0.001; 
score 1 v 0: HR 1.97, 95% CI 0.99-3.89, p=0.052; score 2 v 0: HR 4.15, 95% CI 







The relationship between the necrosis-TSP score and CSS in primary operable ductal breast 
cancer. Kaplan Meier survival graphs for CSS in patients with a necrosis-TSP score of 2 compared 
to 1 compared to 0, in ductal breast cancer.  a) Full cohort n=1080, p<0.001; b) ER positive n=737, 
p<0.001; c) ER negative n=340, p<0.001 
In ER+/HER2- disease, a higher score was associated with worse CSS (10yr CSS 
88% v 80% v 64%, p=0.001; score 1 v 0: HR 1.57, 95% CI 1.01-2.44, p=0.046; score 
2 v 0: HR 3.31, 95% CI 1.86-5.91, p<0.001). In ER+/HER2+ disease, the necrosis-
TSP score was not significantly associated with CSS (10yr CSS 76% v 63% v 74%, 
p=0.173; score 1 v 0: HR 2.11, 95% CI 0.88-5.11, p=0.096; score 2 v 0: HR 1.24, 
95% CI 0.26-5.86, p=0.784). In ER-/HER2+ cancers, the necrosis-TSP score was 
not significantly associated with CSS (10yr CSS 74% v 75% v 55%, p=0.116; score 1 
v 0: HR 0.89, 95% CI 0.25-3.24, p=0.862; score 2 v 0: HR 2.07, 95% CI 0.60-7.21, 
p=0.252). In ER-/HER2- cancer, a score of 2 was associated with worse CSS 
compared to a score of 0 (10yr CSS 85% v 75% v 54%, p=0.003; score 1 v 0: HR 












The relationship between the necrosis-TSP score and CSS in primary operable ductal breast 
cancer, by molecular subtype. Kaplan Meier survival graphs for CSS in patients with a necrosis-
TSP score of 2 compared to 1 compared to 0, in ductal breast cancer. a) ER+/HER2- n=563, 
p<0.001; b) ER+/HER2+ n=81, p=0.222; c) ER-/HER2+ n=87, p=0.091; d) ER-/HER2- n=221, 
p=0.001 
Associations between the necrosis-TSP score and clinicopathological 
characteristics in ductal breast cancer 
A high necrosis-TSP score was significantly associated with larger tumour size 
(p<0.001), higher tumour grade (p<0.001), nodal positivity (p=0.006), ER and PR 
negativity (p<0.001, p<0.001), HER2 positivity (p<0.001) and higher KM grade 
(p<0.001). 
Associations between the budding-TSP score and CSS in ductal breast 
cancer 
In the full ductal cohort, a higher budding-TSP score was associated with worse 
CSS (10yr CSS 84% v 76% v 70%, p=0.001; score 1 v 0: HR 1.58, 95% CI 1.19-2.10, 
p=0.002; score 2 v 0: HR 2.05, 95% CI 1.38-3.06, p<0.001). In ER positive disease, 
a score of 2 was significantly associated with worse CSS compared to a score of 0 
(10yr CSS 83% v 84% v 74%, p=0.139; score 1 v 0: HR 1.00, 95% CI 0.69-1.47, 
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p=0.985; score 2 v 0: HR 1.72, 95% CI 1.07-2.76, p=0.026). In ER negative 
disease, a higher combined score was associated with worse CSS (10yr CSS 85% v 
59% v 53%, p<0.001; score 1 v 0: HR 3.07, 95% CI 1.96-4.81, p<0.001; score 2 v 0: 







The relationship between the budding-TSP score and CSS in primary operable ductal breast 
cancer. Kaplan Meier survival graphs for CSS in patients with a budding-TSP score of 2 compared 
to 1 compared to 0, in ductal breast cancer. a) Full cohort n=1080, p<0.001; b) ER positive n=737, 
p=0.059; c) ER negative n=340, p<0.001. 
In ER+/HER2- disease, a score of 2 was significantly associated with worse CSS 
than a score of 0 (10yr CSS 83% v 85% v 72%, p=0.120; score 1 v 0: HR 1.01, 95% 
CI 0.65-1.57, p=0.959; score 2 v 0: HR 1.80, 95% CI 1.06-3.03, p=0.028). In 
ER+/HER2+ disease, the combined score was not significantly associated with 
CSS (10yr CSS 72% v 65% v 74%, p=0.717; score 1 v 0: HR 1.32, 95% CI 0.55-3.19, 
p=0.534; score 2 v 0: HR 0.94, 95% CI 0.21-4.16, p=0.933). In ER-/HER2+ cancers, 
a higher combined score was associated with worse CSS (10yr CSS 84% v 58% v 
29%, p=0.002; score 1 v 0: HR 3.25, 95% CI 1.27-8.31, p=0.014; score 2 v 0: HR 
9.12, 95% CI 2.74-30.35, p<0.001). In ER-/HER2- disease, a score of 1 was 
significantly associated with worse CSS compared to a score of 0 (10yr CSS 84% v 
55% v 68%, p<0.001; score 1 v 0: HR 3.17, 95% CI 1.85-5.43, p<0.001; score 2 v 0: 












The relationship between the budding-TSP score and CSS in primary operable ductal breast 
cancer, by molecular subtype. Kaplan Meier survival graphs for CSS in patients with a budding-
TSP score of 2 compared to 1 compared to 0, in ductal breast cancer. a) ER+/HER2- n=563, 
p=0.063; b) ER+/HER2+ n=81, p=0.801; c) ER-/HER2+ n=87, p<0.001; d) ER-/HER2- n=221, 
p<0.001. 
Associations between the budding-TSP score and clinicopathological 
characteristics in ductal breast cancer 
A high budding-TSP score was significantly associated with lower tumour grade 
(p<0.001), nodal positivity (p=0.006), ER positivity (p=0.023) and lower KM grade 
(p=0.001). 
Associations between the necrosis-budding-TSP score and CSS in ductal 
breast cancer 
In the full ductal cohort, scores of 2 and 3 were associated with worse CSS 
compared to a score of 0 (10yr CSS 87% v 83% v 69% v 41%, p<0.001; score 1 v 0: 
HR 1.42, 95% CI 0.98-2.04, p=0.063; score 2 v 0: HR 2.76, 95% CI 1.88-4.04, 
p<0.001; score 3 v 0: HR 5.85, 95% CI 3.46-9.90, p<0.001). Scores of 2 and 3 
were associated with worse CSS compared to a score of 0 in both ER positive 
(10yr CSS 86% v 84% v 78% v 48%, p<0.001; score 1 v 0: HR 1.21, 95% CI 0.80-1.84, 
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p=0.370; score 2 v 0: HR 1.73, 95% CI 1.07-2.79, p=0.025; score 3 v 0: HR 4.35, 
95% CI 2.26-8.37, p<0.001) and ER negative disease (10yr CSS 91% v 80% v 56% v 
31%, p<0.001; score 1 v 0: HR 2.54, 95% CI 1.00-6.49, p=0.051; score 2 v 0: HR 








The relationship between the necrosis-budding-TSP score and CSS in primary operable 
ductal breast cancer. Kaplan Meier survival graphs for CSS in patients with a necrosis-budding-
TSP score of 3 compared to 2 compared to 1 compared to 0, in ductal breast cancer. a) Full cohort 
n=1080, p<0.001; b) ER positive n=737, p<0.001; c) ER negative n=340, p<0.001.  
In ER+/HER2- disease, a score of 3 was significantly associated with worse CSS 
than a score of 0 (10yr CSS 86% v 84% v 79% v 42%, p<0.001; score 1 v 0: HR 1.14, 
95% CI 0.70-1.86, p=0.592; score 2 v 0: HR 1.53, 95% CI 0.88-2.66, p=0.129; score 
3 v 0: HR 5.04, 95% CI 2.49-10.20, p<0.001). There was no significant association 
between the combined score and CSS in either ER+/HER2+ (score 1 v 0: HR 2.22, 
95% CI 0.81-6.12, p=0.123; score 2 v 0: HR 2.61, 95% CI 0.84-8.11, p=0.097; score 
3 v 0: HR 1.21, 95% CI 0.15-10.06, p=0.861), or ER-/HER2+ cancers (10yr CSS 73% 
v 84% v 55% v 29%, p=0.005; score 1 v 0: HR 0.55, 95% CI 0.11-2.74, p=0.467; 
score 2 v 0: HR 1.91, 95% CI 0.43-8.40, p=0.393; score 3 v 0: HR 4.92, 95% CI 
0.95-25.51, p=0.058). In HER2 negative cancers, a score of 2 or 3 was associated 
with worse CSS compared to a score of 0 (10yr CSS 92% v 79% v 56% v 36%, 
p<0.001; score 1 v 0: HR 3.10, 95% CI 0.94-10.21, p=0.063; score 2 v 0: HR 7.53, 











The relationship between the necrosis-budding-TSP score and CSS in primary operable 
ductal breast cancer, by molecular subtype. Kaplan Meier survival graphs for CSS in patients 
with a necrosis-budding-TSP score of 3 compared to 2 compared to 1 compared to 0, in ductal 
breast cancer. a) ER+/HER2- n=563, p<0.001; b) ER+/HER2+ n=81, p=0.296; c) ER-/HER2+ 
n=87, p=0.001; d) ER-/HER2- n=221, p<0.001. 
Associations between the necrosis-budding-TSP score and 
clinicopathological characteristics in ductal breast cancer 
A high combined necrosis-budding-TSP score was associated with larger tumour 
size (0.003), nodal (p<0.001) and HER2 positivity (p=0.006), ER and PR negativity 
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